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DENDRITIC CELLS CONTRIBUTE TO PERIVASCULAR 
ADIPOSE TISSUE DYSFUNCTION IN TYPE 2 DIABETES 
Tianyi Qiu 
ABSTRACT 
       T2DM is a chronic disease characterized by low-grade inflammation in adipose tissue. 
Recent investigations have shown that a variety of immune cells can accumulate in adipose 
tissue contributing to the development of chronic inflammation. To date focus has been placed on 
specific immune cell populations including B and T lymphocytes, M1 macrophages, neutrophils, 
mast cells and natural killer cells. However, it remains uncertain about the exact immune cell 
populations in adipose tissue during T2DM. The dendritic cell is a potent antigen presenting cell 
that has been demonstrated to participate in the chronic inflammation associated with multiple 
diseases, including autoimmune disease, atherosclerosis and type 1 diabetes. Thus, it was 
hypothesized that dendritic cells would also play a role in the development of chronic 
inflammation elicited by T2DM. Firstly, our data obtained in db/db mice (T2DM murine model) 
provide evidence that dendritic cells do, indeed, accumulate in multiple depots of perivascular 
and visceral adipose tissue.  Importantly, the dendritic cells target the adipose tissue rather than 
accumulating within the vascular wall, accompanied with increased production of pro-
inflammatory factors TNF-α and IL-6 in adipose tissue. Secondly, depletion of dendritic cells 
within adipose tissue in db/db (dbFlt3l-/ dbFlt3l-) mice attenuated the pro-inflammatory environment. 
As perivascular adipose tissue exerts anti-contractile actions and potentiates vasorelaxation 
under physiological conditions, we examined the effects of fat from db/db mice on vascular 
function. The data showed that in db/db mice, both of these ‘vaso-protective’ effects were lost at 
early (6-10 weeks) and later (18-22 weeks) stages of T2DM in the presence of inflamed 
mesenteric adipose tissue. Depletion of dendritic cells in dbFlt3l-/ dbFlt3l- mice greatly attenuated 
inflammation in perivascular adipose tissue (decreased secretion of TNF-α and IL-6) compared to 
the db/db and partially restored vascular function. Collectively, our studies demonstrate that the 
accumulation of dendritic cells in adipose tissue contributes to the pathogenesis of chronic 
xv 
 
inflammation in T2DM, resulting in impairment of anti-contractile and pro-relaxant actions of 
perivascular adipose tissue. Deletion of dendritic cells restores these physiological actions of 
adipose tissue.
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 CHAPTER I 
EFFECTS OF PERIVASCULAR ADIPOSE TISSUE DYSFUNCTION 
ON BLOOD VESSELS IN TYPE 2 DIABETES 
1.1 Role of adipose tissue in the pathological development  of obesity 
and T2DM                          
     Obesity is a pathological condition that has been commonly considered as a body mass index 
(BMI) greater than 30 kg per m2. This phenomenon of inappropriately increased body weight has 
drawn more and more attention from all over the world, since the prevalence of obesity is 
gradually increasing not only in developed western countries, but also in many developing 
countries (for example China, Pacific Islands and the Middle East). Importantly, this interest has 
been heightened as obesity has been linked to a series of severe consequences, such as type 2 
diabetes (T2DM) and cardiovascular diseases. Thus, it was reported in 2012 that approximately 
9.3% of the population in United States (29.1 million Americans) have been diagnosed with T2DM 
(Olanipekun, Salemi et al. 2016). From an economic perspective, the overall cost of T2DM in 
2012 had reached 245 billion dollars in United States. The escalating costs for treatment of T2DM 
have greatly stimulated research efforts to identify underlying mechanisms and potential 
therapies for both obesity and T2DM.  
      The main causes of morbidity and mortality in T2DM relate to both macro-vascular and micro-
vascular complications. Macro-vascular complications consist of coronary artery occlusion, 
cerebrovascular stroke and kidney failure, while microvascular complications include retinopathy, 
diabetic foot ulcer and neuropathy (Liu, Fu et al. 2010). Vascular endothelial cell dysfunction 
appears to precede the development of the vascular complications and has become a possible 
early marker in their diagnosis (Hwang and Kim 2014). This vascular endothelial dysfunction is 
characterized by impairment of endothelial-dependent relaxation in both small resistance (Zhang, 
Potter et al. 2011) and large conduit arteries (Lee, Zhang et al. 2012). Amongst a number of 
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hypotheses, it is believed that hyperglycemia and hyperlipidemia in T2DM result in the 
overproduction of reactive oxygen species (ROS) and pro-inflammatory cytokines, which lead to 
an uncoupling of endothelial nitric oxide synthase (eNOS) and a decrease of overall nitric oxide 
(NO) bioavailability (Hwang and Kim 2014). As NO is a physiological mediator of endothelial-
dependent relaxation, decreased availability is believed to underlie vascular dysfunction in T2DM.      
        Two critical features in obesity contribute to the development of overt T2DM (Guilherme, 
Virbasius et al. 2008). The first feature is impaired insulin responsiveness of skeletal muscle while 
the other one relates to the failure of pancreatic islet β-cells to produce the required amount of 
‘functional’ insulin to maintain normal fasting blood glucose levels. These two features highlight 
the pivotal role of insulin resistance in the pathological progression from obesity to T2DM.  It is 
generally accepted that the release of multiple free fatty acids, especially non-esterified fatty acid 
(NEFA) is the primary culprit responsible for insulin resistance development in skeletal muscle 
and pancreatic islet β-cell dysfunction (Kahn, Hull et al. 2006, Guilherme, Virbasius et al. 2008). 
This notion has been demonstrated in T2DM patients that lowering of circulating free fatty acids 
by acipimox, a long-acting anti-lipolytic drug, leads to a decrease in insulin resistance and 
improvement of glucose tolerance (Santomauro, Boden et al. 1999, Bajaj, Suraamornkul et al. 
2005). The source of free fatty acids now has been found in adipose tissue and it is believed that 
adipose tissue is the key modulator of lipid and glucose metabolism in the whole body scale 
(Guilherme, Virbasius et al. 2008). Under physiological conditions, adipose tissue sequesters free 
fatty acids causing their circulating concentrations to be relatively low. This action of adipose 
tissue effectively restricts fatty acid toxicity on insulin sensitivity (Guilherme, Virbasius et al. 2008). 
In contrast, in the obese state, the size of adipocytes is enlarged to increase their capability for 
fatty acid storage. Initially, this compensatory response effectively controls the increment of 
circulating fatty acid concentration. However, as obesity continues to develop, the increase in 
adipocyte size becomes ineffective in buffering circulating fatty acids, eventually leading to insulin 
resistance formation (Lewis, Carpentier et al. 2002). 
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     Importantly as obesity develops, the function of adipose tissue as an endocrine/paracrine 
organ becomes compromised.  In particular, the secretion of multiple biologically active molecules 
is affected. Anti-inflammatory cytokines including adiponectin and leptin, have been shown to 
decline in obese adipose tissue (Dandona, Aljada et al. 2004) whereas pro-inflammatory 
cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and monocyte 
chemoattractant protein-1 (MCP-1), have been reported to be increased (Dandona, Aljada et al. 
2004).  The role of TNF-α in modulating adiposity has been suggested to involve activation of 
both IκB kinase β (IKKβ)/nuclear factor-κB (NF-κB) and JUN N-terminal kinase (JNK) intracellular 
pathways to elicit insulin resistance (Moller 2000, Dandona, Aljada et al. 2004, Shoelson, Lee et 
al. 2006).  The proposed mechanisms include accelerated lipolysis with increased circulating free 
fatty acids, decreased protein synthesis of glucose transporter type 4 (GLUT4) and insulin 
receptors, inhibition of insulin receptor auto-phosphorylation, acute inhibition of insulin-stimulated 
glucose transport (Moller 2000). Similarly, high IL-6 expression is also associated with insulin 
resistance development. IL-6 shares the same downstream molecular signaling pathway with 
TNF-α, resulting in decreased synthesis of GLUT-4 and insulin-receptor substrate (IRS), a 
marked reduction of insulin-stimulated tyrosine phosphorylation and peroxisome proliferation-
activated receptor γ (PPAR-γ), but it has no effect on insulin receptor tyrosine phosphorylation  
(Rotter, Nagaev et al. 2003).  Conversely, adiponectin potentiates insulin sensitivity in peripheral 
tissues by activating fatty acid oxidation through both AMP activated protein kinase (AMPK) and 
peroxisome proliferation-activated receptor α (PPAR-α) dependent intracellular pathways 
(Kadowaki, Yamauchi et al. 2006, Scherer 2006).  
1. 2.  Interplay between adipose tissue and T2DM: implication of distinct 
immune cells.  
          As mentioned in the previous section, adipose tissue in T2DM undergoes progressive 
inflammation favoring a pro-inflammatory response that is accompanied by increased production 
of inflammatory factors and a decreased production of anti-inflammatory mediators. The 
underlying mechanism to explain this alteration in secretion profile in T2DM adipose tissue has 
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gained more and more research interest from global scientists (Franco Nitta 2013, Seijkens, 
Kusters et al. 2014, Grant and Dixit 2015). Interestingly, a number of such investigations have 
shown that inflammation in obese adipose tissue is highly associated with the recruitment of 
various immune cells (Huh, Park et al. 2014). The following sections introduce the roles of 
different immune cells implicated in the development of adipose tissue inflammation during 
obesity.  
1.2.1. Macrophages in adipose tissue  
     The macrophage is an indispensable immune cell that participates in the foreign pathogen 
defense (Parkin and Cohen 2001). It plays an important role in both innate and acquired 
immunities, which are two major compartments of the immune system. Resident macrophages in 
peripheral tissues are derived from monocytes leaving the circulation by extravasation (Gordon 
and Taylor 2005). In innate immunity, resident macrophages promptly arrive at infected sites and 
defend against foreign antigens and coordinate leukocyte infiltration (Gordon and Taylor 2005). 
Macrophages are responsible for the clearance of foreign antigens through phagocytosis and 
subsequent degradation of apoptotic cells, microbes and possibly neoplastic cells (Gordon and 
Taylor 2005). In adaptive immunity, macrophages function as antigen presenting cells, which 
deliver antigens to immune effector cells, such as T and B lymphocytes. Activated T and B 
lymphocytes help to clear residual antigens that are missed by macrophages in innate immunity, 
by the release of various cytotoxic cytokines and production of specific antibodies (Duffield 2003). 
Of note, macrophages are also capable of generating a variety of cytokines, chemokines, 
arachidonic acid metabolites and reactive radicals to eradicate lethal microbes. Such cytokines 
include TNF-α and IL-6 (Tejada-Simon and Pestka 1999).  
       Adipose tissue macrophages (ATM) are considered to be a special population of 
macrophages that are located in the stromal vascular fraction of adipose tissue and form a ring-
like configuration called crown-like structure (CLS). Unfortunately, a definitive nomenclature for 
ATM is still lacking (McNelis and Olefsky 2014). However, the F4/80+CD11b+ cell population is 
commonly considered to be ATMs (Zeyda and Stulnig 2007). ATM is generally divided into two 
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subtypes: M1 and M2 types. M1 type of ATM is referred as being pro-inflammatory while the M2 
type is referred as an anti-inflammatory ATM. Under physiological conditions, M2 ATMs are the 
primary tissue-resident macrophage and maintain adipose tissue homeostasis by secretion of 
anti-inflammatory mediators, such as IL-10. In contrast, during the development of obesity, M2 
ATMs progressively switch to the M1 type and promote the pro-inflammatory state in adipose 
tissue by releasing multiple inflammatory factors, such as TNF-α, interleukin 1 β (IL-1β), IL-6, 
interferon gamma (IFN-γ) and leukotriene B4 (Zeyda and Stulnig 2007). The presence of TNF-α 
and IL-6 in adipose tissue has been confirmed to inhibit insulin receptor auto-phosphorylation and 
attenuate the insulin signaling cascade, which eventually promotes the development of the insulin 
resistant state as outlined above (Hajer, van Haeften et al. 2008). Thus it is now generally 
accepted that ATMs are the key effector cell in the propagation of inflammation caused by obesity 
(McNelis and Olefsky 2014, Boutens and Stienstra 2016). It has been demonstrated that 
depletion of M1 macrophages in high fat diet induced mice resulted in the restoration of anti-
inflammatory mediator IL-10 levels in visceral adipose tissue (Lumeng, Bodzin et al. 2007). 
Another piece of evidence also showed that ablation of M1 macrophages not only markedly 
reduced pro-inflammatory cytokines IL-6 and MCP-1 production in obese adipose tissue, but also 
normalized glucose tolerance and insulin sensitivity in high fat diet induced mice (Patsouris, Li et 
al. 2008).  In summary, these results suggested that M1 macrophages are the upstream regulator 
of inflammatory cytokine generation in obese adipose tissue.  
1.2.2. B lymphocytes in adipose tissue  
      In contrast to macrophages, B lymphocytes are both generated and differentiated within bone 
marrow. After maturation, B lymphocytes migrate to various peripheral tissues including lymphoid 
and non-lymphoid organs. The humoral immune system in murine models consists of at least two 
subsets of matured B lymphocytes: referred to as B1 and B2 cell populations (Kaminski and 
Stavnezer 2006). B1 lymphocytes are predominantly distributed to the peritoneal and pleural 
cavities, while B2 lymphocytes are located in the spleen, lymph nodes and Peyer’s patches in the 
intestine (Martin and Kearney 2001). Apart from different locations, the role of B1 lymphocytes in 
humoral responses also differs from that of B2 lymphocytes. B1 lymphocytes are responsible for 
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antibody production preferentially in a T lymphocyte-independent manner, whereas B2 
lymphocytes generate various antibodies through the activation of T lymphocytes. Despite these 
differences in characteristics between B1 and B2 lymphocytes, the principal function of B 
lymphocytes is to generate diverse antibodies against a number of soluble antigens and foreign 
microorganisms. 
            In regard to the role of B lymphocytes within adipose tissue, it is has been shown that they 
infiltrate into inflamed visceral adipose tissue of mice fed with high fat diet (Duffaut, Galitzky et al. 
2009, Winer, Winer et al. 2011). This accumulation of B lymphocytes has been demonstrated to 
contribute to systemic insulin resistance development (Duffaut, Galitzky et al. 2009, Winer, Winer 
et al. 2011). Three distinct mechanisms have been proposed by which B lymphocytes modulate 
insulin resistance in obesity. The first mechanism is through cytokine production. Thus, isolated B 
lymphocytes from T2DM subjects secrete greater amounts of the pro-inflammatory factor 
interleukin 8 (IL-8) into the circulation compared to that of non-diabetic individuals (Jagannathan, 
McDonnell et al. 2010). The increased levels of serum IL-8 are associated with insulin resistance 
development and a reduction of skeletal muscle capillary density during the pathological course 
of T2DM (Sharabiani, Vermeulen et al. 2011, Amir Levy, Ciaraldi et al. 2015). Moreover, serum 
levels of anti-inflammatory factor IL-10 have been reported to be relatively low in T2DM subjects 
(van Exel, Gussekloo et al. 2002). These B lymphocyte infiltration-dependent differences in 
cytokine production promote local and systemic inflammatory responses. The second mechanism 
is through modulation of T lymphocytes, which is linked to the B lymphocyte being a member of 
the antigen-presenting cell family. In diet-induced obese mice, B lymphocytes present antigens to 
T lymphocytes in a major histocompatibility complex (MHC) dependent manner (Winer, Winer et 
al. 2011). In obese visceral adipose tissue, MHC I molecules expressed on B lymphocytes 
present antigens to CD8+ T cells, whereas MHC II molecules on B lymphocytes exhibit antigens 
to CD4+ T cells (Winer, Winer et al. 2011). Local insulin resistance in obese adipose tissue 
becomes worse, accompanied with the rise of IFN-γ production, after both CD4+ and CD8+ T cells 
are activated (Mallat 2011). The third mechanism is through B lymphocyte antibody production. 
Published data from Winer (Winer, Winer et al. 2011) suggested that a specific intracellular 
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antigen involved in protein trafficking between Golgi apparatus and endoplasmic reticulum, 
stimulates B lymphocyte to proliferate and produce multiple antibodies in obese adipose tissue 
from mice fed with high fat diet. It is also recognized that B1 lymphocytes generate IgM antibody, 
which promotes the activation of anti-inflammatory M2 macrophages and regulates the 
inflammatory reaction in obese adipose tissue from high fat diet induced mice (Mallat 2011). In 
contrast, B2 lymphocytes are responsible for the production of pro-inflammatory IgG 
autoantibodies, which capture auto-antigen and form an antigen-antibody complex (Mallat 2011). 
This complex cross-links to Fc receptors expressed on the surface of macrophages and further 
stimulates inflammatory macrophages to produce pro-inflammatory cytokine TNF-α. Moreover, 
antigen-antibody complexes also activate the complement pathway, which exacerbates adipose 
tissue inflammation and remodeling.  In a high fat diet induced murine model, the release of IgM 
antibodies is decreased while IgG antibody production is increased in both serum and visceral 
adipose tissue (Winer, Winer et al. 2011). Depletion of B lymphocytes in adipose tissue results in 
the switching of M2 to M1 inflammatory macrophages and a reduction of CD8+T cells, leading to 
amelioration of glucose intolerance in diet-induced obese mice (Winer, Winer et al. 2011). In 
summary, B lymphocytes promote the development of an inflammatory state in obese adipose 
tissue through the increasing production of pro-inflammatory cytokines and antibodies, as well as 
the interaction with T lymphocytes.   
1.2.3. T lymphocytes in adipose tissue  
        Adipose tissue is also known to contain another important and large group of immune cells - 
T lymphocytes. T lymphocytes can be primarily divided into two types: CD4+ and CD8+ T 
lymphocytes. Also, other small clusters of T lymphocytes, which are not included in either CD4+ 
or CD8+ T lymphocyte populations, have been found in murine adipose tissue, such as natural 
killer T cells (NKT) and mucosal-associated invariant T cells (MAIT). In the following sections, 
these subtypes will be covered in detail. 
1.2.3.1 CD4+T cells in adipose tissue  
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   CD4+ T cells represent a major type of T lymphocytes in the immune system from both human 
and mice. They are activated by antigens presented by class II MHC molecules located on the 
surface of antigen presenting cells (APCs). Effector CD4+ T cells can then differentiate into four 
different subtypes, including T helper (Th) 1, Th2, Th17, and induced regulatory T (iTreg) cells 
(Zhu, Yamane et al. 2010). Th1 cells are characterized by IFN-γ secretion, but also can produce 
interleukin 2 (IL-2) (Fernandez-Botran, Sanders et al. 1988), TNF-α and lymph toxin (Kagami, 
Rizzo et al. 2010). Th2 cells are characterized by the release of IL-4, interleukin 5 (IL-5) and IL-13 
(Fort, Cheung et al. 2001). Th17 cells are signified by the secretion of interleukin 17 (IL-17) and 
interleukin 22 (IL-22) (Liang, Tan et al. 2006). However, there is no specific cytokine exclusively 
secreted by iTreg cells. The proliferation and differentiation of those effector Th cell populations 
have been confirmed to be triggered by a family of special molecules called signaling transducer 
and activator of transcription proteins (STAT). It is known that activation of STAT1 protein is 
indispensable in Th1 cell differentiation and IFN-γ production (Lighvani, Frucht et al. 2001, 
Afkarian, Sedy et al. 2002). STAT3 protein has also been demonstrated to participate in Th17 cell 
differentiation and maintenance (Bettelli, Carrier et al. 2006, Mangan, Harrington et al. 2006).  
The activation of STAT 6 protein is necessary for Th2 cell differentiation and expansion (Shimoda, 
van Deursen et al. 1996, Takeda, Tanaka et al. 1996). 
            At present, only three CD4+ T cell populations have been identified in murine adipose 
tissue, including Th1, Th2 and Th17 cells.  In visceral adipose tissue of diet-induced obese mice, 
the CD4+Foxp3+Th1 cell compartment was discovered to outnumber the static CD4+Foxp3-Th2 
cell compartment, resulting in an increased ratio of Th1 to Th2 cells (Winer, Chan et al. 2009). 
The accumulation of Th1 cells induces the development of M1 pro-inflammatory macrophages in 
adipose tissue by the secretion of IL-6 and TNF-α. Conversely, Th2 cells secrete IL-4 and IL-13 
and promote macrophage differentiation into the anti-inflammatory M2 phenotype (Odegaard, 
Ricardo-Gonzalez et al. 2007, Tiemessen, Jagger et al. 2007). The increase of Th1 to Th2 ratio in 
obese adipose tissue facilitates macrophage polarization from anti-inflammatory M2 into pro-
inflammatory M1 phenotype, further exacerbating the inflammatory state in obese adipose tissue. 
Apart from macrophages, CD4+T cells also interact with surrounding adipocytes and induce the 
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production of pro-inflammatory factors TNF-α and IL-1β (Ilan, Maron et al. 2010). In human 
studies, obese subjects with insulin resistance have elevated CD4+T lymphocytes in visceral 
adipose tissue, particularly Th17 cells (Fabbrini, Cella et al. 2013). These cells are responsible for 
the production of IL-17, which inhibits glucose metabolism in skeletal muscle and reduces insulin 
sensitivity in liver. However, the function of iTreg cells still remains unclear. In summary, CD4+ T 
cells facilitate the inflammatory state in obese adipose tissue by recruitment of more M1 
macrophages and stimulation of adipocytes to generate multiple pro-inflammatory cytokines.   
1.2.3.2. CD8+ T cells in adipose tissue 
      CD8+ T cells belong to an important T lymphocyte subset that controls and eradicates viral, 
bacterial and protozoan infections in adaptive immunity. These cells can recognize and then be 
activated by MHC class I molecules ubiquitously located on the surface of nucleated cells 
(Gallucci and Matzinger 2001). Once activated, effector CD8+ T cells clear up host cells bearing 
intracellular pathogens by releasing large quantities of cytokines, including TNF-α and IL-1β 
(Gallucci and Matzinger 2001).  
       Emerging evidence has demonstrated that CD8+T cells accumulate in visceral adipose tissue 
of diet-induced obese mice (Kintscher, Hartge et al. 2008, Rausch, Weisberg et al. 2008, 
Nishimura, Manabe et al. 2009, Jiang, Perrard et al. 2014, Khan, Dai Perrard et al. 2014). This 
accumulation of CD8+T cells has been revealed to occur early in the development of obesity and 
is responsible for recruitment and activation of macrophages in visceral adipose tissue  
(Nishimura, Manabe et al. 2009). This action is conducted by substantial secretions of interferon-
inducible protein-10, MCP-1 and monocyte chemo attractant protein-3 (MCP-3). Incubation of 
adipocytes with CD8+T cells up-regulates CD11a expression on CD8+T cells, which in turn 
promotes more CD8+T cells to infiltrate adipose tissue (Jiang, Perrard et al. 2014). The inhibitory 
effect of CD8 specific antibodies successfully ameliorates the pro-inflammatory state of obese 
adipose tissue and improves both glucose and insulin tolerance reactions in diet-induced obese 
mice (Nishimura, Manabe et al. 2009). The role of CD8+T cells in adipose tissue inflammation 
appears to be much smaller in human obesity than in mice (Yang, Youm et al. 2010). A significant 
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but small increment of CD8+T cells was detected in obese visceral adipose tissue from humans 
(Yang, Youm et al. 2010). In summary, accumulation of CD8+T cells in adipose tissue promotes 
the development of inflammatory state and deteriorates glucose intolerance in obese murine 
models, yet with little effects on human obesity.   
1.2.3.3 Treg cells in adipose tissue  
The general immune response can be classified into two forms. The first is the induction of the 
immune reaction while the second relates the suppression of immune reaction. Under 
physiological conditions, these two forms are evenly balanced. One subtype of CD4+ T cells, 
FOXP3+CD4+ CD25+ T cells, defined as regulatory T cells (Treg) constitute only 5-20% of the 
overall CD4+ T cell compartment (Zheng and Rudensky 2007, Cipolletta, Kolodin et al. 2011). 
Despite accounting for a small population, Treg cells play an important functional role in the 
negative regulation of immune responses (Teh, Vasanthakumar et al. 2015).  Deficiency of Treg 
cells has been implicated in various autoimmune diseases, including multiple sclerosis, antigen 
induced arthritis, thyroiditis and eczema (Beissert, Schwarz et al. 2006).  
     Under steady state conditions, more than half of the Treg cell population is located in 
abdominal adipose tissue rather than lymphoid organs, including spleen and lymph nodes 
(Feuerer, Herrero et al. 2009).  Emerging evidence has shown that during the development of 
obesity, a striking decrease of Treg cells occurs in visceral adipose tissue of both morbidly obese 
mice and humans (Deiuliis, Shah et al. 2011). Induction of Treg cell proliferation in visceral 
adipose tissue by administration of anti-CD3 antibody plus β-glucosylceramide has been shown 
to enhance production of anti-inflammatory mediators, such as IL-10 and transforming growth 
factor β (TGF-β) (Ilan, Maron et al. 2010). Moreover, systemic restoration of Treg cells attenuated 
hepatic fat accumulation and pancreatic hyperplasia together with lower levels of serum glucose 
and cholesterol (Ilan, Maron et al. 2010). The mechanisms of Treg cell reduction in obesity, 
however, are still unclear. It has been suggested that CD36 plays a role in the high fat diet-
induced reduction of Treg cells in murine epididymal adipose tissue and mesenteric lymph nodes 
(Geys, Vranckx et al. 2015). Furthermore, it has been reported that in normal mice, resident 
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adipose tissue M2 type macrophages are, in part, responsible for the proliferation of Treg cells 
(Onodera, Fukuhara et al. 2015).  In wild type mice, resident adipose tissue M2 macrophages up-
regulate PPAR γ expression, which further induces the proliferation of Treg cells in abdominal 
adipose tissue. Conversely, pro-inflammatory M1 macrophages derived from obese adipose 
tissue blunt the production of PPAR γ and impair the differentiation and proliferation of Treg cells 
(Onodera, Fukuhara et al. 2015). In summary, Treg cells are responsible for anti-inflammatory 
cytokine production, but are decreased in adipose tissue during obesity development.   
1.2.3.4. NKT cells in adipose tissue 
     NKT cells are a lineage of lymphocytes characterized by both T cell and natural killer cell 
features, expressing both αβ T cell receptor (TCR) and cell surface markers of natural killer cells 
(Bendelac, Savage et al. 2007).  Based on TCRα chain expression and MHC restriction, NKT 
cells can be classified into three subtypes. Type I NKT cells, also termed invariant NKT (iNKT) 
cells, are characteristic of an invariant TCR α chain expression accompanied with a restricted 
subtype of TCR β chains. Type I NKT cells receive lipid antigens delivered by CD1d, which is a 
non-classical MHC-like antigen-presenting protein (Boes, Stoppelenburg et al. 2009). Type II NKT 
cells express variant TCRs and are capable of regulating multiple immune responses, such as 
autoimmunity suppression and tumor rejection inhibition (Godfrey, Stankovic et al. 2010). Type III 
NKT cells have diverse TCRα chains and do not rely on CD1d to present antigens. The 
predominant NKT cell population is the type I NKT (iNKT) cell, which in murine models is mainly 
found in the liver and thymus. Only a small fraction is resident in visceral adipose tissue (Schipper, 
Rakhshandehroo et al. 2012). 
     The iNKT cell has been reported to play a crucial role in the control of adipose tissue 
inflammation and metabolic intolerance in diet-induced obese mice (Ji, Sun et al. 2012). It was 
observed that the number of iNKT cells was significantly decreased in obese visceral adipose 
tissue and this was accompanied by infiltration of M1 macrophages (Ji, Sun et al. 2012). Marine 
sponge-derived α-galactosylceramide (α-GalCer) is a special lipid antigen that was used recently 
to specifically expand iNKT cell populations in a murine model (Bendelac, Savage et al. 2007). 
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Administration of α-GalCer not only proliferated adipose-resident iNKT cell populations and 
ameliorated systemic glucose intolerance (Ji, Sun et al. 2012), but also promoted M2 
macrophage polarization in visceral adipose tissue from obese mice (Ji, Sun et al. 2012). This 
polarization was mediated by activation of IL-4 in adipose tissue (Ji, Sun et al. 2012), which 
further phosphorylated tyrosine residues of STAT6 and triggered the expansion of M2 
macrophages (Ji, Sun et al. 2012). Restoration of iNKT cells in adipose tissue results in declining 
levels of pro-inflammatory factors IL-13 and IFN-γ in diet-induced obese mice (Schipper, 
Rakhshandehroo et al. 2012). However, some investigators also reported that activation of iNKT 
cells exacerbated glucose intolerance and promoted macrophage accumulation in adipose tissue 
as well as pro-inflammatory cytokine secretion, rather than ameliorated metabolic parameters 
(Ohmura, Ishimori et al. 2010). Given these disparate results, the role of iNKT cells in obese 
adipose tissue needs to be further explored. 
1.2.3.5. MAIT cells in adipose tissue  
     MAIT cells are a novel unconventional subset of invariant T cells, which were discovered 
during the late 1980s in both human (Bender and Kabelitz 1990) and mice (Miescher, Howe et al. 
1988). The MAIT cell displays neither CD4 nor CD8 molecules on the cellular surface. Moreover, 
the development of MAIT cells is not restricted by MHC molecules, but by the MHC related 
molecule, MR1 (Tilloy, Treiner et al. 1999). This characteristic leads to the recruitment of MAIT 
cells into intestinal lamina propria (Treiner, Duban et al. 2003), which acquires MR1 receptors.  
Further investigation of MAIT cells revealed that they also infiltrate the peripheral circulation, liver, 
and adipose tissue (Magalhaes, Pingris et al. 2015). The principal role of MAIT cells is to mediate 
anti-bacterial actions by releasing IFN-γ and IL-17 cytokines (Gold, Cerri et al. 2010).  
       Delving further into MAIT cells in obese humans, Carolan and colleagues have found that the 
distribution and secretion profile of MAIT cells are changed in human tissue (Carolan, Tobin et al. 
2015). In healthy adults and children, MAIT cells were enriched in the circulation rather than 
adipose tissue. However, in obese individuals, circulating MAIT cells were depleted and instead 
recruited into adipose tissue. The MAIT cells in adipose tissue appeared to produce more pro-
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inflammatory cytokine IL-17 rather than anti-inflammatory mediator IL-10. The IL-17+ MAIT cells 
have further been shown to be directly related to the degree of insulin resistance in obese 
humans (Fabbrini, Cella et al. 2013, Magalhaes, Pingris et al. 2015).  It has also been reported 
that cytokine IL-17 suppresses adipocyte maturation and function by impairing gene expression 
of adipokines and adipose triglyceride lipase (Zuniga, Shen et al. 2010). Furthermore, IL-17 
induces IL-6 generation in pre-adipocytes, which is known to induce insulin resistance in vivo and 
in vitro (Kern, Ranganathan et al. 2001, Rotter, Nagaev et al. 2003). Collectively, MAIT cells are 
involved in the promotion of inflammatory state in obese adipose tissue induced by high fat diet. 
1.2.4. Eosinophils in adipose tissue  
       The eosinophil is another type of immune cell belonging to innate immune system. It is 
generated from hematopoietic stem cells in the bone marrow and later resides in various 
peripheral tissues and organs. Eosinophils play an important role in the defense of bacterial and 
parasitic invasion, as well as allergen-induced inflammatory responses (Rothenberg and Hogan 
2006).  Activated eosinophils kill bacteria by the release of tissue destructive granular molecules 
and extracellular traps composed of mitochondrial DNA. Similarly, parasitic infection is eliminated, 
in part, by eosinophil degranulation of major basic or cationic proteins (Bystrom, Amin et al. 2011). 
In the inflammatory response induced by allergens, eosinophils secrete cationic or tissue 
destructive proteins resulting in tissue or organ damage (Amin, Ludviksdottir et al. 2000).   
 In the perspective of adipose tissue immunity, eosinophils act as a negative regulator in 
modulating adipose tissue inflammation and metabolic dysfunction (Wu, Molofsky et al. 2011, 
Molofsky, Nussbaum et al. 2013). Under physiological conditions, the presence of the cytokine 
interleukin 33 (IL-33) has been demonstrated to facilitate the activation and secretion of a novel 
type of lymphocyte, innate lymphoid type 2 cells (ILC2s), in murine visceral adipose tissue 
(Molofsky, Nussbaum et al. 2013, Brestoff, Kim et al. 2015). The activated ILC2s are responsible 
for the secretion of IL-5, which promotes the recruitment of eosinophils from the circulation into 
visceral adipose tissue (Molofsky, Nussbaum et al. 2013). The eosinophils in adipose tissue are 
responsible for the secretion of IL-4, which then activates M2 polarization of macrophages (Wu, 
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Molofsky et al. 2011). This macrophage polarization promotes the anti-inflammatory, rather than 
pro-inflammatory, environment in visceral adipose tissue, resulting in restoration of metabolic 
disorders. In contrast, the number of eosinophils in visceral adipose tissue has been found to be 
decreased in high fat diet-induced obese mice (Wu, Molofsky et al. 2011). This reduction further 
impairs the M2 polarization of macrophages and finally leads to adipose tissue inflammation and 
impaired insulin sensitivity (Wu, Molofsky et al. 2011).   
1.2.5. Dendritic cells in adipose tissue  
      Dendritic cells are potent antigen-presenting and processing cells that play a pivotal role in 
the orchestration of both innate and adaptive immune systems. They are also referred to as 
“sentinels” or “sensors” of the immune system because they are located in nearly every organ 
and maintain surveillance for a wide spectrum of environmental invaders (Steinman 2006). Once 
dendritic cells sense antigen invasion, they immediately migrate into the threatened region and 
capture, phagocytize, process and finally present these antigens on their surface (Banchereau 
and Steinman 1998). After activation by these antigens, dendritic cells leave the peripheral tissue 
and carry the antigens into lymphoid organs where they present antigens to B or T lymphocytes. 
Due to the essential signals provided by dendritic cells, B and T lymphocytes are stimulated and 
migrate through the peripheral circulation into attacked region, where invading antigens are 
recognized and subsequently cleared (Banchereau and Steinman 1998). Despite the relative 
paucity of dendritic cells, they have been suggested to play a role in the pathologies of 
atherosclerosis (Dieterlen, John et al. 2016) and type 1 diabetes (Besin, Gaudreau et al. 2008).  
            Dendritic cells have been shown to initiate and enhance the development of type 1 
diabetes, including contribution to the onset of diabetes (Rosmalen, Leenen et al. 1997). The role 
of dendritic cells in the pathogenesis of type 1 diabetes appears to be associated with the 
activation of T lymphocytes (Machen, Harnaha et al. 2004). The full activation of T lymphocytes 
requires two signals provided by dendritic cells. The first signal is processed antigen presented by 
dendritic cells to the T cell receptor on T lymphocytes. This signal triggers T lymphocytes to 
increase the expression of CD40 ligand (CD40L) on their surface, which incites the second signal 
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referred to as ‘co-activation’ (Machen, Harnaha et al. 2004). Initially, CD40L on the T lymphocyte 
interacts with CD40 on dendritic cells. This event up-regulates CD80 and CD86 expression on 
dendritic cells, which then act as the second signal and engages CD28 on T lymphocyte. The 
combination of both first and second signals consequently leads to full activation of T 
lymphocytes, which subsequently mediates pancreatic β cell destruction and type 1 diabetic 
development. Several lines of evidence have shown that any disturbance in these two signals for 
T lymphocyte activation can result in suppression of type 1 diabetic development (Machen, 
Harnaha et al. 2004, Acharya, Dolgova et al. 2011). 
      In regard to mechanisms underlying obesity and T2DM, a contribution of dendritic cells has 
also been suggested (Bertola, Ciucci et al. 2012, Reynolds, McGillicuddy et al. 2012, Stefanovic-
Racic, Yang et al. 2012). In a high fat diet-induced obese murine model, dendritic cells have been 
found to infiltrate hypertrophic adipose tissue (Reynolds, McGillicuddy et al. 2012). These high fat 
diet-derived dendritic cells are switched  to a pro-inflammatory phenotype with enhanced 
production of inflammatory cytokines, including IL-1β, interleukin 1 receptor type 1 (IL-1R1), toll 
like receptor 4 (TLR4) and caspase-1 (Reynolds, McGillicuddy et al. 2012). It is believed that free 
fatty acids can directly prime the nucleotide-binding domain, leucine-rich repeat containing protein 
3 (NLRP3) inflammasome via TLR4 on dendritic cells, which subsequently promote adipocyte 
inflammation and development of insulin resistance (Reynolds, McGillicuddy et al. 2012). Another 
line of evidence showed that dendritic cells contribute to the systemic metabolic response to 
obesity by promoting macrophage infiltration into adipose tissue (Stefanovic-Racic, Yang et al. 
2012). Emerging studies also indicate that dendritic cells in obese adipose tissue induce T 
lymphocyte differentiation into Th17 cells which secrete IL-17 into peripheral tissues (Bertola, 
Ciucci et al. 2012). Although IL-17 has an anti-adipogenic property, the exact function of IL-17 in 
the pathogenesis of obesity remains unclear. Nevertheless, the expansion of Th17 cells has been 
shown to exacerbate autoimmunity in rodent disease models of colitis and autoimmune 
encephalomyelitis (Ahmed and Gaffen 2010). Taken together, although the exact mechanisms of 
dendritic cell recruitment into obese adipose tissue are still unknown, dendritic cells appear to 
play an important role in the pathological processes underlying obesity and T2DM. 
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1.2.6. Summary of the different immune cells in obese adipose tissue           
        From the above, it is apparent that when adipose tissue progresses to the obese state, the 
composition of various immune cells is altered. Greater numbers of B lymphocytes, CD4+ and 
CD8+ T lymphocytes, MAIT cells, M1 macrophages and dendritic cells accumulate in the obese 
adipose tissue, whereas fewer Treg cells, NKT cells, eosinophils and M2 macrophages are 
present. This alteration results in an imbalance in the secretion of pro-inflammatory and anti-
inflammatory cytokines, as shown in Fig1-1.  More pro-inflammatory factors TNF-α, IFN-γ, IL-1β, 
IL-6, IL-8, IL-13 and IL-17 are secreted in the obese adipose tissue while there is a reduction in 
anti-inflammatory factors, including IL-10, IL-4 and TGF-β. Ultimately, the inflammatory state in 
obese adipose tissue that results from immune cell imbalance leads to the development of insulin 
resistance and progression to overt T2DM.   
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 Figure1-1. Obesity induces immune cell infiltration and inflammatory state in adipose tissue.   
 
17 
 
1.3. Role of Perivascular Adipose Tissue (PVAT) in T2DM 
     PVAT is defined as the adipose tissue directly surrounding blood vessels without any 
separation from the adventitia of vasculature (Eringa, Bakker et al. 2012). According to this 
definition, PVAT includes epicardial adipose tissue, periaortic adipose tissue, mesenteric adipose 
tissue, perirenal adipose tissue and adipose tissue around orbital arteries. PVAT differs from 
visceral adipose tissue (VAT) mainly by the different fat distribution in that VAT is typically located 
at the abdominal cavity of human or animal models (Ng, Wai et al. 2012). Apart from these 
differences, both VAT and PVAT can be histologically divided into two compartments: namely, 
adipocytes and the stromal vascular fraction. The stromal vascular fraction is a specialized term 
encompassing the remainder of cells in adipose tissue apart from adipocytes. It is enriched with 
various cell populations, such as pre-adipocytes, mesenchymal stem cells, vascular progenitor 
cells, hematopoietic stem cells, pericytes, fibroblasts, smooth muscle cells, endothelial cells and 
blood cells (Bourin, Bunnell et al. 2013). In addition, VAT or PVAT contains a network of 
capillaries, sympathetic and parasympathetic nerve systems, which are capable of delivering 
information to the central nervous system (Gu and Xu 2013). During the development of T2DM, 
immune cells, such as macrophages, B or T lymphocytes infiltrate into the stromal vascular 
fraction portion of VAT or PVAT (Feldon, O'Loughlin C et al. 2006, Police, Thatcher et al. 2009).   
1.3.1 Versatility in PVAT function  
       It has become gradually accepted that PVAT has a number of effects on surrounding blood 
vessels. PVAT not only provides structural support and insulation to vasculature, but also 
secretes a variety of factors that affect the pathophysiological function of the vasculature it 
encases. Cultured PVAT cells have been shown to differentiate into mesenchymal stem cells and 
then obtain migratory property (Crisan, Yap et al. 2008). Visfatin, a novel protein factor that was 
identified in PVAT, has been demonstrated to inhibit vascular smooth muscle cell contraction and 
enhance vascular smooth muscle cell proliferation (Wang, Xu et al. 2009). Interestingly, 
adiponectin secreted from epicardial adipose tissue has been confirmed to protectively maintain 
the sinus rhythm following cardiac surgery (Kourliouros, Karastergiou et al. 2011). Importantly, 
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PVAT has been documented to influence vascular function in both canine (Noblet, Owen et al. 
2015) and swine animal models (Payne, Bohlen et al. 2009).  Under physiological conditions, the 
presence of PVAT attenuates vascular contraction induced by a variety of pharmacological 
vasoconstrictors, including phenylephrine and 5-hydroxytryptamine (Gao, Lu et al. 2007). The 
mechanism behind this phenomenon is associated with the release of a reservoir of vasoactive 
substances generated within PVAT (Lastra and Manrique 2015). These vasoactive factors 
include adiponectin, angiotensin 1-7, hydrogen peroxide (H2S), leptin, nitric oxide (NO) and the 
yet to be fully characterized, adipocyte-derived relaxing factor (ADRF). The overall effect on 
vascular function from those vasoactive molecules is beneficial to vasodilatory rather than 
vasoconstriction responses. The mechanisms behind ADRF involves both endothelial-dependent 
and vascular smooth muscle cell-dependent relaxation (Gao 2007). This anti-contractile effect on 
vasculature has been suggested to be essential for vascular resistance maintenance under 
physiological conditions (Gollasch and Dubrovska 2004, Gao 2007).  
1.3.2. Loss of anti-contractile effect of PVAT in obesity 
       Under physiological conditions, the anti-contractile effect of PVAT is increased in relation to 
the amount of PVAT (Verlohren, Dubrovska et al. 2004). As such, it is conceivable that the anti-
contractile effect of obese PVAT also would be increased. However, in obesity, both the structure 
and function of PVAT are considerably changed. The anti-contractile action of obese PVAT has 
been shown to be severely impaired in various animal models (Gao, Holloway et al. 2005). In 
obese rats, increased adiposity of peri-aortic adipose tissue attenuates thoracic aorta relaxation. 
Similarly, a diminished anti-contractile effect in mesenteric arteries was observed in New Zealand 
obese mice (Fesus, Dubrovska et al. 2007). Notably, this anti-contractile effect in mesenteric 
arteries declined with age (and duration) in New Zealand obese mice. In an obese Ossabaw 
swine model, despite an increase in weight of epicardial adipose tissue, adenosine-induced 
vasodilation was attenuated by impairment of calcium-dependent potassium channels and 
voltage-dependent KV7 channels (Noblet, Owen et al. 2015). In this context, an imbalance in 
secretion of pro-inflammatory and anti-inflammatory cytokines was observed in PVAT of obese 
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animals (Vieira-Potter, Lee et al. 2015). Further, increased production of pro-inflammatory factors, 
such as IL-6 and MCP-1, has been shown  to diminish the anti-contractile effect of PVAT 
(Rajsheker, Manka et al. 2010). The possible mechanisms leading to impairment of anti-
contractile effect of obese PVAT will be discussed in the following sections in detail.      
1.3.2.1. Impairment of ADRF in obesity  
       Under normal conditions, healthy PVAT generates an unidentified factor which has been 
named ADRF. This factor (or factors), acting in a paracrine manner, promotes relaxation 
responses in the adjacent vasculature. It was first reported by Löhn et al (Lohn, Dubrovska et al. 
2002) that ADRF is a transferrable and vasoactive group of compounds that relax pre-contracted 
rat aorta isolated from adherent PVAT. It is an active regulator of arterial tone by antagonism of 
contraction shown by donor-acceptor transfer bioassays (Lohn, Dubrovska et al. 2002). Moreover, 
Löhn et al described ADRF as a special group of proteins rather than a collection of lipids. Their 
experiment showed that ADRF is inactivated by high temperature (greater than 65°C) and not 
bound by serum albumin, which suggests that it is not a fatty acid. Interestingly, the secretion of 
ADRF from PVAT is dependent on external Ca2+ concentration and can be inhibited by either 
protein kinase A or tyrosine kinase inhibitors (Lohn, Dubrovska et al. 2002). In contrast, the 
production of ADRF and the resultant relaxation are independent of functional adenosine, leptin, 
vanilloid, cannabinoid and cyclooxygenase pathway; calcitonin gene-related peptide receptors; 
cytochrome P450 pathway; the formation of NO; or the endothelium (Lohn, Dubrovska et al. 
2002). Evidence does, however, suggest that the modulation of arterial tone exerted by ADRF 
involves the activation of different potassium channels on vascular smooth muscle cells. 
Pharmacological experiments from Löhn et al demonstrated that the anti-contractile effect of 
PVAT from rat aorta is diminished by the presence of the ATP-dependent potassium channel 
inhibitor glibenclamide (Lohn, Dubrovska et al. 2002). Bath bioassay experiments using PVAT 
from around human internal thoracic artery have suggested that calcium-dependent potassium 
channel inhibitor tetraethylammonium chloride significantly blocks the relaxation induced by 
PVAT (Gao, Zeng et al. 2005). Recently, accumulating evidence supports an interaction between 
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ADRF and potassium channels on vascular smooth muscle cells (Weston, Egner et al. 2013, 
Zavaritskaya, Zhuravleva et al. 2013, Noblet, Owen et al. 2015). Thus, it is considered that the 
release of ADRF from adjacent PVAT activates different potassium channels, including voltage-
gated potassium channels, ATP-dependent potassium channels and Ca2+-activated potassium 
channels on vascular smooth muscle cells, resulting in hyperpolarization and relaxation of smooth 
muscle cells. 
           In obese conditions, the anti-contractile effect from PVAT is impaired in both animals 
(Owen, Witzmann et al. 2013, Noblet, Owen et al. 2015) and humans (Meijer, Serne et al. 2015). 
Accumulating evidence suggests that voltage-gated potassium channels (Berwick, Dick et al. 
2013), Ca2+-activated potassium channels (Borbouse, Dick et al. 2009) and ATP-dependent 
potassium channels (Climent, Simonsen et al. 2014) may all be impaired in the microcirculation of 
obese animals. This effect is attributable to the loss of ADRF. In addition to a role for potassium 
channels, it has been shown that inhibition of cyclooxygenase in obese PVAT significantly 
restores the anti-contractile effect on thoracic aorta (Meyer, Fredette et al. 2013). It is believed 
that inhibition of cyclooxygenase reduces the production of vasoconstrictors and promotes the 
restoration of ADRF generation in PVAT. Overall, loss of ADRF and dysfunctional potassium 
channels appear to be involved in the impairment of PVAT anti-contractile effects in obesity.   
1.3.2.2. Decrease of NO and H2S in obese PVAT 
       NO and H2S are two different gaseous molecules that have been suggested to participate in 
the anti-contractile effects of PVAT. Under physiological conditions, NO is produced by both 
endothelial cells lining blood vessels and PVAT. It has been well-known that endothelial cell NO 
synthase is responsible for the generation of NO that subsequently elicits endothelial cell-
dependent acetylcholine-induced relaxation responses in both large conduit (Rees, Palmer et al. 
1989) and small resistance vessels (Kubes, Suzuki et al. 1991). Notably, recent investigations  
have indicated that adipocytes within PVAT can also express NO synthase and generate 
bioactive NO into adjacent vasculature (Xia, Horke et al. 2016). Interestingly, NO produced by 
PVAT plays a pivotal role in the endothelium-independent, anti-contractile function of PVAT by 
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pharmacological inhibition of NO synthase on vascular endothelial cells (Aghamohammadzadeh, 
Unwin et al. 2016). Under obese conditions, it has long been believed that impaired endothelium-
dependent vasodilation in small vessels from obese animals  is due to the reduction of NO 
bioavailability derived from endothelial cells (Perticone, Ceravolo et al. 2001). However, further 
investigations of obesity suggest that NO production from PVAT is also reduced in the late stages 
of obesity (Xia, Horke et al. 2016). This decrease in NO production is associated with impaired 
anti-contractile effects of obese PVAT (Bussey, Withers et al. 2016). Interestingly, during the 
early stage of obesity, NO production is increased in PVAT (Aghamohammadzadeh, Unwin et al. 
2016). This abnormal situation is believed to be an adaptive reaction to the development of 
obesity, but the exact underlying mechanism is still unclear. With the progression of obesity, 
adaptive NO overproduction in PVAT is reduced to undetectable levels (Aghamohammadzadeh, 
Unwin et al. 2016). Moreover, leptin has been confirmed to stimulate NO production in PVAT (Gil-
Ortega, Stucchi et al. 2010).  Consistent with this, leptin deficient ob/ob mice did not exhibit NO 
production within adipocytes of PVAT (Gil-Ortega, Stucchi et al. 2010). However, restoration of 
leptin expression in ob/ob mice promoted NO generation in PVAT(Gil-Ortega, Stucchi et al. 2010). 
     Apart from NO, H2S is also generated within PVAT, as has been shown in both periaortic and 
mesenteric adipose tissues (Fang, Zhao et al. 2009, Schleifenbaum, Kohn et al. 2010). H2S is 
synthesized from L-homocysteine or L-cysteine by cystathionine β-synthase, cysteine 
aminotransferase, or cystathionine γ-lyase (CSE), as well as 3- mercaptopyruvate sulfur 
transferase (Kimura 2014).  Within PVAT, CSE is the main source of H2S production 
(Schleifenbaum, Kohn et al. 2010). Recently, H2S has been considered as one element in the 
ADRF family (Gollasch 2012), due to its role in mediating anti-contractile effects of PVAT(Fang, 
Zhao et al. 2009). The mechanism of H2S induced relaxation is considered to involve activation of 
different potassium channels in vascular smooth muscle cells, such as voltage-dependent 
potassium channels (Schleifenbaum, Kohn et al. 2010, Kohn, Schleifenbaum et al. 2012) and 
ATP dependent potassium channels (Zhao, Zhang et al. 2001). Moreover, H2S can also stimulate 
endothelial NO synthase, promote NO production and finally enhance relaxation responses 
elicited by PVAT (Beltowski and Jamroz-Wisniewska 2014). In addition, H2S can exert other 
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protective mechanisms to maintain healthy vascular homeostasis, such as inhibition of vascular 
smooth muscle cell proliferation (Li, Liu et al. 2013) and suppression of inflammatory reactions 
(Yu, Cui et al. 2014). Surprisingly, obesity does not appear to influence the sensitivity of vascular 
smooth muscle cells to H2S (Beltowski 2013). However, 3 month-old, high calorie diet-induced 
obese mice have decreased H2S production in adipose tissue compared to 1 month-old high 
calorie fed obese mice (Beltowski, Wojcicka et al. 2009).  However, at present, there is no 
evidence to reveal a direct link between lower H2S production and loss of anti-contractile effect of 
obese PVAT. Overall, obesity causes a reduction of NO and H2S production within PVAT, which 
may contribute to the impairment of anti-contractile effects in obese PVAT. 
1.3.2.3. Increased oxidative stress and inflammatory response in obese PVAT 
      The regulation of vascular function by PVAT under physiological and pathological conditions 
is not limited to the release of relaxing factors, such as ADRF. Most of the modulation in 
vasculature-PVAT system consists of a balance between anti-contractile and pro-contractile 
factors. Oxidative stress is characterized by the production of ROS, which are primarily 
composed of superoxide anion, hydrogen peroxide (H2O2) and hydroxyl radicals. In the 
vasculature-PVAT system, ROS is produced by various tissues, including PVAT (De Ciuceis, 
Amiri et al. 2005). Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is the major 
enzyme to produce ROS in the vasculature (Schiffrin 2008). This enzyme complex is also 
expressed in rat mesenteric adipose tissue (Gao, Takemori et al. 2006). NADPH oxidase within 
PVAT generates superoxide anion that activates tyrosine kinase and mitogen-activated protein 
kinase/extracellular signal-regulated protein kinase (MAPK/ERK) pathways in the vasculature, 
promoting arterial contractile rather than anti-contractile responses (Gao, Takemori et al. 2006). 
Superoxide anions can also be converted by superoxide dismutase (SOD) to H2O2. H2O2 is a 
vasoactive ROS that induces vasorelaxation response when endothelial and smooth muscle cell 
potassium channels are activated (Gil-Longo and Gonzalez-Vazquez 2005). Therefore, the 
overall outcome of vascular tone regulated by ROS is dependent on the relative production of 
both superoxide anion and H2O2.  
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 A recent murine study showed that endothelial dysfunction in a high fat diet could be 
associated with the presence of PVAT (Chadderdon, Belcik et al. 2014). Further, impaired H2O2 
production due to a reduction in SOD expression, contributes to the abolishment of anti-
contractile effects of obese PVAT (Marchesi, Ebrahimian et al. 2009). In Ossabaw obese swine, 
anti-contractile effects mediated by H2O2 were also markedly decreased by the presence of 
coronary PVAT (Gao, Zeng et al. 2005). Another mechanism to explain excessive oxidative 
stress on vascular dysfunction has been explored (Marchesi, Ebrahimian et al. 2009). It is 
believed that in the presence of PVAT oxidative stress, uncoupled endothelial NO synthase 
produces superoxide anions rather than NO, resulting in reduction of NO bioavailability, 
endothelial dysfunction and vasoconstriction (Marchesi, Ebrahimian et al. 2009). 
1.3.2.4. Dysregulation of PVAT-derived adipokines in obesity 
     Adipokines are a group of proteins secreted from adipocytes within PVAT in both a paracrine 
and endocrine manner (Ouwens, Sell et al. 2010). This protein family includes multiple 
components, such as leptin, adiponectin, resistin, chemerin, plasminogen activator inhibitor 1, 
adrenomedullin and visfatin (Ozen, Daci et al. 2015). Among them, leptin and adiponectin have 
received particular attention in a number of vascular diseases. 
      Leptin is a 167-amino acid paracrine-acting cytokine secreted by PVAT (Beltowski 2006). 
Recent studies have suggested that PVAT-derived leptin promotes a switch in vascular smooth 
muscle cell phenotype, from a contractile to synthetic phenotype (Li, Wang et al. 2014).  This 
switch in phenotype appears to involve a p38 mitogen-activated protein kinase (MAPK)-
dependent pathway and exacerbates vascular remodeling processes (Li, Wang et al. 2014). 
Interestingly, leptin has also been proposed to regulate vascular function by two distinct actions. 
On one hand, a very high concentration of leptin, much higher than concentrations seen in 
obesity, elicits a NO-dependent vasorelaxation response in isolated canine coronary arteries 
without any influence on coronary blood flow (Knudson, Dincer et al. 2005). On the other hand, 
obese epicardial PVAT- derived leptin blunts the coronary NO-dependent vasorelaxation 
response via a protein kinase C-β pathway (Payne, Borbouse et al. 2010).  Further, improved 
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endothelial dependent relaxation responses elicited by PVAT are seen in the presence of a leptin 
antagonist (Payne, Borbouse et al. 2010). Collectively, the available data are inconsistent, 
leading to the conclusion that the exact mechanism of leptin on vascular function requires further 
exploration. 
         Adiponectin is another important adipokine implicated in the cross-talk between PVAT and 
the vasculature. Adiponectin is a 244-amino acid polypeptide primarily secreted by adipocytes 
within PVAT. It has been demonstrated that adiponectin activates and up-regulates endothelial 
NO synthase, leading to increasing NO production and its beneficial effects on the cardiovascular 
system (Chen, Montagnani et al. 2003, Hattori, Suzuki et al. 2003). Furthermore, recent 
investigation has shown that PVAT-derived adiponectin stimulates Ca2+-activated potassium 
channels on vascular smooth muscle cells and mediates anti-contractile effects on vascular tone 
(Lynch, Withers et al. 2013). However, this anti-contractile capacity induced by adiponectin is lost 
in obesity during the development of adipocyte hypertrophy (Greenstein, Khavandi et al. 2009). 
Additional evidence  also shows that the loss of PVAT anti-contractile function correlates with 
lower levels of adiponectin in obese rat and human PVAT (Aghamohammadzadeh, Unwin et al. 
2015). Incubation of inflamed internal mammary artery with 10 μg/mL adiponectin for 6 hours has 
been shown to induce endothelial cell synthase phosphorylation and augment tetrahydrobiopterin 
bioavailability, eventually restoring endothelial cell synthase coupling (Margaritis, Antonopoulos et 
al. 2013). Induced release of adiponectin through administration of atrial natriuretic peptide has 
also been shown to activate adiponectin receptors on vascular smooth muscle cells, leading to 
downstream events including the phosphorylation of endothelial NO synthase, subsequent NO 
signaling and endothelium-dependent relaxation with the presence of PVAT(Withers, Simpson et 
al. 2014).  Overall, the available data suggest that adiponectin is a vaso-protective cytokine that 
participates in the anti-contractile function of PVAT and is beneficial for the maintenance of 
vascular antioxidant state in cardiovascular diseases. 
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       Aspects of the above discussion are summarized in Figure 1-2. Under physiological 
conditions, PVAT surrounding blood vessels provides a number of vasoactive anti-contractile 
factors, including ADRF, NO, H2S, leptin, adiponectin. These PVAT-derived factors act at a local 
level to attenuate vasoconstriction responses. Conversely, in obese conditions, expanded PVAT 
exhibits a higher degree of oxidative stress and inflammatory cytokines, as opposed to anti-
contractile factors of the normal state.  Thus inflamed PVAT alters the balance between 
vasoconstriction and vasodilation. 
 1.4. Immune cell infiltration and vascular dysfunction  
  It is generally accepted that T2DM is characterized by chronic low grade inflammation and 
vascular dysfunction (Stehouwer, Gall et al. 2002). As discussed, considerable evidence also 
suggests that alteration to the normal crosstalk between PVAT and blood vessels underlies 
cardiovascular disease present in T2DM (Szasz, Bomfim et al. 2013, Even, Dulak-Lis et al. 2014).  
As shown in Figure 1-2, the PVAT-derived vasoactive molecules are accompanied by a 
background amount of Treg cell, NKT cell, eosinophils and M2 macrophages (see also Figure 1-
1). Importantly, the presence of these immune cells contributes to the maintenance of an anti-
inflammatory environment in adipose tissue favoring the normal function of the PVAT-derived 
vasoactive molecules (Even, Dulak-Lis et al. 2014).  Under T2DM conditions, PVAT undergoes 
hypertrophy and remodeling processes, which trigger M1 pro-inflammatory phenotypic 
polarization and infiltration/accumulation of macrophages as well as other immune cells, including 
B and T lymphocytes (Gu and Xu 2013). The change in PVAT immune cell composition also 
alters the secretion profile favoring both inflammatory response and oxidative stress, which 
impairs the anti-contractile function of PVAT and subsequently leads to vascular endothelial 
dysfunction (Gu and Xu 2013).  
  Withers et al. have suggested that macrophages within PVAT are responsible for the 
increase in contractility of small resistance arteries when incubated with inflamed PVAT (Withers, 
Agabiti-Rosei et al. 2011). Consistent with this, depletion of macrophages in inflamed PVAT 
restores the anti-contractile capacity of PVAT and maintains vascular contractility in small arteries 
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(Withers, Agabiti-Rosei et al. 2011). These results provide a direct link between vascular 
contractility induced by PVAT and macrophage accumulation. Surprisingly, there are no other 
studies which have explored the association between vascular contractility induced by PVAT and 
the recruitment of other immune cells to PVAT, including dendritic cells. Therefore, future 
investigations are required to unveil the relationship between vascular contractility induced by 
PVAT and accumulation of varying immune cells.  
1.5. Rationale and Hypothesis 
       The prevalence of obesity is rising each year, and represents a major cause of global 
morbidity and mortality. Obesity is one of major risk factors for metabolic syndrome, insulin 
resistance and T2DM along with associated cardiovascular complications (Osborn and Olefsky 
2012). However, the mechanisms of obesity and T2DM remain poorly understood and efficient 
therapeutic treatment against T2DM and cardiovascular complications are still deficient. Recent 
studies have shown that obesity is tightly associated with chronic low-grade inflammation, 
especially in the expanded adipose tissue (Weisberg, McCann et al. 2003). More pro-
inflammatory cytokines , such as TNF-α and IL-6, are produced while fewer anti-inflammatory 
cytokines, such as adiponectin and IL-10, are generated (Franco Nitta 2013). This imbalance of 
pro-inflammatory and anti-inflammatory factors has recently been demonstrated to be associated 
with infiltration of multiple immune cells (including B and T lymphocytes, M1 macrophages and 
dendritic cells) into adipose tissue (Grant and Dixit 2015). Prior studies have confirmed that the 
pro-inflammatory cytokines, TNF-α (Zhang, Park et al. 2009) and IL-6 (Hartge, Unger et al. 2007), 
decrease NO bioavailability, resulting in impaired endothelial-dependent vascular dysfunction in 
obesity and T2DM. Further, these pro-inflammatory cytokines attenuate the anti-contractile 
function of PVAT on small arteries (Greenstein, Khavandi et al. 2009). These observations 
suggest a possible link between immune cell infiltration and ablation of anti-contractile activity of 
PVAT. Consistent with this, it has recently been demonstrated in rodent models that depletion of 
macrophages in inflamed adipose tissue restores anti-contractile capacity of PVAT on small 
resistance arteries (Withers, Agabiti-Rosei et al. 2011). However, the relationship between 
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dendritic cell infiltration into PVAT and the anti-contractile capacity of PVAT in obese and/or 
T2DM models is unknown. Thus studies described in this dissertation focused on the effects of 
dendritic cells on the anti-contractile response of PVAT from T2DM. The studies are divided into 
two main goals, which are fully discussed in the following sections.           
      The first goal of this work is to investigate whether dendritic cells are recruited into PVAT of 
T2DM and whether there is an alteration of inflammatory state of PVAT from T2DM. The following 
hypotheses were tested in Chapter II:  
a. Dendritic cells are predominately located in the PVAT rather than in the vascular wall. 
b. More dendritic cells accumulate in the PVAT derived from T2DM, compared to PVAT 
under physiological conditions. 
c. More pro-inflammatory cytokines and fewer anti-inflammatory cytokines are produced 
in PVAT from T2DM. 
The second goal of this work was to investigate whether dendritic cells are associated with the 
development of inflammatory state in adipose tissue from T2DM and whether infiltration of 
dendritic cells into PVAT was related to vascular dysfunction in T2DM. The following hypotheses 
were tested in Chapter III:  
a. Genetic depletion of dendritic cells restores the balance between pro-inflammatory 
and anti-inflammatory cytokine production in PVAT from T2DM. 
b. The anti-contractile function of PVAT on small arteries is diminished in T2DM rodent 
models, while dendritic cell depletion restores this function of PVAT.  
c. There is a progressive age-dependent impairment in the anti-contractile effects of 
PVAT in T2DM model and this is prevented by depletion of dendritic cells.  
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2.1. ABSTRACT 
 
Objective: It is well-accepted that obesity is associated with chronic inflammation and 
accumulation of multiple immune cells in adipose tissue. However, little information is available as 
to whether the development of type 2 diabetes (T2DM) is associated with imbalanced production 
of inflammatory factors and accumulation of CD11c+ immunocytes, including dendritic cells and 
macrophages in perivascular adipose tissue. Therefore, our study aimed to determine whether 
CD11c+ cells infiltrate into diabetic perivascular adipose tissue and whether diabetic perivascular 
adipose tissue exhibits an imbalance production of pro- and anti-inflammatory cytokines. Also, 
our study sought to test whether above changes would be impacted by disease progression.  
Methods:  db/db mice, a T2DM murine model, were divided into 6-10, 12-16, 18-22 and > 24 
weeks groups, along with their corresponding DbHET controls. Regional vasculatures and 
associated perivascular adipose tissue were collected. Subsequently, mRNA expression of 
CD11c, pro-inflammatory (tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6)) and anti-
inflammatory markers (adiponectin and interleukin 10 (IL-10)) were determined by real-time PCR. 
Identification of CD11c+ cells in adipose tissue was also performed by immunofluorescence 
staining and flow cytometry.  
Results: CD11c mRNA expression in multiple adipose tissues from db/db mice dramatically 
increased compared to DbHET mice. In contrast, regional arteries expressed very low CD11c 
mRNA levels. Flow cytometry data confirmed the presence of more CD11c+F4/80- and 
CD83+CD86+ dendritic cells accumulated in VAT from db/db mice compared to DbHET mice at 
both 6-10 and 18-22 weeks. Similarly, increasing numbers of CD11c+F4/80+ macrophages were 
also accumulated in VAT from db/db mice compared to controls at both age groups. In agreement 
with flow cytometry data, immunohistochemistry results showed the presence of more CD11c+ 
cells in the stromal vascular fraction of VAT from db/db than DbHET mice at both 6-10 and 18-22 
weeks. PCR data showed that pro-inflammatory cytokine TNF-α and IL-6 mRNA levels were 
higher in VAT and MAT from db/db mice compared to DbHET mice at both 6-10 and 18-22 weeks, 
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except that there was no significant difference of TNF-α expression between db/db and DbHET 
mice at 6-10 weeks. In contrast, mRNA levels of the anti-inflammatory cytokine adiponectin were 
lower in VAT from db/db mice than DbHET at both age groups. The decrease of adiponectin 
mRNA levels in MAT from db/db mice was only detected at 18-22 weeks. Interestingly, anti-
inflammatory cytokine IL-10 mRNA levels were increased in VAT and MAT from db/db, compared 
to DbHET mice at both age groups. Moreover, IL-10 mRNA levels were increased in MAT from 
db/db mice at 18-22 weeks compared to 6-10 weeks.    
Conclusion: In a model of T2DM, CD11c+ cells accumulate in the stromal vascular fraction of 
perivascular adipose tissue rather than in the vasculature wall, per se. More CD11c+ cells 
comprised of dendritic cells and M1 macrophages accumulated in diabetic adipose tissue. 
Moreover, increased pro-inflammatory cytokines and decreased anti-inflammatory mediators are 
produced in diabetic perivascular adipose tissue. This imbalanced production of inflammatory 
factors becomes more severe with the development of T2DM.   
Key Words: adipose tissue; type 2 diabetes; CD11c+ cells; dendritic cells; macrophages; TNF-
α; IL-6; adiponectin; IL-10.  
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2.2. Introduction 
       Obesity is defined as a pathological condition with a body-mass index (BMI) greater than 30 
kg/m2 (Flegal, Carroll et al. 2012). It has been reported that between the years of 1980 and 2013, 
the global incidence of obesity increased from 28.8% to 36.9% in men, and from 29.8% to 38% 
(Ng, Fleming et al. 2014). According to data from the world health organization (WHO) (Sundara 
Rajan and Longhi 2016), the prevalence of obesity in children and adolescents has also 
increased dramatically in the past two decades.  The development of obesity has been 
demonstrated to be associated with a variety of complications, including coronary heart disease, 
hypertension, type 2 diabetes (T2DM), cancers, sleep apnea, gallstones, osteoarthritis and 
infertility (Kahn, Hull et al. 2006). The most devastating complication of the above is T2DM, as 
this is a risk factor for the development of life threatening cardio/cerebrovascular diseases, 
particularly seen as coronary heart disease and stroke (Schlienger 2013).  Furthermore, diabetes 
became the 7th leading cause of death in United States, causing more than 200 million civilian 
deaths in 2010 (Chamberlain, Rhinehart et al. 2016).  As a result of these alarming statistics, 
worldwide health professionals are focusing their attention on research to discover effective 
interventions.   
       Growing evidence suggests that both obesity and T2DM share common pathological 
mechanisms (Ferreira, Silva et al. 2016, Genser, Casella Mariolo et al. 2016). Both diseases 
exhibit chronic low-grade, local and systemic, inflammation, which contribute to the pathogenesis 
of insulin resistance (Dandona, Aljada et al. 2004, Kahn, Hull et al. 2006). This chronic 
inflammation is characterized by an increase in expression of pro-inflammatory cytokines and a 
decrease in expression of anti-inflammatory factors. Specifically, evidence supports a role for pro-
inflammatory cytokine tumor necrosis factor-alpha (TNF-α) in mediating insulin resistance in both 
human and rodent models (Pina, Armesto et al. 2015, Al-Mutairi and Shabaan 2016). 
Administration of a TNF-α blocker in T2DM patients (Al-Mutairi and Shabaan 2016) or genetic 
depletion of TNF-α ligand in mice (Uysal, Wiesbrock et al. 1997) partially ameliorates obesity-
induced insulin resistance. Another inflammatory marker interleukin-6 (IL-6), also has been found 
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to induce insulin resistance in adipocytes (Rotter, Nagaev et al. 2003) and is strongly correlated 
with the occurrence of T2DM (Almuraikhy, Kafienah et al. 2016, Liu, Feng et al. 2016). 
Adiponectin, as an important anti-inflammatory cytokine, has been shown to increase insulin 
sensitivity in adipocytes and decrease insulin resistance in obese mice (Yamauchi, Kamon et al. 
2001, Kadowaki, Yamauchi et al. 2006). Thus evidence supports the concept that T2DM is 
positively correlated with elevated levels of inflammatory cytokines TNF-α and IL-6, and 
negatively correlated with lower levels of adiponectin (Daniele, Guardado Mendoza et al. 2014, 
Liu, Feng et al. 2016).   
     Another feature of chronic inflammation in T2DM is increasing infiltration of immune cells, 
particularly macrophages, into adipose tissue (Ye, Gao et al. 2007). It has been demonstrated 
that diet-induced obesity leads to accumulation of macrophages in inflamed visceral adipose 
tissue (Weisberg, McCann et al. 2003, Lumeng, Bodzin et al. 2007). Moreover, these 
macrophages in obese adipose tissue are activated to switch their phenotype from M2 anti-
inflammatory to M1 pro-inflammatory form (Curat, Wegner et al. 2006, Lumeng, Bodzin et al. 
2007, Kraakman, Murphy et al. 2014). As an extension of this, it is thought that accumulated M1 
macrophages are a prominent source of TNF-α and IL-6 production, which subsequently impair 
insulin signaling in adipocytes, leading to obesity-associated insulin resistance (Lumeng, Bodzin 
et al. 2007). Apart from macrophages, CD8+ effector T cells also accumulate in epididymal 
adipose tissue in obese mice fed with a high-fat diet (Wu, Ghosh et al. 2007, Nishimura, Manabe 
et al. 2009). In contrast, the number of CD4+ T cells and regulatory T cells are lower in adipose 
tissue of the obese mice. Interestingly, the recruitment of CD8+ effector T cells has been shown to 
precede the infiltration of M1 macrophages into adipose tissue, which amplifies TNF-α production 
and aggravates adipose tissue inflammation (Nishimura, Manabe et al. 2009). Consistent with 
this, inhibition of CD8+ T cells by treatment with neutralizing antibodies not only significantly 
reduced M1 macrophage accumulation in adipose tissue, but also decreased pro-inflammatory 
TNF-α and IL-6 secretion in epididymal fat pads. Importantly, this also resulted in improvement of 
glucose tolerance and reduction of insulin resistance in diet-induced obese mice (Nishimura, 
Manabe et al. 2009). Interestingly, B lymphocytes have also been found to infiltrate into obese 
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adipose tissue from high fat diet treated mice (DeFuria, Belkina et al. 2013, Shaikh, Haas et al. 
2015). It is believed that B lymphocytes present antigens to T lymphocytes and activate both 
CD8+ effector T lymphocytes and M1 macrophages (Shaikh, Haas et al. 2015). This maneuver 
amplifies the production of a series of pro-inflammatory cytokines and promotes the development 
of chronic inflammation as well as insulin resistance in adipose tissue of obese mice. With the 
investigation of potential mechanisms of obesity-associated insulin resistance, other types of 
immune cells have been discovered to participate in the chronic inflammation in adipose tissue, 
such as natural killer cells, mast cells and eosinophils (Franco Nitta 2013, Seijkens, Kusters et al. 
2014).  Thus it appears that in obesity, the interplay among these immune cells within adipose 
tissue orchestrates the secretions of pro-inflammatory and anti-inflammatory mediators, which 
promote the development of chronic inflammation and T2DM.  
     CD11c is an integrin alpha X chain protein expressed on the cell surface of lymphocytes, 
predominantly on dendritic cells and M1 macrophages. Dendritic cells are well known to locate in 
a variety of tissues, including brain (Shi, Shen et al. 2011), spleen (Yang, Hu et al. 2006), lung 
(Patsouris, Li et al. 2008), liver (Pillarisetty, Shah et al. 2004) and intestine (Schulz, Jaensson et 
al. 2009). Accumulated evidence has demonstrated that dendritic cells also infiltrate into the 
vascular wall and accelerate the progression of atherosclerosis in rodent models (McArdle, 
Mikulski et al. 2016, Rombouts, Ammi et al. 2016).  To date, however, there is little evidence 
documenting a role for dendritic cells in the development of T2DM. It is also unclear whether 
dendritic cells accumulate in the vasculature or adipose tissue during the development of T2DM. 
Further, although it is known that M1 macrophages are recruited into adipose tissue in the context 
of diet-induced obesity, it is still uncertain whether M1 macrophages also infiltrate into 
perivascular adipose tissue in T2DM rodent models. Therefore, the purpose of this study was to 
determine whether CD11c+ cells would be associated with the development of T2DM by using the 
Leprdb mouse model, which is genetically depleted of leptin receptors. We hypothesized that the 
majority of CD11c+ cells are recruited into perivascular adipose tissue in T2DM mice, rather than 
the vasculature. Moreover, the increased numbers of CD11c+ cells in adipose tissue of T2DM is 
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hypothesized to be accompanied by increased secretion of pro-inflammatory cytokines and the 
decreased production of anti-inflammatory mediators.  
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2.3. Methods 
Animal Model 
   Male and female heterozygous mice (mLeprdb, DbHET mice) on C57BLKS/J background were 
purchased from Jackson Laboratory and used as breeding pairs to produce homozygous T2DM 
mice (Leprdb, db/db mice) and DbHET mice. All the above mice were maintained on a normal 
rodent chow diet and housed in a temperature and humidity controlled (25°C) facility with a 12-
hour light/dark cycle. Mice were subsequently divided into four age groups: 6-10 weeks, 12-16 
weeks, 18-22 weeks and more than 24 weeks groups.  Non-fasting blood glucose measurements 
were performed using ReliOn prime blood glucose monitoring system (ReliOn Company, WA, 
USA) on each mouse before administration of anesthesia. A surgical plane of anesthesia was 
induced by intraperitoneal injection of sodium Nembutal (60mg kg-1) (Sigma Company, Cream 
Ridge, NJ, USA) (Kato, Kashiwagi et al. 2006) and then tissues were collected. Total body weight, 
intestinal mesentery weight and weights of various adipose tissues were recorded. Mice were 
euthanized after anesthesia and tissue collection. All animal procedures were conducted in 
accordance with protocols approved by the Laboratory Animal Care and Use Committee at 
University of Missouri, Columbia.  
Measurement of mRNA expression  
After anesthesia, the spleen and visceral (VAT), mesenteric (MAT), periaortic (ATA), and 
pericardial (AH) adipose tissues were collected along with segments of first or second order 
mesenteric arteries (MA), thoracic aorta (TA), left anterior descending coronary artery (LAD) were 
dissected and snap frozen in liquid N2. Tissues were subsequently prepared for measurement of 
mRNA expression using real-time, quantitative, polymerase chain reaction (qPCR). Total RNA of 
VAT, MAT, ATA and AH were extracted by RNeasy lipid tissue mini kits (Qiagen Company, 
Valencia, CA, USA). Total RNA of spleen was similarly extracted by the RNeasy mini kit (Qiagen). 
Total RNA of MA and LAD were extracted by Arcturus Pico Pure RNA isolation kit (Life 
Technologies Company, Grand Island, NY, USA). Total RNA of TA was extracted by RNeasy 
57 
 
fibrous tissue mini kit (Qiagen). The quality and quantity of total RNA were measured using a 
Nano Drop ND-1000 Spectrophotometer (Nano Drop Technologies, Wilmington, DE). cDNA was 
reverse transcribed using equal amounts of total RNA by the SuperScript III First-Strand 
Synthesis System (Invitrogen Company, Grand Island, NY, USA). Amplification of cDNA was 
conducted using Platinum® SYBR® Green qPCR SuperMix-UDG (Invitrogen) and an iQ5 Real-
Time PCR system (Bio-Rad company, Hercules, CA, USA). qPCR reactions were performed 
according to the following protocol: 2 minute reactions at 50° C and 95 °C followed by 40 cycles 
of 95°C 3s and 56°C 30s. Melting/dissociation curves were performed on each well to assure 
specificity of the amplicon product. “No template” cDNA was used as a negative control in each 
plate to detect contamination. The housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used for internal normalization. Spleen cDNA from a male DbHET 
mouse at 12 weeks was used as a calibrator. The same calibrator sample was included in all 
PCR reactions together with cDNA samples from the various adipose tissue and blood vessel 
samples. Primers were used as follows in Table.2-1:  
Table. 2-2. Properties of Primers for q PCR detection in DbHET and db/db mice 
Target gene Primer sequence  Amplification  
efficiency 
CD11c F:5’-CTGGATAGCCTTT 
CTTCTGCTG-3’ 
1.97 
R:5’-GCACACTGTGTCC 
GAACTCA-3’ 
GAPDH F:5’-AATGGTGAAGGTC  
GGTGTG-3’ 
1.99 
R:5’-GTGGAGTCATACT 
GGAACATGTAG-3’ 
TNF-α F:5’-GTCCCCAAAGGGA 
TGAGAAG-3’ 
1.98 
R:5’-CACTTGGTGGTTT  
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GCTACGA-3’ 
IL-6 F:5’-CCGGAGAGGAGA 
CTTCACAG-3’ 
1.98 
R:5’-TCCACGATTTCCC 
AGAGAAC-3’ 
Adiponectin F:5’-GTCTCACCCTTAG 
GACCAAGAA-3’ 
1.99 
R:5’-AGGTTGGATGGCA 
GGC-3’ 
IL-10 F:5’-ATGGCCTTGTAGA 
CACCTTG-3’ 
1.98 
R:5’-GTCATCGATTTCT 
CCCCTGTG-3’ 
The mean threshold cycle (CT) values were calculated by the 2-ΔΔCT method (ΔΔCT=CT.CD11c-
CT.GAPDH) (Pfaffl 2001). Results were presented as fold change of transcripts for CD11c 
normalized to GAPDH, compared with the calibrator (defined as 1.0 fold). mRNA levels of TNF-α, 
IL-6, adiponectin and IL-10 were presented as fold change of transcripts for different inflammatory 
cytokines normalized to GAPDH, compared to DbHET mice at 6-10 weeks (defined as 1.0 fold).   
Isolation of Stromal Vascular Fraction from Adipose Tissue 
     VAT was harvested from both db/db and DbHET mice at 6-10 and 18-22 weeks of age. The 
tissue was then placed in freshly prepared buffer containing 1x Phosphate Buffered Saline 
(Ca/Mg2+ free) (Gibco Company, Waltham, MA, USA), 0.5% bovine serum albumin (Sigma-
Aldrich Company, Cream Ridge, NJ, USA) and 10mM CaCl2. Sterile scissors were used to mince 
adipose tissue into fine particles (< 10 mg). Type II collagenase purified from Clostridium 
histolyticum (Sigma-Aldrich Company, Cream Ridge, NJ, USA) at a concentration of 2 mg/ml was 
added to the minced adipose tissue, mixed and incubated at 37° C (20 minutes) on an orbital 
shaker (Thermo Scientific Company, Philadelphia, PA, USA). Enzymatic digestion was terminated 
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by 1 mM EDTA. The solution was then passed through a sterile 100-μm nylon strainer (Fisher 
Scientific Company, Waltham, MA, USA) and the suspension centrifuged at 1600 rpm for 5 
minutes at room temperature. The suspension was separated into two divisions. The upper layer 
or supernatant contained ‘floating’ cells and is referred to as the adipocyte-enriched fraction. The 
pellet was collected as the stromal vascular cell fraction. The stromal vascular fraction was then 
re-suspended in erythrocyte lysis buffer (Bio legend Company, San Diego, CA, USA) and 
incubated at room temperature for 5 minutes without shaking. 1x Phosphate Buffered Saline 
depleted of Ca2+ and Mg2+ was then added to the samples to terminate the lysis reaction. The 
suspension was subsequently centrifuged at 1600 rpm for 5 minutes at 4 °C and the pelleted 
cells were considered to be the erythrocyte-depleted stromal vascular fraction cells and re-
suspended in 1x Phosphate Buffered Saline without Ca2+ and Mg2+.  
 
Flow Cytometry  
The erythrocyte-depleted stromal vascular fraction was cooled in ice for 10 minutes and cell 
number determined using a hemcytometer. Cell survival was determined by Trypan blue (0.4% 
solution) (Sclen Cell Research Laboratories, Carlsbad, CA, USA). Cell survival rate was 
determined to be approximately 90%. After cell number and survival rate measurements, cells 
were centrifuged at 1600 rpm for 5 minutes at 4°C. After aspiration of the supernatant, pelleted 
cells were then re-suspended in flow cytometry staining buffer (E-bioscience Company, San 
Diego, CA, USA). After cells were washed twice with flow cytometry staining buffer, the final cell 
count was approximately 1 ×106 cell counts/ml. To prevent non-specific binding of antibodies, Fc-
blocker (1 μg/ml, sigma-Aldrich Company, Cream Ridge, NJ, USA) was added to the samples 
and then incubated in the refrigerator at 4 ° C for 15 minutes in the absence of light. Without any 
washing, the following antibodies and corresponding isotype controls in Table 2-2 were incubated 
with above cells in the dark at 4°C for 45 minutes. 
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 Table.3-2. Properties of antibodies for flow cytometry measurements in DbHET and db/db 
mice.  
Antibody Conjugated 
fluorochrome 
Commercial 
Company  
Dilution 
CD11c antibody APC 
(Allophycocyanin) 
BD Pharmingen 
Company, San Jose, 
CA, USA 
1:200 
F4/80 antibody PE (phycoerythrin)  E-bioscience 
Company, San Diego, 
CA, USA 
1:400 
CD83 antibody APC Bio legend Company, 
San Diego, CA, USA 
1:200 
CD86 antibody PE E-bioscience 
Company, San Diego, 
CA, USA 
1:200 
      Following this, 2ml flow cytometry staining buffer was added to wash the cell samples. The 
suspension was then centrifuged at 1600 rpm at 4 ° C for 5 minutes and the pelleted cells re-
suspended in 2 ml flow cytometry staining buffer. This washing procedure was repeated twice. 
Cells were then identified in CyAn ADP High-Performance Flow Cytometer according to the 
expression of fluorochromes. The Summit and Flowjo software were used to quantify 
CD11c+F4/80- and CD83+CD86+ dendritic cell populations as well as the CD11c+F4/80+ 
macrophage population.  
Immunohistochemical Identification of CD11c+ cells  
     VAT was harvested from DbHET and db/db mice at 6-10 and 18-22 weeks and samples fixed 
in 10% formalin (Sigma Company, Cream Ridge, NJ, USA) for 18-24 hours. Tissue samples were 
then embedded in paraffin and cut into 5 μm thick sections (Wentworth, Naselli et al. 2010). 
Sections were then de-paraffinized with xylene and series concentrations of ethanol at 100%, 
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95%, 75% and 50%. After deparaffinization, all the sections were incubated in sodium citrate 
buffer (10mM Sodium Citrate, 0.05% Tween 20, pH 6.0) around 100° C for 20 minutes. Following 
this antigen retrieval step, VAT sections were incubated with 10% goat serum at room 
temperature for 1 hour to prevent nonspecific binding of the primary antibodies. Tissue sections 
were then incubated (4°C) overnight with hamster anti-mouse CD11c primary antibodies (1:200 
dilution, Abcam Company, Cambridge, United Kingdom). After washing with TBS (Tris-Buffered 
Saline), VAT sections were incubated at room temperature for 3 hours with goat anti-hamster 
secondary antibodies conjugated with Texas-Red (1:1000 dilution, Abcam Company, Cambridge, 
United Kingdom). Nuclei were identified by DAPI (4', 6-diamidino-2-phenylindole) staining 
(1mg/ml) (Invitrogen, Carlsbad CA, USA). Fluorescence staining was visualized using an 
Olympus microscope (model IX81).  To evaluate the presence of CD11c+ cells in VAT, adipocytes 
and CD11c+ cells were counted from 10 random high power view fields (×200) on each section 
(Kosteli, Sugaru et al. 2010, Zhang, Sugiyama et al. 2011). Six sections were collected from each 
mouse and the percentage of CD11c+ cells for each sample expressed as the sum of the number 
of CD11c-expressing cells divided by the total number of surrounding adipocytes in each field of 
view (Kosteli, Sugaru et al. 2010).  
Statistical Analysis 
     All data are presented as mean ± SEM. Basic parameters of mice and CD11c mRNA levels 
were analyzed with two-way Analysis of variance (ANOVA), while the flow cytometry data, 
immunohistochemistry analysis and inflammatory cytokine mRNA levels were analyzed by one-
way ANOVA using Graph pad Prism 4.0 software (Graph pad Company, CA, USA). The post-hoc 
test used in one-way ANOVA was Tukey’s test. The P value < 0.05 was considered statistically 
significant. 
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2.4. Results 
Characteristics of regional perivascular adipose tissues  
       To determine the impact of diabetic duration on phenotypic changes of T2DM mice, db/db 
and DbHET mice were studied at 6-10 weeks, 12-16 weeks, 18-22 weeks and > 24 weeks of age. 
db/db mice had higher non-fasting glucose levels (Fig. 2-1-B) and were more obese than DbHET 
controls at each age group (Fig. 2-1-A). In addition to increased whole body weight, db/db mice 
exhibited increased weights of VAT (Fig. 2-1-C) and perivascular adipose tissue compared to 
DbHET mice (Fig. 2-1-D-F).  VAT and perivascular adipose tissue weights did not, however, 
significantly change with age in T2DM mice. Taken together, db/db mice had higher body weight 
and non-fasting glucose levels than control mice, accompanied with heavier VAT and 
perivascular adipose tissue weights, including intestinal mesentery, AH, and ATA. However, 
those parameters were not significantly altered with the development of T2DM.  
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Expression of CD11c mRNA levels on different vasculature  
Since dendritic cells and macrophages have been found in the walls of blood vessels and have 
been implicated in both the induction and progression of inflammation in atherosclerosis of 
murine thoracic aorta (Chistiakov, Sobenin et al. 2015, Van Brussel, Ammi et al. 2015), we 
hypothesize that CD11c+ cells also may accumulate in different vasculatures from T2DM mice. To 
test this postulation, regional arteries were collected from DbHET and db/db mice at four different 
age groups as aforementioned. RNA was extracted from all the samples and reverse-transcribed 
into cDNA. The cDNA samples were then transcribed and amplified into RNA via qPCR reactions. 
A spleen sample from a male mouse at 12 weeks was used as a calibrator for each PCR reaction. 
The purpose of calibrator was to compare CD11c m RNA expression between adipose tissue and 
their corresponding vasculature. 
Figure 2-1. Basic characteristics of study groups. A-F: body weight (A); non-fasting 
blood glucose (B); VAT weight (C); intestinal mesentery weight (D); AH weight (E); ATA 
weight (F) in heterozygous control (DbHET) and diabetic (db/db) mice. db/db mice 
showed greater body weight and increased non-fasting blood glucose level compared to 
DbHET mice. db/db mice exhibited significantly greater weights of intestinal mesentery 
and multiple perivascular adipose tissues compared to DbHET mice. These increases in 
these variables were similar, however, in all four age groups of db/db mice. Data are 
presented as mean ± SEM. * P <0.05 between db/db and DbHET mice.   
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Extremely low levels of CD11c mRNA expression were detected in the TA, MA and LAD 
samples from DbHET and db/db mice compared to the spleen calibrator (Fig.2-2). Furthermore, 
there were no significant differences of CD11c mRNA expression in vascular walls across T2DM 
duration in either DbHET or db/db mice.  
 
Expression of mRNA for CD11c in regional perivascular adipose tissue 
samples   
 A growing body of evidence has demonstrated that adipose tissue harbors various immune 
cells in the development of obesity (Grant, Youm et al. 2013, Grant and Dixit 2015). It is 
hypothesized that CD11c+ cells would also be recruited into perivascular adipose tissue in the 
Figure 2-2. Vascular wall CD11c mRNA expression.  A-C: In the vascular walls of 
TA (A), MA (B) and LAD (C), no significant differences of CD11c mRNA expression 
were detected between DbHET and db/db mice at any age group examined. n=6 in 
each column, including 3 female and 3 male mice. Data were showed in means ± 
SEM.   
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development of T2DM. To test this hypothesis, multiple perivascular adipose tissues were 
collected from both DbHET and db/db mice at the four different age groups. CD11c mRNA levels 
were again detected by qPCR. CD11c mRNA levels were strikingly increased in VAT (Fig. 2-3-A) 
and MAT (Fig. 2-3-B) of both DbHET and db/db mice, compared to the previously described 
splenic calibrator. Further, CD11c mRNA levels were significantly greater in VAT (Fig. 2-3-A), 
MAT (Fig. 2-3-B), AH (Fig. 2-3-C) and ATA (Fig. 2-3-D) from db/db mice compared to age-
matched DbHET controls. Higher CD11c mRNA levels in AH of db/db mice (Fig. 2-3-C) were 
evident at the age greater than 18 weeks compared to DbHET controls. CD11c mRNA levels in 
VAT and MAT were higher in db/db mice at > 24 weeks, compared to db/db mice at  6-10 and 12-
16 weeks groups, consistent with a duration of diabetes-dependent effect. In contrast, in DbHET 
mice, CD11c mRNA expression of VAT, MAT, AH and ATA remained constant among all the four 
age groups, suggesting the lack of an aging effect. Comparing CD11c mRNA levels of DbHET 
and db/db mice at > 24 weeks, the largest fraction of CD11c mRNA expression in db/db mice was 
located in VAT and MAT (Fig. 2-3-E). In contrast, CD11c mRNA levels in DbHET mice were 
comparable among VAT, MAT, AH and ATA, and significantly lower than db/db mice. Combined 
with the data in Fig.2-2, these results suggest that in this T2DM model, the majority of CD11c+ 
cells accumulate in the perivascular adipose tissue, rather than in the vascular wall, itself.   
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Quantification of CD11c+ cells in VAT by flow cytometry  
      It has previously been shown that the majority of CD11c+ cells consist of two different 
subsets of immune cells: dendritic cells and M1 macrophages (Kassim, Rajasagi et al. 2006, Li, 
Lu et al. 2010). Our previous data showed that CD11c mRNA levels were elevated in VAT 
obtained from db/db mice compared to DbHET mice. However, it is still unclear whether, in 
diabetes, the numbers of dendritic cells or M1 macrophages (or both) are increased in adipose 
tissue during the development of T2DM. To quantify the numbers of dendritic cells and M1 
Figure 2-3. CD11c mRNA expression on different perivascular adipose tissue. A-B: 
Higher CD11c mRNA levels were observed in VAT (panel A) and MAT (panel B) from db/db 
than DbHET mice in all the age groups. C: db/db mice showed higher CD11c mRNA 
expression on AH than DbHET mice only at 18-22 and > 24 weeks groups. D: Higher CD11c 
mRNA levels were observed in ATA from db/db than DbHET mice at each age group. E: 
CD11c m RNA expression in VAT, MAT, AH and ATA from DbHET and db/db mice at > 24 
weeks. n=6 in each column, including 3 female and 3 male mice. Data were showed in 
means ± SEM. *: P < 0.05 between db/db and DbHET mice. $: P < 0.05 among all the four 
age groups from db/db mice.  
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macrophages, flow cytometry was performed on VAT from both DbHET and db/db mice. In this 
study, we identified the dendritic cells with two combinations of cell surface molecular markers: 
CD11c+F4/80- and CD83+CD86+ cells (Stefanovic-Racic, Yang et al. 2012). The M1 macrophages 
were identified as the CD11c+F4/80+ cells (Lumeng, Bodzin et al. 2007). In order to study the 
influence of duration of T2DM, we examined 6-10 and 18-22 weeks groups.  As shown in Fig. 2-4, 
an approximate 2 fold increase in CD11c+F4/80- dendritic cells (Fig. 2-4-A, B) and a 2.5 fold 
increase in CD83+CD86+dendritic cells (Fig. 2-4-D, E) were detected in VAT from db/db mice 
compared to DbHET at both 6-10 and 18-22 weeks. The numbers of CD11c+F4/80- and 
CD83+CD86+dendritic cells in diabetic mice were similar in both the 6-10 and 18-22 week groups 
(Fig. 2-4-A, B, 2-4-D, E). Similarly, no significant differences in dendritic cell numbers were 
detected in DbHET at 6-10 and 18-22 weeks (Fig 2-4-B, E). Along with the increase in dendritic 
cells, db/db mice showed 2 fold increase of CD11c+F4/80+ M1 macrophages (Fig. 2-4-A, C) in 
VAT compared to DbHET controls. Similarly to the dendritic cell, there was no significant change 
in M1 macrophage numbers in VAT of db/db mice at both 6-10 and 18-22 weeks groups (Fig. 2-
4-A, C). Furthermore, no significant differences in M1 macrophage numbers were apparent in 
DbHET mice between 6-10 and 18-22 week groups (Fig. 2-4-A, C). Collectively, the results 
suggest that, at protein levels, more CD11c+ cells, including both dendritic cells and M1 
macrophages were recruited into VAT of diabetic mice, compared to DbHET. However, there 
were no significant changes in CD11c+ cell numbers in VAT with respect to duration of disease 
development. 
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Immunohistochemical location of CD11c+ cells in VAT  
      We next investigated the location of the CD11c+ cell population within the adipose tissue by 
immunohistochemical examination in sections of VAT from db/db mice and DbHET control (6-10 
and 18-22 week time-points). Fig.2-5-A depicts a bright field image for the membrane and shape 
of the adipocytes in VAT. In both DbHET and db/db mice, CD11c+ cells were located within the 
stromal vascular fraction of VAT, between the adipocytes. To provide a quantitative measurement, 
the relative number of CD11c+ cells was estimated by counting the number of positive signals 
(crown-like structure) and divided by the number of surrounding adipocytes in Fig.2-5-B 
(Hellmann, Tang et al. 2011, Zhang, Sugiyama et al. 2011). Consistent with our flow cytometry 
data, the immunohistochemical data showed that a greater number of CD11c+ cells infiltrated into 
Figure. 2-4. Dendritic cells and M1 macrophages infiltrate into VAT in db/db mice at 
both 6-10 and 18-22 weeks. A: Identification of dendritic cells (CD11c+F4/80- cells, in the left 
upper quadrant) and M1 macrophages (CD11c+F4/80+ cells, in the right upper quadrant) in 
flow cytometry analysis were shown. B-C: Dendritic cells and M1 macrophages were 
quantified as percentage of all stromal vascular fraction cells from VAT. No significant 
difference of CD11c+F4/80- dendritic cells or CD11c+F4/80+ M1 macrophages was observed 
between 6-10 and 18-22 weeks in either DbHET or db/db mice. D: Identification of dendritic 
cells (CD83+CD86+ cells, in the right upper quadrant) in flow cytometry analysis was shown. 
E: Quantification of CD83+CD86+ dendritic cells as percentage of all stromal vascular fraction 
cells. There was no significant difference of CD83+CD86+ dendritic cells between 6-10 and 
18-22 weeks in either DbHET and db/db mice. Data were shown in means ± SEM. * : P < 
0.05 between DbHET and db/db mice. 
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VAT of db/db mice compared to that in DbHET controls; at both 6-10 and 18-22 weeks of age. 
Also consistent with the flow cytometry data, db/db mice at 6-10 weeks expressed similar 
numbers of CD11c+ cells in VAT compared to db/db mice at 18-22 weeks. Similarly, there was no 
apparent difference in CD11c+ cell numbers in VAT from DbHET mice between 6-10 and 18-22 
weeks. 
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Effect of T2DM on Inflammatory cytokine mRNA expression in adipose 
tissue 
Obesity is reported to be associated with altered adipokine production, which regulates 
systemic and local chronic inflammation (Wronkowitz, Romacho et al. 2014, Lastra and Manrique 
2015). Since T2DM appears to share similar pathological process with obesity, it is conceivable 
that in diabetes, perivascular adipose tissue exhibits an inflammatory environment due to greater 
pro-inflammatory cytokine production together with diminished availability of anti-inflammatory 
mediators. In order to test this hypothesis, VAT and MAT were collected from db/db and DbHET 
mice at both 6-10 and 18-22 weeks of age. mRNA levels of pro-inflammatory cytokines TNF-α 
and IL-6, anti-inflammatory mediators adiponectin and IL-10, were subsequently detected by 
qPCR.  
Figure 2-5. Distribution of CD11c+ cells in VAT of DbHET and db/db mice. A: 
Immunofluorescence staining of CD11c+ cells in paraffin-embedded VAT sections from 
DbHET and db/db mice at both 6-10 and 18-22 weeks. BF = bright field vision of VAT. 
CD11c+ cells were stained in Texas Red. Nuclei were stained in blue color (DAPI). 
Scale bar represented 50 μm. Sections from six mice were analyzed for each staining.  
B: Quantitative analysis of the extent of CD11c+ cells infiltration into VAT. CD11c+ cells 
were analyzed and plotted as the mean ± SEM from six independent experiments. n=6. 
There was no significant difference of CD11c+ cells in VAT of db/db mice between 6-10 
and 18-22 weeks.  *: P < 0.05 between DbHET and db/db mice.  
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 At both 6-10 and 18-22 weeks, a significant increase of TNF-α mRNA level was detected in 
VAT from db/db mice, compared to their respective DbHET controls (Fig.2-6-A). Moreover, db/db 
mice at 18-22 weeks expressed higher TNF-α mRNA level than db/db mice at 6-10 weeks. 
Similarly, IL-6 mRNA levels in VAT were increased in db/db mice at both 6-10 and 18-22 weeks, 
compared to DbHET controls. However, no significant change of IL-6 mRNA expression in VAT 
was detected in db/db mice between 6-10 and 18-22 weeks (Fig.2-6-B). As with anti-
inflammatory mediator adiponectin mRNA expression, dramatically decreased levels were found 
in VAT from db/db mice, compared to DbHET mice at both age groups (Fig. 2-6-C). We did not, 
however, observe any significant change of adiponectin mRNA levels in VAT from db/db mice 
between 6-10 and 18-22 weeks of age. Unexpectedly, in contrast to adiponectin, we detected a 
significant increase of anti-inflammatory cytokine IL-10 mRNA level in VAT from db/db mice at 18-
22 weeks compared to the DbHET control, whereas no significant change of IL-10 mRNA level 
was observed between db/db and DbHET mice at 6-10 weeks (Fig.2-6-D). In summary, VAT from 
diabetic mice shows increased mRNA expressions of pro-inflammatory cytokines TNF-α and IL-6, 
along with anti-inflammatory mediator IL-10. Conversely, a reduction of mRNA level of anti-
inflammatory mediator adiponectin occurs in VAT from diabetic mice.  
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          As shown in Fig. 2-7-A, a significantly increased level of TNF-α mRNA was found in MAT 
from db/db mice, compared to DbHET controls at 18-22 weeks. Additionally, db/db mice at 18-22 
weeks had higher TNF-α mRNA level in MAT than db/db mice at 6-10 weeks, whereas no 
significant difference of TNF-α mRNA levels was observed between db/db and DbHET mice at 6-
10 weeks. Similarly to VAT, increased IL-6 mRNA levels were found in MAT from db/db mice in 
comparison to DbHET controls at both age groups  (Fig. 2-7-B). However, there was no 
significant difference of IL-6 expression in db/db mice between 6-10 and 18-22 weeks. 
Unexpectedly, no significant difference of adiponectin mRNA expression in MAT was observed 
between db/db and DbHET controls at 6-10 weeks. In contrast, in 18-22 weeks, db/db mice had 
significantly lower adiponectin mRNA levels in MAT than DbHET mice (Fig. 2-7-C). Interestingly, 
a significant higher IL-10 mRNA level was detected in db/db mice at 18-22 weeks, compared to 
their DbHET controls (Fig. 2-7-D). Meanwhile, db/db mice from 18-22 weeks had higher IL-10 
mRNA expression in MAT than db/db mice from 6-10 weeks, whereas IL-10 mRNA expression 
was comparable between db/db and DbHET mice at 6-10 weeks. In summary, MAT from diabetic 
Figure 2-6. Gene expression of pro-inflammatory cytokines and anti-
inflammatory mediators in VAT. A. Pro-inflammatory cytokine TNF-α mRNA levels 
of db/db and DbHET mice at both 6-10 and 18-22 weeks. B. Pro-inflammatory 
cytokine IL-6 mRNA levels of db/db and DbHET mice at both 6-10 and 18-22 weeks. 
C. Anti-inflammatory mediator adiponectin mRNA levels of db/db and DbHET mice at 
both 6-10 and 18-22 weeks. D. Anti-inflammatory mediator IL-10 mRNA levels of 
db/db and DbHET mice at both 6-10 and 18-22 weeks. Data were presented as the 
mean ± S.E.M. One way- ANOVA statistical analysis was performed. *: P < 0.05.  
75 
 
mice have increased mRNA levels of pro-inflammatory cytokines TNF-α and IL-6, and fewer anti-
inflammatory mediator adiponectin. Unexpectedly, anti-inflammatory cytokine IL-10 mRNA 
expression is elevated in MAT with the progression of T2DM. 
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Figure 2-7. Gene expression of pro-inflammatory cytokines and anti-inflammatory 
mediators in MAT. A. Pro-inflammatory cytokine TNF-α gene expression of db/db and 
DbHET mice at both 6-10 and 18-22 weeks. B. Pro-inflammatory cytokine IL-6 gene 
expression of db/db and DbHET mice at both 6-10 and 18-22 weeks. C. Anti-inflammatory 
mediator adiponectin gene expression of db/db and DbHET mice at both 6-10 and 18-22 
weeks. D. Anti-inflammatory mediator IL-10 gene expression of db/db and DbHET mice at 
both 6-10 and 18-22 weeks. Data were presented as the mean ± S.E.M. One way-ANOVA 
statistical analysis was performed. *: P < 0.05. 
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2.5. Discussion 
The studies had three principal aims, the first being to identify whether CD11c+ cells 
accumulated in the perivascular adipose tissue and/or in the vascular wall. The second aim was 
to determine whether more dendritic cells accumulated in perivascular adipose tissue over the 
duration of T2DM. The last aim was to examine whether a chronic state of inflammation was 
evident in perivascular adipose tissue and whether this was affected by the duration of T2DM. 
Our data indicate that CD11c+ cells accumulate in perivascular adipose tissue rather than in the 
vascular wall. Further, a greater number of M1 macrophages and dendritic cells accumulate in 
VAT of diabetic mice compared to their normoglycemic, non-obese controls. Associated with this 
is an increased production of perivascular adipose tissue pro-inflammatory cytokines and 
decreased production of anti-inflammatory mediators found in T2DM animals.  
  Consistent with previous studies, db/db mice were much heavier than their heterozygote 
controls and this was accompanied by a large expansion of VAT and perivascular adipose tissues. 
With the progression of T2DM, total body weight and the expansion of adipose tissue remained 
constant, consistent with other reports (Koya, Haneda et al. 2000, Martinez-Botas, Anderson et al. 
2000). In agreement with other findings, db/db mice exhibited significantly higher non-fasting 
glucose levels compared to DbHET mice, indicating that db/db mice qualified as a T2DM murine 
model in the current study (Koya, Haneda et al. 2000, Xie, Zhou et al. 2002).  
      Dendritic cells have been identified to cluster with T lymphocytes in atherosclerotic lesions of 
thoracic aorta at the early stage of atherosclerosis and are believed to promote plaque 
destabilization in murine models (Bobryshev 2005, Niessner, Sato et al. 2006). Moreover, M1 
macrophages have also been reported to infiltrate into atherosclerotic plaques of murine aorta 
roots and human coronary arteries to promote plaque rupture in high fat diet models (Libby, Geng 
et al. 1996, Xu, Shah et al. 2001). Since CD11c+ cells are primarily composed of dendritic cells 
and M1 macrophages, it is possible that CD11c+ cells resident in the vasculature play a critical 
role in the pathological development of atherosclerosis. However, in the pathogenesis of obesity 
and T2DM, M1 macrophages accumulated in adipose tissue and activated the inflammatory 
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response, potentiating the development of chronic inflammation as well as insulin resistance in 
obese mice (Weisberg, McCann et al. 2003, Boutens and Stienstra 2016). It is acknowledged that 
atherosclerosis and diabetes share a similar pathological process related to chronic low grade 
inflammation (Beckman, Creager et al. 2002, Mangge, Schauenstein et al. 2004). It is possible 
that CD11c+ cells could accumulate in either the vasculature or perivascular adipose tissue during 
the development of T2DM, but so far has not been studied. Thus, in the current study, both 
different vasculatures and corresponding perivascular adipose tissues along with VAT were 
collected to examine their CD11c mRNA expressions. Our qPCR data showed that extremely low 
CD11c mRNA levels were found on multiple types of blood vessels from both diabetic and 
heterozygous control mice, compared to a control mouse spleen calibrator. There was no 
significant difference of CD11c mRNA expression between diabetic and control mice. In contrast, 
much higher levels of CD11c mRNA expression, compared to the same calibrator, were detected 
in all collected perivascular adipose tissues as well as VAT from both diabetic and control mice. 
Diabetic mice had higher CD11c mRNA levels on adipose tissue than non-diabetic mice at all the 
four age groups. Our study is the first to compare the amount of CD11c mRNA expression 
between vasculature and perivascular adipose tissues over time in a murine T2DM model. Our 
data showed that the majority of CD11c+ cells are resident in perivascular adipose tissue instead 
of the vasculature itself. With the development of T2DM, more CD11c+ cells accumulated in 
perivascular adipose tissue from diabetic mice than control mice.  
       Our flow cytometry data indicated that both dendritic cells (CD11c+F4/80- cells, CD83+CD86+ 
cells) and M1 macrophages (CD11c+F4/80+ cells) were elevated in VAT of diabetic mice than 
control mice in either 6-10 or 18-22 weeks. There was no significant increment of dendritic cells 
or M1 macrophages accumulation in VAT in the duration of T2DM. Those results implicated that 
CD11c+ cells participated in the pathological process of T2DM at both early (6-10 weeks) and late 
(18-22 weeks) stages and the amount of CD11c+ cells remained constant during the development 
of T2DM. However, these data were inconsistent with previous qPCR results, which showed an 
increment of CD11c mRNA expression in VAT and MAT over the duration of T2DM. It is possibly 
due to the increasing apoptosis of CD11c+ cells in adipose tissue of T2DM, which in turn 
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stimulates more gene expression of CD11c+ cells, as reflected by the increase of CD11c mRNA 
levels. It has been demonstrated that not only adipocytes undergo apoptosis in obese mice, but 
also T lymphocytes were prone to apoptosis in leptin-deficient obese mice, db/db mice (Fujita, 
Murakami et al. 2002, Fantuzzi 2005). Leptin, secreted from adipocytes, has been showed to 
protect macrophages, B and T lymphocytes from apoptosis and regulate the immune response in 
adipose tissue (Matarese, Moschos et al. 2005, Lolmede, Zakaroff-Girard et al. 2015). It is 
believed that in leptin-deficient obese mice, db/db mice, this suppression of apoptosis was 
eliminated. It is possible that the absence of increment of CD11c+ cells in the duration of T2DM, 
detected by flow cytometry measurement, is due to the increasing apoptosis of infiltrated CD11c+ 
cells in the adipose tissue from leptin-deficient mice. 
        Recently, evidence supports the concept that adipose tissue is an immunological organ 
involved in multiple aspects of hemostasis regulation (Huh, Park et al. 2014). Obesity has been 
reported to be associated with prominent inflammation in adipose tissue with infiltration of various 
immune cells, such as macrophages, neutrophils, mast cells, B and T lymphocytes (Seijkens, 
Kusters et al. 2014). The accumulation of those immune cells in obese adipose tissue has been 
reported to be responsible for high levels of pro-inflammatory factors including TNF-α, IFN-γ and 
IL-6, and low levels of anti-inflammatory mediators including IL-10 and IL-4 (Grant and Dixit 2015). 
However, little literature is available to show the alteration of those inflammatory markers in 
adipose tissue during the pathological process of T2DM. Here, in our study, we tried to reveal that 
alteration by measuring TNF-α, IL-6, adiponectin and IL-10 m RNA levels in different adipose 
tissues from both early (6-10 weeks) and late (18-22 weeks) stages of T2DM. Our qPCR data 
showed that in VAT and MAT, TNF-α mRNA levels were increased with the pathological 
progression of T2DM. Additionally, IL-6 mRNA levels were increased in VAT and MAT from 
diabetic mice, compared to control mice. However, there was no increment of IL-6 mRNA levels 
in the different age groups of diabetic mice. Collectively, more pro-inflammatory cytokines, TNF-α 
and IL-6 were produced in VAT and MAT from diabetic mice. This data were consistent with other 
reports, which revealed that circulating levels of TNF-α and IL-6 were elevated in T2DM patients 
and associated with insulin resistance development (Pedersen, Bruunsgaard et al. 2003, Mirza, 
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Hossain et al. 2012). As for the anti-inflammatory cytokine adiponectin, decreasing mRNA level 
was detected in VAT from diabetic mice at both age groups. However, decreasing mRNA levels 
of adiponectin in MAT were only detected in diabetic mice in the late stage of T2DM. This data is 
still consistent with other findings (Hotta, Funahashi et al. 2000, Hotta, Funahashi et al. 2001, Li, 
Shin et al. 2009). Unexpectedly, increasing mRNA levels of anti-inflammatory mediator IL-10 
were found in both VAT and MAT of diabetic mice. Also, IL-10 mRNA level in MAT was increased 
in all age groups of diabetic mice. This result was still consistent with other findings, which 
showed that circulating IL-10 plasma levels were increased in overweight and obese 
chimpanzees (Nehete, Magden et al. 2014). Since IL-10 is considered as a classic anti-
inflammatory cytokine that improves insulin sensitivity (Straczkowski, Kowalska et al. 2005), 
Esposito et al. has proposed that this elevation of IL-10 level in obese individuals was a 
compensatory response in order to suppress the increase of pro-inflammatory cytokine 
production (Esposito, Pontillo et al. 2003). Experiments from Esposito et al. also demonstrated 
that 1 year of physical activity plus body weight loss significantly reduced circulating IL-10 levels 
in obese objects (Esposito, Pontillo et al. 2003). Those findings supported our suggestion that the 
increase of IL-10 mRNA levels in VAT and MAT was due to the compensatory response to the 
progressive development of inflammation triggered by T2DM. Taken together, this imbalance 
production of pro-inflammatory factors and anti-inflammatory mediators in perivascular adipose 
tissue contributes to the local low-grade inflammation caused by T2DM (Zhang, Potter et al. 
2011).  
     In conclusion, our data provide distinct insights into T2DM development, including CD11c+ 
cells accumulation and chronic inflammation formation in perivascular adipose tissue. However, 
we still do not know the relationship between these two events in the development of T2DM. 
Since it has already been established that accumulation of M1 macrophages is responsible for 
this chronic inflammation in diabetic adipose tissue (Weisberg, McCann et al. 2003, Lumeng, 
Bodzin et al. 2007), it is possible that dendritic cells would also participate in the chronic 
inflammation of T2DM perivascular adipose tissue, which is one of the aims in the next chapter.   
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3.1. ABSTRACT 
 
Objective: The aim of this study was to investigate the role of perivascular adipose tissue 
dendritic cells in the regulation of vascular function in T2DM mice.  
Background: It is well known that impaired vasodilator responses and chronic local 
inflammation are evident in a number of metabolic disorders, including obesity and diabetes. The 
underlying mechanisms have recently been shown to involve the accumulation of multiple 
immune cell types, such as macrophages. However, the contribution of another important 
immune cell subtype, the dendritic cell, in the development of vascular dysfunction in T2DM has 
not been clarified.  
Methods: DbHET controls, db/db T2DM mice, and dendritic cell depleted DbHET Flt3l-/- and 
dbFlt3l-/ dbFlt3l- mice were used in the following studies. To first confirm the efficacy of dendritic cell 
ablation, visceral adipose tissue (VAT) was harvested from the above groups of mice and 
subjected to flow cytometry analysis. Glucose and insulin tolerance tests were conducted to 
investigate the effect of dendritic cell depletion on glucose homeostasis. Subsequently, the four 
groups of mice were divided into two age groups: 6-10 and 18-22 weeks of age. VAT and 
mesenteric adipose tissue (MAT) were collected to detect mRNA levels of pro-inflammatory 
cytokines TNF-α and IL-6, as well as the anti-inflammatory mediators, adiponectin and IL-10. 
Furthermore, ACh- induced vasorelaxation and PE- induced vasoconstriction were examined 
using first order mesenteric arteries incubated in the absence and presence of MAT isolated from 
above mice.  
Results: Increased numbers of CD11c+F4/80- and CD83+CD86+ dendritic cells accumulated in 
VAT from db/db mice, compared to DbHET controls. Depletion of Flt3l dramatically reduced 
dendritic cell numbers in VAT from dbFlt3l-/ dbFlt3l- mice, indicating the suitability of this murine 
model. Glucose and insulin tolerance tests showed dbFlt3l-/ dbFlt3l- mice had markedly lower 
glucose levels than db/db mice, while remaining elevated compared to DbHET and DbHET Flt3l-/- 
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mice. Increased mRNA levels of pro-inflammatory factors, TNF-α and IL-6, as well as decreased 
levels of the anti-inflammatory cytokine, adiponectin, were found in VAT and MAT from db/db, 
compared to DbHET mice. The anti-inflammatory factor IL-10 was surprisingly increased in db/db 
mice possibly as compensation for the overproduction of pro-inflammatory factors. Depletion of 
dendritic cells significantly reduced TNF-α, IL-6 and IL-10 mRNA levels in VAT and MAT from 
dbFlt3l-/ dbFlt3l- mice compared to db/db mice without an apparent influence on adiponectin levels. 
Dendritic cell depletion during the early stage of T2DM further rescued impaired ACh-induced 
vasorelaxation and PE-induced vasoconstriction in mesenteric arteries resulting from MAT 
incubation.   
Conclusion: Dendritic cells accumulate in the adipose tissue of T2DM mice. The presence of 
this population of immune cells leads to overproduction of pro-inflammatory cytokines, which 
contributes to impaired vasodilator and anti-contractile functions normally exerted by perivascular 
adipose tissue.   
Key Words: dendritic cells, perivascular adipose tissue, inflammation, vasorelaxation, anti-
contractile function.  
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3.2. Introduction 
The prevalence of obesity and type 2 diabetes (T2DM) in adults and children has increased 
dramatically in the last 20 years. While previously being largely associated with western societies, 
this is now occurring on a global scale. Further, the estimated total economic cost of obesity and 
T2DM is progressively increasing, approaching $92.6 billion dollars in 2002 and representing 
approximately 9% of the annual health expenditure in United States (Nguyen and El-Serag 2010). 
In terms of risk factors, it has been acknowledged that obesity is a major contributor to the 
development of T2DM and its cardiovascular complications (Creely, McTernan et al. 2007). 
Supporting this, approximately 80% of patients with T2DM are diagnosed with obesity. In 
particular, central obesity (characterized by increased waist circumference) is believed to be the 
primary cause of metabolic syndromes, such as T2DM (Greenstein, Khavandi et al. 2009).  
 Although adipose tissue has traditionally been considered as a relatively inert energy storage 
depot, it is now accepted that adipose tissue is also an active immunological organ capable of 
secreting a variety of bioactive molecules in a paracrine or endocrine manner under different 
pathological conditions (Yang, Graham et al. 2005, Grant and Dixit 2015). Many studies have 
now shown that obesity and T2DM are associated with a low-grade systemic inflammatory 
process (Zhang, Potter et al. 2011) and that adipose tissue contributes to the progression of this 
inflammation (Grant and Dixit 2015).  Further, the inflammation is characterized by an imbalance 
in the production of pro-inflammatory and anti-inflammatory factors within adipose tissue (Creely, 
McTernan et al. 2007, Esser, Legrand-Poels et al. 2014). The levels of pro-inflammatory factors 
tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and monocyte chemo attractant protein-
1(MCP-1) are elevated both systemically and in peripheral adipose tissue in the context of obesity 
(Zhang, Potter et al. 2011, Grant and Dixit 2015), whereas the level of the anti-inflammatory 
factor, adiponectin, is decreased in obese adipose tissue. The presence of TNF-α and IL-6 has 
been shown to impair glucose uptake and insulin action in peripheral tissues, such as skeletal 
muscle and liver, and this effect facilitates the development of insulin resistance and T2DM 
(Grant and Dixit 2015). Locally, in obese adipose tissue, these cytokines modulate adipocyte 
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lipolysis and potentiate inflammation by recruitment of inflammatory immune cells, such as 
macrophages, B and T lymphocytes (Guilherme, Virbasius et al. 2008, Winer, Chan et al. 2009, 
Winer, Winer et al. 2011). The accumulated immune cells subsequently become activated and 
secrete more pro-inflammatory cytokines (such as TNF-α, IL-6 and interferon-gamma (IFN-γ)) 
into obese adipose tissue. This facilitates the formation of a vicious circle, which further amplifies 
the inflammatory response that is thought to promote insulin resistance and ultimately contributes 
to the development of overt T2DM. Consistent with this, it has been reported that macrophage 
ablation results in normalization of insulin sensitivity in obese, insulin-resistant mice and is 
accompanied by lower levels of pro-inflammatory cytokines IL-6 and MCP-1 in obese adipose 
tissue (Patsouris, Li et al. 2008). Similarly, depletion of B (Winer, Winer et al. 2011) or T 
lymphocytes (Winer, Chan et al. 2009) in adipose tissue also restores insulin reactivity in obesity-
associated insulin resistant mice. Collectively, in the context of obesity and T2DM, adipose tissue 
switches to an inflammatory profile with accumulation of various immune cells, leading to the 
development of insulin resistance.  
  Perivascular adipose tissue (PVAT) is defined as adipose tissue directly surrounding blood 
vessels and can thus be viewed as being continuous with the vascular adventitia (Eringa, Bakker 
et al. 2012). Accumulating evidence shows that under physiological conditions, the presence of 
PVAT opposes vascular constriction induced by pharmacological vasoconstrictors, such as 
serotonin (Chang, Milton et al. 2013, Gu and Xu 2013, Even, Dulak-Lis et al. 2014). This 
phenomenon is termed as the ‘anti-contractile’ property of PVAT. Consistent with this, co-
incubation of PVAT with isolated arteries augments vascular relaxation induced by 
pharmacological vasodilators, such as acetylcholine (Wang, Luo et al. 2012, Meijer, Bakker et al. 
2013). These anti-contractile and augmentation of vasorelaxation functions of PVAT appear to be 
mediated by a number of bioactive molecules secreted by PVAT, which are collectively termed as 
adipocyte-derived relaxing factors (ADRFs) (Even, Dulak-Lis et al. 2014, Oriowo 2015). However, 
the exact components of ADRFs are still unclear. It has been proposed  that ADRFs might consist 
of adiponectin (Fesus, Dubrovska et al. 2007), hydrogen sulfide (H2S) (Wojcicka, Jamroz-
Wisniewska et al. 2011), nitric oxide (NO) (Gao, Lu et al. 2007) and/or angiotensin (Ang)1-7(Lee, 
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Lu et al. 2009). These vasoactive molecules except NO act on different potassium channels on 
vascular smooth muscle cells, causing membrane hyperpolarization and leading to an anti-
contractile response (Malinowski, Deja et al. 2013, Tano, Schleifenbaum et al. 2014). Additionally, 
ADRFs act on endothelial cells and enhance vasorelaxation (Cheng, Ndisang et al. 2004, 
Goldstein and Scalia 2004).  In contrast to the physiological state,  obesity results in impairment 
of the anti-contractile activity of PVAT (Meijer, Bakker et al. 2013, Agabiti-Rosei, De Ciuceis et al. 
2014), which has been implicated in local chronic inflammation and hypoxia caused by obesity 
(Greenstein, Khavandi et al. 2009). Increased TNF-α and IL-6 levels in PVAT largely abolished 
anti-contractile response induced by norepinephrine, while application of TNF-α antagonist, 
superoxide dismutase (SOD) or catalase rescued the anti-contractile reactivity from obese PVAT 
(Greenstein, Khavandi et al. 2009). Under obese conditions, the augmentation of vasorelaxation 
elicited by PVAT is also blunted, which can be partially restored by application of soluble 
adiponectin (Meijer, Bakker et al. 2013). Collectively, PVAT displays anti-contractile properties 
and augments vasorelaxation under physiological conditions, whereas in obesity local 
inflammation attenuates anti-contractile and augmentation of vasorelaxation of PVAT. As the 
accumulation of immune cells in obese adipose tissue results in an overproduction of 
inflammatory cytokines, it is conceivable that depletion of such cells would rescue the anti-
contractile and augmentation of vasorelaxation in PVAT. However, to date this hypothesis has not 
been tested.   
    Dendritic cells are professional and potent antigen presenting cells characterized by tree-
like extensions from the cell surface (Steinman 1991). Under physiological conditions, dendritic 
cells are generated from bone marrow hematopoietic stem cells and migrate into peripheral 
tissues acting as sentinels to surveillance the immune system (Steinman 1991). Once the 
immune system is insulted by foreign antigens, dendritic cells are usually the first immune cells to 
arrive at the site of insult and act to capture the foreign antigens. Further, the dendritic cells 
become activated and acquire the capacity to migrate from peripheral tissue to lymphoid organs, 
such as lymph nodes and spleen. In these organs, dendritic cells present processed antigens to 
immature B and T lymphocytes. Through this interaction, dendritic cells activate B and T effector 
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cells and direct them towards the site of insult where these effector cells eradicate foreign 
antigens and maintain immunological homeostasis (Steinman 2007). Defects in dendritic cell 
function have been shown  to contribute to the pathological processes underlying a number of 
diseases, including cancer, immunodeficiency diseases (Vacas-Cordoba, Climent et al. 2014), 
autoimmune disease (Liao, Reihl et al. 2016), atherosclerosis (Dieterlen, John et al. 2016), and 
type 1 diabetes (Price and Tarbell 2015). Importantly, evidence suggests that in obesity dendritic 
cells have a weakened antigen presenting function and, instead, increase the capability for 
inflammatory cytokine secretion (Macia, Delacre et al. 2006). It is therefore possible that the 
accumulation of dendritic cells in obese adipose tissue contributes to the local production of 
inflammatory cytokines and contributes to the chronic inflammation seen in T2DM. If this is the 
case, the accumulation of dendritic cells in adipose tissue may play a role in the impairment of 
anti-contractile and augmentation of vasorelaxation caused by chronic inflammation in T2DM.  
As a result of the above discussion, we proposed to examine the following hypotheses:  
• That depletion of dendritic cells would reduce the production of pro-inflammatory 
cytokines and restore the secretion of anti-inflammatory mediators in obese PVAT from 
murine T2DM model.  
• That accumulation of dendritic cells in adipose tissue is associated with vascular 
dysfunction caused by T2DM. Dendritic cell accumulation would impair the anti-
contractile and augmentation of vasorelaxation elicited by obese PVAT.  
• That there is a progressive (i.e. age/duration of diabetes-dependent) impairment of anti-
contractile and enhanced vasorelaxation exerted by PVAT in a T2DM model.   
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3.3. Methods 
Animal Models 
Male and female homozygote T2DM mice (Leprdb, db/db mice) and heterozygote controls (m 
Leprdb, DbHET mice) on the same C57BLKS/J strain were purchased from Jackson Laboratory. 
Male and female Flt3l-/- mice, used as a murine model of dendritic cell depletion, were acquired 
from Taconic Farms (Stefanovic-Racic, Yang et al. 2012). To obtain T2DM mice depleted of 
dendritic cells, dbFlt3l-/ dbFlt3l- mice, Flt3l-/- mice were cross-bred with m Leprdb mice to generate m 
Leprdb Flt3l+/- offspring. In the second generation, male m Leprdb Flt3l+/- mice were bred with 
female m Leprdb Flt3l+/- mice to generate the third hybrid generation m Leprdb Flt3l-/- mice 
(abbreviated as DbHET Flt3l-/- mice). The DbHET Flt3l-/- mice were used as breeding pairs to 
generate DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice which were later used in our studies. Male and 
female DbHET, db/db, DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice were subdivided into two age groups: 
6-10 and 18-22 weeks. All mice were housed in a constant temperature and humidity 
environment on a 12-hour light/dark cycle. All mice had ad libitum access to water and a standard 
chow diet. All the following procedures were approved by the Laboratory Animal Care Committee 
at University of Missouri, Columbia.  
Glucose and insulin tolerance tests 
      Mice were deprived of food overnight for approximately 16 hours in preparation for glucose 
tolerance tests while mice were fasted for 4 hours before insulin tolerance tests. After the 
appropriate fasting procedure, tail tips of mice were cut with sterile scissors and baseline glucose 
levels measured by the ReliOn Prime glucometer (ReliOn Company, WA, USA). 20% glucose 
solution or 0.5 U/kg insulin (Humalin® R; Eli Lilly) were administered intraperitoneally (Lee, Park 
et al. 2011); volume was based on bodyweight. Blood glucose levels were taken from the initial 
tail cut at time 0, 30, 60, 90, and 120 minutes by gently massaging tail blood onto glucometer test 
strips.     
Measurements of adipose tissue weights and non-fasting glucose levels 
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      Weights of total body, intestinal mesentery, visceral adipose tissue (VAT), peri-aortic adipose 
tissue (ATA), pericardial adipose tissue (AH) from the above mice were measured on the same 
weight scale. Non-fasting blood glucose levels were measured by a ReliOn prime blood glucose 
monitoring system (ReliOn Company, WA, USA). Then all the mice were anesthetized with 
Nembutal (65mg/kg) (Sigma Company, Cream Ridge, NJ, USA) and euthanized under 
anesthesia (Kato, Kashiwagi et al. 2006).  
Isolation of the Cellular Stromal Vascular Fraction from Adipose Tissue 
      The procedures for cell isolation from adipose tissue were described in detail previously in 
Chapter II. In brief, VAT was collected from DbHET, db/db, DbHET Flt3l-/-and dbFlt3l-/ dbFlt3l- mice at 
6-10 weeks. The VAT was placed in a freshly made solution of 1x Phosphate Buffered Saline 
(Ca/Mg2+ free)(Gibco Company, Waltham, MA, USA), 0.5% bovine serum albumin (Sigma 
Company, Cream Ridge, NJ, USA) and 10mM CaCl2 and minced into fine particles (< 10 mg) 
using sterile scissors. 2 mg/ml type II collagenase (Sigma Company, Cream Ridge, NJ, USA) was 
added into the above solution and shaken at 37° C for 20 minutes. The enzymatic digestion was 
terminated by 1 mM EDTA and the solution was passed through 100-μm nylon strainers to 
remove undigested adipose tissue. The resulting suspension was centrifuged at 1600 rpm for 5 
minutes at room temperature. The pellet was considered to be the stromal vascular fraction and 
was re-suspended in erythrocyte lysis buffer (Bio legend Company, San Diego, CA, USA). After 
removal of erythrocytes, the remaining cells were re-suspended in 1x Phosphate Buffered Saline 
without Ca2+ and Mg2+ for analysis by flow cytometry. 
 
Flow Cytometry Analysis 
      Procedures for detecting dendritic cell and macrophage populations were similar to Chapter 
II. After determining cell number and survival rate of erythrocyte-depleted stromal vascular 
fraction cells, flow cytometry staining buffer (E-bioscience Company, San Diego, CA, USA) was 
used to wash those cells twice. Then 1 μg/ml Fc-blocker (Sigma Company, Cream Ridge, NJ, 
USA) was added into cell suspension to avoid non-specific binding of the primary antibodies. 
98 
 
After Fc-blocker incubation at 4 ° C in the dark for 15 minutes, cells subsequently underwent 
primary antibody incubation at the same environment for the following 45 minutes. The primary 
antibodies used in this experiment were list in Table.3-1. 
Table.3-1. Properties of primary antibodies for flow cytometry measurements in DbHET, db/db, 
DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice.   
Primary antibody Dilution Conjugated 
fluorophore 
Company 
Anti-CD11c 1:200 APC BD Pharmingen 
Company 
Anti-F4/80 1:400 PE E-bioscience 
Company 
Anti-CD83 1:200 PE Bio legend Company 
Anti-CD86 1:200 APC E-bioscience 
Company 
 
       After washing with flow cytometry staining buffer twice, cells were assessed using the CyAn 
ADP High-Performance Flow Cytometer and Summit software. The final data were presented 
using Flowjo software.  Dendritic cells were identified as CD11c+F4/80- and CD83+CD86+ cell 
populations whereas macrophages were identified as CD11c+F4/80+ cell populations. 
Inflammatory marker mRNA expression in adipose tissue 
       The protocols to detect mRNA levels of inflammatory factors were similar to that outlined in 
Chapter II. In brief, total RNA of VAT and mesenteric adipose tissue (MAT) was extracted using 
RNeasy lipid tissue mini kits (Qiagen Company, Valencia, CA, USA). Quality and quantity of the 
RNA preparations were measured by a Nano Drop ND-1000 Spectrophotometer (Nano Drop 
Technologies, Wilmington, DE). 100ng RNA was reversely transcribed into cDNA using the 
SuperScript III First-Strand Synthesis System (Invitrogen Company, Grand Island, NY, USA). 
Amplification of cDNA into mRNA was conducted by Platinum® SYBR® Green qPCR SuperMix-
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UDG (Invitrogen Company, Grand Island, NY, USA) in an iQ5 Real-Time PCR system (Bio-Rad 
company, Hercules, CA, USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used 
for internal normalization. Inflammatory factor primers were used as follows: 
Table. 3-2. Properties of Primers for q PCR detection in DbHET, db/db, DbHET Flt3l-/- and dbFlt3l-/ 
dbFlt3l- mice  
Primers Forward Reverse 
TNF-α gtccccaaagggatgagaag cacttggtggtttgctacga 
IL-6 ccggagaggagacttcacag tccacgatttcccagagaac 
Adiponectin gtctcacccttaggaccaagaa aggttggatggcaggc 
IL-10 atggccttgtagacaccttg gtcatcgatttctcccctgtg 
GAPDH aatggtgaaggtcggtgtg gtggagtcatactggaacatgtag 
 
      The mean threshold cycle (CT) values were calculated by the 2-ΔΔCT method (ΔΔCT=CT.CD11c-
CT.GAPDH) (Pfaffl 2001). Data were presented as fold change of a given transcript normalized to 
GAPDH, compared with DbHET mice (defined as 1.0-fold).  
Immunohistochemistry 
     Immunohistochemistry was performed in a similar fashion to that described in chapter II. 
Briefly, VAT was harvested from DbHET, db/db, DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice at 18-22 
weeks. Samples were fixed in 10% formalin (Sigma Company) for 18-24 hours, and then were 
embedded in paraffin and cut into 5 μm thick sections (Wentworth, Naselli et al. 2010). Sections 
were de-paraffinized with xylene and processed through a series of ethanol concentrations. 
Following antigen retrieval steps, VAT sections were incubated with blocking serum at room 
temperature for 1 hour to limit nonspecific bindings. Sections were then incubated overnight with 
rabbit anti-mouse TNF-α antibody (1:100 dilution, Abcam Company, Cambridge, United Kingdom) 
and goat anti-mouse perilipin antibody (1:50 dilution, Santa Cruz company, California, USA) at 
4°C. After washing with Tris-buffered saline (TBS), sections were incubated at room temperature 
for 3 hours with goat anti-rabbit secondary antibody conjugated with Texas-Red (1:1000 dilution, 
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Abcam Company, Cambridge, United Kingdom) and donkey anti-goat secondary antibody 
conjugated with FITC (1:100 dilution, Santa Cruz Company, California, USA). Nuclei were 
identified by DAPI staining (Invitrogen, Carlsbad CA, USA). To evaluate the production of TNF-α 
in VAT, the number of positive signals from TNF-α along with surrounding adipocytes were 
calculated from 10 random ×200 view fields on each section (Kosteli, Sugaru et al. 2010, Zhang, 
Sugiyama et al. 2011). Six sections were collected from each mouse (Kosteli, Sugaru et al. 2010). 
The percentage of TNF-α for each sample was determined as the sum of the number of positive 
signals of TNF-α divided by the total number of surrounding adipocytes in each view field. 
Functional assessment of mesenteric artery reactivity with or without MAT 
co-incubation 
        After mice (DbHET, db/db, DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice at both 6-10 and 18-22 
weeks of age) reached a surgical plane of anesthesia, the intestinal mesentery was quickly 
excised and immediately placed in cold and freshly made physiological saline solution (PSS). 
PSS was composed of 4.69 mM KCl, 118.99 mM NaCl, 2.50 mM CaCl2•2H2O, 1.18 mM KH2PO4, 
1.17 mM MgSO4•7H2O, 14.9 mM NaHCO3, 5.5 mM D-Glucose, and 0.03 mM EDTA. First order 
mesenteric arteries (MA) were dissected, cleaned of surrounding tissue and cut into rings 
approximately 2mm in length. Approximately 0.5 gram of MAT was saved in PSS solution for co-
incubation experiments. The MA rings were carefully positioned between 2 stainless steel wires 
(diameter 17  μm) in organ chambers of a DMT wire myograph (model 610M; A&D Instruments) 
(Zhang, Potter et al. 2011). Tension was applied to the mounted MA rings to a trans mural 
pressure of approximately 100 mmHg (Zhang, Potter et al. 2011). Passive length-tension 
relationships of MA were then determined via a Power Lab system (AD instruments, CO, USA) 
(Lee, Yang et al. 2015). During the following experiments, the circumference of the MA rings was 
maintained constant and responses were examined under isometric condition. All MA rings were 
maintained in 37° C PSS aerated continuously with 95% air--5% CO2 (Withers, Simpson et al. 
2014).  
After 30 minutes equilibration, MA rings were first challenged with 80mmol/L KCl and this 
procedure was repeated 3 times until a constant vasoconstriction was achieved. Next, contractile 
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responses to phenylephrine (PE) were investigated in a cumulative dose manner (PE; 10-9—10-5 
mol/L). Endothelium-dependent vasodilation in response to acetylcholine (ACh) was examined 
using a cumulative dose approach (ACh; 10-9—10-5 mol/L) after ring segments were pre-
contracted with PE (1×10-5 mol/L). PE-induced vasoconstriction responses were expressed as a 
percentage of the contraction to 80mmol/L KCl whereas ACh-induced vasorelaxation responses 
were calculated as a percentage of reduced contraction to PE. In adipose tissue co-incubation 
protocols, 0.5g MAT was placed directly in the organ bath chamber in which a given MA ring had 
been mounted. Co-incubation was performed for 1 hour, which was termed as “MAT incubation”. 
MA rings mounted in organ chamber and not incubated with MAT, were termed as “time controls”. 
After 1 hour incubation with MAT, PE-induced vasoconstriction and ACh-induced vasorelaxation 
were examined again to reveal the effects of MAT on vascular function.  In order to test whether 
MAT effects could be reversed by washing, PE-induced vasoconstriction and ACh-induced 
vasorelaxation were repeated in both MAT incubation and time control groups after MA rings 
were washed with PSS for 1 hour (6 x 10mins).  
MAT transfer bioassay experiments 
      The protocols were identical to the above functional assessment experiments, except for the 
preparation of MAT incubation. In these experiments, MAs from DbHET mice at 18-22 weeks 
were isolated and mounted in organ chambers. MAT from these DbHET mice was saved in PSS 
while MAT from db/db mice (18-22 weeks) was also saved in PSS. After determining PE-induced 
vasoconstriction and ACh-induced vasorelaxation without MAT incubation, one MA ring from 
DbHET mouse was co-incubated with 0.5g MAT from the same DbHET mouse, whereas an 
additional MA ring from the DbHET mouse was co-incubated with 0.5g MAT from db/db mouse. 
Additionally, a MA ring from DbHET mouse without MAT co-incubation was termed as a “time 
control”. After the 1 hour co-incubation period, PE-induced vasoconstriction and ACh-induced 
vasorelaxation were investigated to reveal the MAT’s effect on MA vascular function. Similarly, 
MA rings from DbHETFlt3l-/- mice at 18-22 weeks were mounted in organ chambers and set up 
three groups, including DbHETFlt3l-/- mice’s MAT incubation, dbFlt3l-/ dbFlt3l- mice’s MAT incubation 
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and time control groups. PE-induced vasoconstriction and ACh-induced vasorelaxation were 
studied with and without MAT incubation.  
Statistical Analysis 
        All the results were expressed as mean (SEM). Basic parameter measurements, flow 
cytometry data and PCR results were analyzed by one-way Analysis of Variance (ANOVA), along 
with Tukey's multiple comparison post-test. For the functional experiments and MAT transfer 
bioassay data, two-way ANOVA was performed, along with Bonferroni post-test. P < 0.05 was 
considered statistically significant in all of the studies.   
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3.4. Results 
Total body and adipose tissue weights and glucose levels  
       Earlier studies  have demonstrated that ablation of CD11c+ cells (including dendritic cells 
and macrophages) normalizes insulin sensitivity in diet-induced obese mice (Probst, Tschannen 
et al. 2005, Patsouris, Li et al. 2008). Moreover, it has been shown that Flt3l-/- mice display 
increased metabolic rate and are protected against diet-induced obesity (Stefanovic-Racic, Yang 
et al. 2012). As DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice used in the present studies would also exhibit 
low blood glucose levels and high metabolic rate, non-fasting glucose levels, total body weight 
along with intestinal mesentery, VAT, AH and ATA weights were measured in DbHET, db/db, 
DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice (6-10 and 18-22 weeks of age). As shown in Fig.3-1, in the 
early stage of T2DM (6-10 weeks), db/db mice displayed significantly higher body weight, 
intestinal mesentery weight, VAT, AH and ATA weights, along with higher non-fasting glucose 
levels, compared to DbHET mice. Similar results were observed at the later stage of T2DM (18-
22 weeks; Fig.3-2). Depletion of dendritic cells did not alter those parameters in either DbHETFlt3l-
/- nor dbFlt3l-/ dbFlt3l- mice at 6-10 weeks, while at 18-22 weeks, dendritic cell depletion was 
associated with decreased intestinal mesentery (Fig.3-2-C) and VAT (Fig.3-2-D) weights and 
decreased non-fasting glucose levels (Fig.3-2-B). Glucose and insulin tolerance tests (Fig.3-3) 
performed at 18-22 weeks of age similarly showed significantly lower blood glucose levels in 
dbFlt3l-/ dbFlt3l- mice in comparison with db/db mice, but higher glucose levels in dbFlt3l-/ dbFlt3l- mice  
than DbHET or DbHET Flt3l-/- mice. These data indicated a partial restoration of insulin reactivity in 
diabetic mice after dendritic cell depletion. Collectively, the depletion of dendritic cells reduced 
intestinal mesentery and VAT weights, as well as decreased blood glucose levels in dbFlt3l-/ dbFlt3l- 
mice only at the late stage of T2DM.  
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Figure.3-1. Total body and adipose tissue weights along with non-fasting glucose 
levels in experimental groups of mice (at 6-10 weeks) In the early stage of T2DM, 
db/db mice exhibited significantly heavier weights for total body (A), intestinal mesentery 
(C), VAT (D), AH (E) and ATA (F), compared to DbHET control mice. In addition, db/db 
mice showed dramatically higher non-fasting glucose levels (B) than controls. However, 
the depletion of Flt3l did not markedly affect those parameters in DbHET Flt3l-/- or dbFlt3l-/ 
dbFlt3l- mice. Data are shown as mean ± SEM. *: P < 0.05.  
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Figure. 3-2. Total body and adipose tissue weights along with non-fasting glucose 
levels in experimental groups of mice (at 18-22 weeks). In the later stage of T2DM, 
db/db mice exhibited significantly heavier weights of total body (A), intestinal mesentery (C), 
VAT (D), AH (E) and ATA (F), compared to DbHET controls. Further, db/db mice displayed 
markedly higher non-fasting glucose levels (B) than controls. In contrast to dbFlt3l-/ dbFlt3l- 
mice at 6-10 weeks, depletion of dendritic cells reduced intestinal mesentery (C) and VAT 
(D) weights along with non-fasting glucose levels (B) in dbFlt3l-/ dbFlt3l- mice at 18-22 weeks, 
without any influence on AH (E), ATA (F) and total body weights (A). Depletion of dendritic 
cells did not affect those parameters in DbHET mice. Data are shown as mean ± SEM. *, #: 
P < 0.05. 
 
107 
 
  
 
 
 
 
 
Glucose tolerance test
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Figure.3-3. Glucose and insulin tolerance tests in experimental groups of mice at 
18-22 weeks. During both tests, db/db mice had significantly higher glucose levels than 
DbHET, DbHET Flt3l-/- or dbFlt3l-/ dbFlt3l- mice. Although dbFlt3l-/ dbFlt3l- mice exhibited lower 
blood glucose levels than db/db mice, they had significantly higher glucose levels than 
DbHET or DbHET Flt3l-/- mice. No difference was found between DbHET and DbHET Flt3l-/- 
mice. *: db/db mice v.s. other three groups of mice. ^: dbFlt3l-/ dbFlt3l- mice v.s. DbHET or 
DbHET Flt3l-/- mice.  Data are shown as mean ± SEM. 
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Flow cytometry measurements of markers for dendritic cell and 
macrophage populations in VAT  
        To confirm whether genetic depletion of Flt3l, in murine models, would lead to depletion of 
dendritic cells (without influence of macrophage populations), VAT samples from DbHET, db/db, 
DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice were collected at 6-10 weeks. Dendritic cells were identified 
by two cell populations, CD11c+F4/80- and CD83+CD86+ cell populations. The usage of two sets 
of markers allowed for more specific detection of dendritic cells. M1 macrophages were identified 
as the CD11c+F4/80+ cell population. Flow cytometry analysis of VAT stromal vascular fraction 
showed, db/db mice had significantly increased levels of CD11c+F4/80- (Fig.3-4-B) and 
CD83+CD86+ (Fig.3-5-B) dendritic cells  than DbHET mice (Fig.3-4-A, Fig.3-5-A) at 6-10 weeks. 
Similarly, more CD11c+F4/80+ macrophages were observed to accumulate in VAT from db/db 
mice (Fig.3-4-B), compared to DbHET mice (Fig.3-4-A). Genetic depletion of Flt3l significantly 
decreased CD11c+F4/80- (Fig.3-4-C, D) and CD83+CD86+ (Fig.3-5-C, D) dendritic cell 
populations in VAT from DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice. Our data also showed that 
CD11c+F4/80- (Fig.3-4-E) and CD83+CD86+ (Fig.3-5-E) dendritic cells were comparable between 
DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice. Importantly, Flt3l depletion did not significantly alter the 
number of CD11c+F4/80+ macrophages in either DbHET Flt3l-/- (Fig.3-4-C) or dbFlt3l-/ dbFlt3l- mice 
(Fig.3-4-D). More CD11c+F4/80+ macrophages infiltrated into VAT from dbFlt3l-/ dbFlt3l- than 
DbHET Flt3l-/- mice (Fig.3-4-F). Collectively, genetic depletion of Flt3l significantly reduced 
dendritic cell populations in VAT from DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice, without any influence 
on the macrophage population. On the basis of these observations, DbHET Flt3l-/- and dbFlt3l-/ 
dbFlt3l- mice were suitable in the following studies. 
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Figure.3-4. Flow cytometry data quantifying dendritic cell and macrophage 
populations in VAT from DbHET, db/db, DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice (at 6-
10 weeks). Panels A-D showed example flow cytometry data. More CD11c+F4/80- 
dendritic cells (shown in the upper left quadrant) and CD11c+F4/80+ macrophages 
(shown in the upper right quadrant) accumulated in VAT from db/db mice (B) than 
DbHET mice (A). Genetic depletion of Flt3l significantly decreased dendritic cell 
numbers in both DbHET Flt3l-/- (C) and dbFlt3l-/ dbFlt3l- mice (D). However, Flt3l depletion 
did not affect macrophage numbers in either DbHET Flt3l-/- (C) or dbFlt3l-/ dbFlt3l- mice (D). 
Panels E and F showed group data as mean ± SEM. *: P < 0.05. Between db/db and 
DbHET mice; between DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice. #: P < 0.05. Between 
DbHET and DbHET Flt3l-/-mice. ^: P < 0.05. Between db/db and dbFlt3l-/ dbFlt3l- mice.    
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mRNA expression for pro-inflammatory and anti-inflammatory factors  
       Earlier studies have shown that depletion of CD11c+ cells, in an obese murine model, led to a 
significant reduction of adipose tissue and systemic inflammation (Patsouris, Li et al. 2008). An 
improved inflammatory state was evident  by decreased levels of pro-inflammatory cytokines 
TNF-α, IL-6 and MCP-1, and increased levels of anti-inflammatory factor, IL-10 (Patsouris, Li et al. 
2008). We therefore hypothesized that depletion of Flt3l would significantly decrease production 
of pro-inflammatory cytokines while increasing availability of anti-inflammatory factors in adipose 
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Figure.3-5. Flow cytometry data quantifying dendritic cell population in VAT 
from DbHET, db/db, DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice (at 6-10 weeks). Panels 
A-D showed example flow cytometry data.  More CD83+CD86+ dendritic cells (shown 
in the upper right quadrant) accumulated in VAT from db/db mice (B) compared to 
DbHET mice (A). Genetic Flt3l depletion significantly decreased dendritic cell 
population in both DbHET Flt3l-/- (C) or dbFlt3l-/ dbFlt3l- mice (D). Panels E showed group 
data as mean ± SEM. *: P < 0.05. Between db/db and DbHET mice. #: P < 0.05. 
Between DbHET and DbHET Flt3l-/-mice.  ^: P < 0.05. Between db/db and dbFlt3l-/ dbFlt3l- 
mice. 
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tissue of genetically diabetic mice. In order to test this hypothesis, we used qPCR to measure 
mRNA levels of pro-inflammatory factors TNF-α and IL-6, along with anti-inflammatory mediators 
adiponectin and IL-10 mRNA levels in VAT and MAT from DbHET, db/db, DbHET Flt3l-/- and dbFlt3l-/ 
dbFlt3l- mice (aged 6-10 and 18-22 weeks). In the early stage of T2DM, mRNA levels for TNF-α 
and IL-6 were increased in VAT and MAT from db/db mice, compared to DbHET mice (Fig.3-6). 
Depletion of dendritic cells significantly decreased TNF-α and IL-6 levels in VAT and MAT from 
dbFlt3l-/ dbFlt3l-  mice, except for IL-6 mRNA levels in VAT (Fig.3-6-A,B,C,D). In contrast, mRNA 
levels of adiponectin were decreased in the VAT from db/db mice, compared to controls (Fig.3-6-
E).  Depletion of dendritic cells did not restore adiponectin production in dbFlt3l-/ dbFlt3l- mice. 
Additionally, mRNA levels for adiponectin in MAT, along with IL-10 in VAT and MAT were not 
different between db/db and DbHET mice. Depletion of dendritic cells did not affect these patterns 
of results (Fig.3-6-F, G, and H). In the later stage of T2DM, mRNA levels for TNF-α and IL-6 
were increased in VAT and MAT from db/db mice, compared to controls (Fig.3-7). Dendritic cell 
depletion significantly reduced TNF-α and IL-6 mRNA levels in VAT and MAT from dbFlt3l-/ dbFlt3l-   
mice (Fig.3-7-A, B, C, D). TNF-α protein levels in VAT were consistent with the above findings 
(Fig. 3-8). In contrast, mRNA levels for adiponectin were decreased in VAT and MAT from db/db 
mice, compared to controls (Fig.3-7-E, F). However, depletion of dendritic cells did not restore 
adiponectin production in dbFlt3l-/ dbFlt3l-   mice. Interestingly, mRNA levels of IL-10 were increased 
in VAT and MAT from db/db mice, compared to controls (Fig.3-7-G, H). Dendritic cell depletion 
significantly reduced IL-10 mRNA levels only in MAT from dbFlt3l-/ dbFlt3l-   mice (Fig.3-7-H). Taken 
together, depletion of dendritic cells led to a reduction of pro-inflammatory factors and 
ameliorated chronic inflammation caused by T2DM. 
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Figure. 3-6. mRNA expressions of inflammatory factors in VAT and MAT from DbHET, 
db/db, DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice (at 6-10 weeks). Panels A-D showed 
increased mRNA levels of pro-inflammatory factors TNF-α (A-B) and IL-6 (C-D) in VAT and 
MAT from db/db mice compared to DbHET mice. Flt3l depletion significantly decreased TNF-
α mRNA levels in diabetic VAT and MAT, while IL-6 levels were decreased only in diabetic 
MAT. Panel E showed that mRNA levels of the anti-inflammatory factor adiponectin were 
decreased in VAT from db/db mice, compared to DbHET mice. However, Flt3l depletion did 
not restore adiponectin production in db/db mice. Panel F showed adiponectin mRNA levels 
in MAT were similar in all four groups of mice. Panels G-H showed there was no significant 
difference of anti-inflammatory factor IL-10 levels in either VAT or MAT among all four 
groups of mice. Data are shown as mean ± SEM. *, #: P < 0.05.  
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Figure. 3-7. mRNA expressions of inflammatory factors in VAT and MAT from DbHET, 
db/db, DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice (at 18-22 weeks). Panels A-D showed  
increased TNF-α (A-B) and IL-6 (C-D) mRNA levels were found in VAT and MAT from db/db 
mice, compared to DbHET mice. Flt3l depletion significantly decreased TNF-α and IL-6 
mRNA levels in diabetic VAT and MAT. Panels E-F showed decreased adiponectin mRNA 
levels in both VAT and MAT from db/db mice, compared to DbHET mice. However, Flt3l 
depletion did not restore adiponectin production in diabetic mice. Panels G-H showed 
increased IL-10 mRNA levels in VAT and MAT from db/db mice, compared to DbHET mice. 
Flt3l depletion significantly reduced IL-10 levels only in diabetic MAT. Data were shown as 
mean ± SEM. *, #: P < 0.05.  
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Effect of dendritic cell depletion in T2DM on vascular function 
      To investigate the effects of dendritic cell depletion on vascular function in T2DM, MAs from 
DbHET, db/db, DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice (at 6-10 and 18-22 weeks) were examined by 
wire myograph. As shown in Fig.3-9-A, DbHET control mice show similar ACh-induced 
endothelial dependent vasorelaxation at 6-10 and 18-22 weeks. There was no significant 
difference in ACh-induced vasorelaxation between db/db and control mice at age 6-10 weeks. 
However, db/db mice at 18-22 weeks exhibited severely impaired ACh induced vasorelaxation in 
comparison with their corresponding controls (Fig.3-9-A). Thus, a progressive impairment of MA 
ACh-induced vasorelaxation was observed in the T2DM mice. In contrast to the impaired dilator 
response, there were no significant differences in PE-induced vasoconstriction between DbHET 
controls and db/db mice at either 6-10 or 18-22 weeks of age (Fig.3-9-B).  
In additional studies, we investigated whether dendritic cell depletion in PVAT would 
affect vascular function of MA from DbHET and db/db mice (at both 6-10 and 18-22 weeks). At 6-
10 weeks, there was no significant difference in ACh-induced vasorelaxation between DbHET 
and DbHET Flt3l-/- mice (Fig.3-9-E). However, after dendritic cell depletion, dbFlt3l-/ dbFlt3l- mice 
displayed significantly improved ACh-induced vasorelaxation relative to db/db mice. As shown in 
Fig.3-9-G, at 18-22 weeks there was still no significant difference in ACh-induced vasorelaxation 
between DbHET and DbHET Flt3l-/- mice. However, dbFlt3l-/ dbFlt3l- mice showed restored ACh-
induced vasorelaxation, compared to db/db mice. No significant difference of ACh-induced 
vasorelaxation was observed between DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice at either 6-10 or 18-22 
Figure.3-8. TNF-α protein levels in VAT from DbHET, db/db, DbHET Flt3l-/- and dbFlt3l-/ 
dbFlt3l- mice (at 18-22 weeks). (A) Immunofluorescent staining for perilipin and TNF-α in 
VAT. More TNF-α positive signals were found in db/db mice, compared to DbHET mice. 
However, depletion of dendritic cells significantly reduced TNF-α protein levels in dbFlt3l-/ 
dbFlt3l- mice, compared to db/db mice. Nuclei were stained by DAPI while the outline of 
adipocytes was stained by perilipin. (B) Quantification of TNF-α positive signals in 
experimental groups of mice. Note that dbFlt3l-/ dbFlt3l- mice produced more TNF-α than 
DbHETFlt3l-/- mice. No difference in TNF-α protein levels was observed between DbHET and 
DbHETFlt3l-/- mice.  Data were shown as mean ± SEM. *: P < 0.05.  
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weeks (Fig.3-9-C). Thus, dendritic cell depletion significantly restored ACh-induced 
vasorelaxation in db/db mice.  
      In regard to vasoconstrictor responses, no significant differences in PE-induced constriction 
were detected amongst DbHET, db/db, DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice at 6-10 weeks (Fig.3-
9-F). At 18-22 weeks, dbFlt3l-/ dbFlt3l- mice showed reduced PE-induced vasoconstriction compared 
to DbHET, db/db and DbHET Flt3l-/- mice (Fig.3-9-H). Moreover, dbFlt3l-/dbFlt3l- mice at 18-22 weeks 
displayed reduced PE-induced vasoconstriction compared to dbFlt3l-/dbFlt3l- mice at 6-10 weeks 
(Fig.3-9-D). Thus, depletion of dendritic cells did not affect PE induced vasoconstriction on MA in 
the early stage of T2DM, but significantly reduced vasoconstriction response in the late stage of 
T2DM. Taken together, in the duration of T2DM, ACh induced vasorelaxation was progressively 
impaired on MA, whereas PE induced vasoconstriction was not affected. However, dendritic cell 
depletion significantly restored vasorelaxation on MA in the duration of T2DM.  
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Figure. 3-9. ACh and PE concentration-response curves for MA from DbHET, 
db/db, DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l- mice at both 6-10 and 18-22 weeks of age. (A) 
db/db mice at 18-22 weeks had impaired ACh induced vasorelaxation response 
compared to DbHET mice and db/db mice at 6-10 weeks. #: P < 0.05. db/db mice at 18-
22 weeks v.s. DbHET mice at 18-22 weeks. ^: P < 0.05. db/db mice at 18-22 weeks v.s. 
db/db mice at 6-10 weeks. (B-C, F) There was no significant difference of vasomotor 
response among all the four groups. (D) dbFlt3l-/dbFlt3l- mice at 18-22 weeks presented 
reduced PE induced vasoconstriction in comparison with other mice. *: P < 0.05. dbFlt3l-
/dbFlt3l- mice at 18-22 weeks v.s. dbFlt3l-/dbFlt3l- mice at 6-10 weeks. #: P < 0.05. dbFlt3l-
/dbFlt3l- mice at 18-22 weeks v.s. DbHET mice at 18-22 weeks. (E) DbHETFlt3l-/- and dbFlt3l-
/dbFlt3l- mice displayed better ACh induced vasorelaxation response than db/db mice at 6-
10 weeks. #: P < 0.05. db/db mice v.s. DbHETFlt3l-/- mice. ^: P < 0.05. db/db mice v.s. 
dbFlt3l-/dbFlt3l- mice. (G) db/db mice at 18-22 weeks had impaired ACh induced 
vasorelaxation. *: P < 0.05. db/db mice v.s. DbHET, DbHETFlt3l-/- and dbFlt3l-/dbFlt3l- mice. 
(H) dbFlt3l-/dbFlt3l- mice at 18-22 weeks displayed reduced PE induced vasoconstriction. #: 
P < 0.05. dbFlt3l-/dbFlt3l- mice v.s. DbHETFlt3l-/- mice. *: P < 0.05. dbFlt3l-/dbFlt3l- mice v.s. 
db/db mice.  ^: P < 0.05. dbFlt3l-/dbFlt3l- mice v.s. DbHET mice. All data was analyzed by 
Two-way ANOVA. 
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Effect of MAT incubation on vascular reactivity in DbHET mice at 6-10 and 
18-22 weeks  
       Studies have shown that under physiological conditions, PVAT exerts an anti-contractile 
action on the adjacent vasculature (Fernández-Alfonso, Gil-Ortega et al. 2013, Even, Dulak-Lis et 
al. 2014). This effect of adipose tissue is considered to be mediated via paracrine and/or 
endocrine mechanisms.  However, it is unclear whether this anti-contractile property is present in 
db/db and DbHET mice. Also, it is still unknown that whether this effect is age-dependent. To 
address these questions, first order MAs from DbHET mice were prepared and divided into two 
groups: namely, a time control and one co-incubation with MAT. Both groups subjected to 
cumulative concentrations of ACh and PE at 3 time points: 1. before MAT incubation, 2. after 1 
hour MAT incubation and 3. after 1 hour of washout. DbHET mice were subdivided into 6-10 and 
18-22 weeks groups similarly to previous experiments. As shown in Fig.3-10-B and Fig.3-11-B, 1 
hour exposure to MAT significantly enhanced ACh-induced relaxation in MA from DbHET mice at 
both ages. This was reflected by a significant difference of logEC50 values between time control 
and MAT incubation (Fig.3-10-D and Fig.3-11-D). Further, 1 hour exposure to MAT also 
significantly reduced PE-induced vasoconstriction in MA from DbHET mice at both ages (Fig.3-
10-F and Fig. 3-11-F). A significant difference in logEC50 values between time control and MAT 
incubation supported the anti-contractile property of MAT from DbHET mice, shown in Fig.3-10-H 
and Fig. 3-11-H. Collectively, MAT from DbHET mice enhanced vasorelaxation and maintained 
its anti-contractile property, which was not affected by the age.  Moreover, those effects from 
MAT were reversed by washing.  
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Figure. 3-10. ACh and PE concentration-response curves: effect of MAT co-
incubation in DbHET mice (6-10 weeks). (A and E) There were no significant 
differences in ACh (A) or PE (E) concentration response between time control and MA 
intended for MAT incubation, termed “before MAT incubation”. (B and F) following 1 hour 
MAT co-incubation, MA rings exhibited enhanced ACh-induced vasorelaxation (B) and 
reduced PE-induced vasoconstriction responses (F), compared to the time control in the 
absence of MAT. (C and G). After repeated washing (every 10 minutes for 1 hour) of ring 
segments exposed to MAT, ACh-induced vasorelaxation (C) and PE-induced 
vasoconstriction (G) were similar to those of time controls. (D and H) MA with MAT 
incubation showed significantly different LogEC50 values for ACh (D) and PE (H) 
concentration response curves compared to time controls. *: P < 0.05. Panels (B) and (F), 
Two-way ANOVA; Panels (D) and (H), student t-test. All data are presented as mean± 
SEM. 
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Effect of MAT incubation on vascular reactivity in db/db mice at 6-10 and 
18-22 weeks  
       Published studies have shown that the anti-contractile function derived from PVAT is 
impaired in obese animal models (Meijer, Serne et al. 2011, Lastra and Manrique 2015). 
Moreover, a recent investigation  has also revealed that insulin-induced vasodilation of muscle 
resistance arteries was abrogated by the presence of PVAT from db/db mice (Meijer, Bakker et al. 
2013). On the basis of above evidence, it was considered possible that MAT from db/db mice 
would abolish the anti-contractile property and the enhancement of vasorelaxation on MA from 
db/db mice. Since T2DM is a chronic progressive disease, it was also considered that the 
influence of MAT from db/db mice may exhibit a progressive nature. To confirm these hypotheses, 
the same study protocol as DbHET mice was adopted in the following experiments. db/db mice 
were divided into 6-10 and 18-22 weeks age groups. As shown in Fig.3-12, 1 hour MAT co-
incubation did not affect ACh-induced vasorelaxation (Fig.3-12-B) or PE-induced vasoconstriction 
(Fig.3-12-F) responses compared to time controls in db/db mice at 6-10 weeks. Calculation of 
logEC50 values (Fig.3-12-D and H) further supported the above findings. After washing, no 
significant differences in ACh-induced vasorelaxation (Fig.3-12-C) or PE-induced 
vasoconstriction (Fig.3-12-G) responses were observed between time control and MAT 
incubation MA. Similarly, 1 hour MAT incubation still did not change ACh induced vasorelaxation 
and PE induced vasoconstriction in db/db mice at 18-22 weeks, shown in Fig. 3-13. Collectively, 
Figure. 3-11. ACh and PE concentration-response curves: effect of MAT co-
incubation in DbHET mice (18-22 weeks). (A and E) There was no significant difference 
of ACh induced vasorelaxation(A) or PE induced vasoconstriction (E) response between 
time control and “before MAT incubation” group. (B and F) Significant increase of ACh 
induced vasorelaxation (B) and reduction of PE induced vasoconstriction (F) responses 
were observed in MAT incubation group. (C and G). After repeated washing (every 10 
minutes for 1 hour) of ring segments exposed to MAT, ACh-induced vasorelaxation (C) 
and PE-induced vasoconstriction (G) were similar to those of time controls. (D and H) MA 
with MAT incubation showed significantly different LogEC50 values for ACh (D) and PE 
(H) concentration response curves compared to time controls. *: P < 0.05. In (B) and (F) 
panels, Two-way ANOVA. In (D) and (H) panels, student t-test. All data presented as 
mean± SEM. 
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db/db mice at both 6-10 and 18-22 weeks did not exhibit the anti-contractile property and 
enhancement of ACh induced vasorelaxation derived from MAT. 
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Figure.3-12. ACh and PE concentration response curves – effect of MAT co-
incubation in db/db mice (6-10 weeks). (A and E) There was no significant difference of 
ACh (A) or PE(E) concentration response curve between time control and “before MAT 
incubation” group. (B and F) There was still no significant difference of ACh induced 
vasorelaxation (B) or PE induced vasoconstriction (F) response between time control and 
MAT incubation group. (C and G) After repeated washing (every 10 minutes for 1 hour) of 
ring segments, ACh-induced vasorelaxation (C) and PE-induced vasoconstriction (G) were 
similar to those of time controls. (D and H) No significant logEC50 difference of ACh (D) or 
PE (H) concentration response curve was observed between time control and MAT 
incubation. All data presented as mean± SEM. 
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Effect of MAT incubation on vascular reactivity in DbHET Flt3l-/- mice at 6-10 
and 18-22 weeks  
        Our earlier data showed that VAT from DbHET Flt3l-/- mice was deficient of dendritic cells. 
This raises the question as to whether dendritic cell depletion in adipose tissue would affect the 
vascular function in DbHET Flt3l-/- mice. In order to address this, the vascular function protocol, 
used above, was applied to studies of DbHET Flt3l-/- mice at both 6-10 and 18-22 weeks. 1 hour 
MAT co-incubation from DbHET Flt3l-/- mice at both 6-10 (Fig.3-14) and 18-22 (Fig.3-15) weeks 
significantly enhanced ACh induced vasorelaxation and reduced PE induced vasoconstriction. 
Calculated logEC50 values for both ACh (Fig.3-14-D and Fig.3-15-D) and PE concentration-
response curves (Fig.3-14-H and Fig. 3-15-H) showed significant differences between time 
control and MAT incubation, supporting the above findings. The 1 hour wash procedure abolished 
the differences between time controls and arterial rings undergoing MAT incubation at both 6-10 
(Fig.3-14-C and G) and 18-22(Fig.3-15-C and G) weeks. Collectively, MAT from DbHET Flt3l-/- 
mice at both 6-10 and 18-22 weeks enhanced vasorelaxation and exhibited anti-contractile 
Figure.3-13. ACh and PE concentration-response curves: effect of MAT co-
incubation in db/db mice (18-22 weeks). (A and E) There was no significant difference 
of ACh (A) or PE (E) concentration response curve between time control and “before 
MAT incubation” MA. (B and F) There was no significant difference of ACh induced 
vasorelaxation (B) or PE induced vasoconstriction (F) response between time control and 
MAT incubation MA. (C and G) After 1 hour washing procedure, ACh-induced 
vasorelaxation (C) and PE-induced vasoconstriction (G) were similar to those of time 
controls.  (D and H) No significant logEC50 difference of ACh (D) or PE (H) concentration 
response curve was observed between time control and MAT incubation. All data 
presented as mean± SEM. 
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property, which could be removed by washing. These findings were, therefore, considered to be 
similar to DbHET mice.   
 
 
 
 
 
130 
 
  
 
 
 
 
 
 
 
 
 
Figure.3-14. ACh and PE concentration-response curves: effect of MAT co-incubation 
in DbHET Flt3l-/- mice (6-10 weeks). (A and E) There was no significant difference of ACh 
(A) or PE (E) concentration response curve between time control and “before MAT 
incubation” MA. (B and F) Significant increase of ACh induced vasorelaxation (B) and 
reduction of PE induced vasoconstriction (F) responses were found in MAT incubation 
group. (C and G) After repeated 1 hour washing of ring segments exposed to MAT, ACh-
induced vasorelaxation (C) and PE-induced vasoconstriction (G) were similar to those of 
time controls. (D and H) MA with MAT incubation showed significantly different LogEC50 
values for ACh (D) and PE (H) concentration response curves compared to time controls.  *: 
P < 0.05. In (B) and (F) panels, Two-way ANOVA. In (D) and (H) panels, student t-test. All 
data presented as mean± SEM. 
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Effect of MAT incubation on vascular reactivity in dbFlt3l-/dbFlt3l- mice at 6-10 
and 18-22 weeks  
       Previous studies have shown that the pro-inflammatory factor TNF-α decreases NO 
bioavailability and induces the production of reactive oxygen species, leading to endothelial 
dysfunction in T2DM (Zhang, Park et al. 2009, Zhang and Zhang 2012). Moreover, 
overproduction of TNF-α and IL-6 contributes to the loss of anti-contractile function of PVAT in a 
mouse model of obesity (Even, Dulak-Lis et al. 2014). Our previous qPCR data have shown that 
db/db mice had elevated mRNA levels of TNF-α and IL-6 in VAT and MAT. Dendritic cell 
depletion successfully decreased TNF-α and IL-6 production in both VAT and MAT from dbFlt3l-
/dbFlt3l- mice. We therefore hypothesized that dendritic cell depletion would restore anti-contractile 
activity of MAT in db/db mice at both early and late stages of T2DM. In order to confirm this 
hypothesis, the same vascular function protocol as db/db mice was used in studies of dbFlt3l-
/dbFlt3l- mice. Shown in Fig.3-16, a 1 hour co-incubation with MAT significantly enhanced arterial 
Figure.3-15. ACh and PE concentration-response curves: effect of MAT co-
incubation in DbHET Flt3l-/- mice (18-22 weeks). (A and E) There was no significant 
difference of ACh (A) or PE (E) concentration response curve between time control and 
“before MAT incubation” MA. (B and F) Significant increase of ACh induced 
vasorelaxation (B) and reduction of PE induced vasoconstriction (F) responses were 
found in MAT incubation group. (C and G) After repeated 1 hour washing of ring 
segments exposed to MAT, ACh-induced vasorelaxation (C) and PE-induced 
vasoconstriction (G) were similar to those of time controls. (D and H) MA with MAT 
incubation showed significantly different LogEC50 values for ACh (D) and PE (H) 
concentration response curves compared to time controls.  *: P < 0.05. In (B) and (F) 
panels, Two-way ANOVA. In (D) and (H) panels, student t-test. All data presented as 
mean± SEM. 
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ring ACh-induced vasorelaxation (Fig.3-16-B) and reduced PE induced vasoconstriction (Fig.3-
16-F) responses in dbFlt3l-/dbFlt3l- mice at 6-10 weeks. LogEC50 values for MA ring ACh (Fig.3-16-
D) and PE (Fig.3-16-H) concentration curves showed significant differences between time control 
and MAT incubation. A 1 hour wash abolished these differences (Fig.3-16-C and G). Interestingly, 
dbFlt3l-/dbFlt3l- mice at 18-22 weeks, 1 hour co-incubation with MAT significantly enhanced arterial 
ring ACh-induced vasorelaxation (Fig.3-17-B), but had no effect on PE induced vasoconstriction 
(Fig.3-17-F), which was supported by the calculation of LogEC50 values (Fig.3-17-D and H). The 
following 1 hour washing abolished those differences (Fig.3-17-C and G).  Collectively, MAT from 
dbFlt3l-/dbFlt3l- mice at 6-10 weeks augmented vasorelaxation and maintained anti-contractile 
activity, in a manner that could be reversed by wash out. However, MAT from dbFlt3l-/dbFlt3l- mice 
at 18-22 weeks augmented vasorelaxation that could be abolished by washing, but lost anti-
contractile activity, compared to dbFlt3l-/dbFlt3l- mice at 6-10 weeks. 
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Figure.3-16. ACh and PE concentration-response curves: effect of MAT co-
incubation in dbFlt3l-/dbFlt3l- mice (6-10 weeks). (A and E) There was no significant 
difference of ACh (A) or PE (E) concentration response curve between time control 
and “before MAT incubation” MA. (B and F) Significant increase of ACh induced 
vasorelaxation (B) and reduction of PE induced vasoconstriction (F) responses were 
found in MAT incubation, compared to time control. (C and G) After repeated 1 hour 
washing of ring segments exposed to MAT, ACh-induced vasorelaxation (C) and PE-
induced vasoconstriction (G) were similar to those of time controls. (D and H) MA with 
MAT incubation showed significantly different LogEC50 values for ACh (D) and PE (H) 
concentration response curves compared to time controls.  *: P < 0.05. In (B) and (F) 
panels, Two-way ANOVA. In (D) and (H) panels, student t-test. All data presented as 
mean± SEM. 
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Figure.3-17. ACh and PE concentration-response curves: effect of MAT co-incubation 
in dbFlt3l-/dbFlt3l- mice (18-22 weeks).  (A and E) There was no significant difference of ACh 
(A) or PE (E) concentration response curve between time control and “before MAT 
incubation” MA. (B) A significant increase of ACh induced vasorelaxation response was 
found in MAT incubation. (C and G) After repeated 1 hour washing of ring segments 
exposed to MAT, ACh-induced vasorelaxation (C) and PE-induced vasoconstriction (G) 
were similar to those of time controls. (D) MA with MAT incubation showed significantly 
different LogEC50 values for ACh concentration response curve compared to time control. 
(F and H) Interestingly, no significant difference of PE induced vasoconstriction was 
observed between time control and MAT incubation MA (F), which was supported by their 
logEC50 values (H). *: P < 0.05. In (B) panel, Two-way ANOVA. In (D) panel, student t-test. 
All data presented as mean± SEM. 
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MAT transfer assay between DbHET and db/db mice at 18-22 weeks 
      To further confirm that the impairment of vascular function with MAT incubation in db/db mice 
was due to dysfunction of the adipose tissue, we conducted MAT transfer assay experiments. As 
shown in Fig.3-18-A, ACh induced vasorelaxation was enhanced in DbHET mice’s MA with MAT 
incubation from the same mice, which was consistent with previous data in Fig.3-11. However, if 
MA rings from DbHET mice were incubated with MAT from db/db mice, the augmentation of ACh-
induced relaxation was abolished. Calculated logEC50 values for ACh concentration response 
curves did not show a significant difference between time control and db/db MAT incubation 
(Fig.3-18-B). Consistent with previous data in Fig.3-11, PE-induced vasoconstriction was 
reduced in MA rings from DbHET mice incubated with their own adipose tissue (Fig.3-18-C). 
When the MA was incubated with MAT from db/db mice, this reduction of vasoconstriction was 
still preserved. However, this effect was decreased in MA incubated with MAT from db/db mice, 
compared to MA incubated with MAT from DbHET mice (Fig.3-26-D). Taken together, acute 
incubation of normal vessels with MAT from db/db mice impaired the augmentation of ACh-
induced relaxation and the reduction of PE-induced vasoconstriction, when exposed to fat from 
non-diabetic animals.  
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MAT transfer assay between DbHETFlt3l-/- and dbFlt3l-/dbFlt3l- mice at 18-22 
weeks 
      Additional studies were conducted to examine the effects of MAT from dbFlt3l-/dbFlt3l- mice on 
normally functioning vessels. First order MA from DbHETFlt3l-/- mice were exposed to MAT from 
either DbHETFlt3l-/- or dbFlt3l-/dbFlt3l- mice. As shown in Fig. 3-19, MA rings co-incubated with MAT 
from DbHETFlt3l-/- mice exhibited significant enhancement of ACh-induced relaxation and an 
attenuation of PE-induced vasoconstriction responses, compared to time control group. 
Calculated logEC50 values also showed a significant difference between time control and MAT 
incubation from DbHETFlt3l-/- mice. Unlike MAT from db/db mice (Fig. 3-18), MAT incubation from 
dbFlt3l-/dbFlt3l- mice continued to display an enhancement of ACh induced relaxation and 
comparable reduction in PE-induced constriction responses to MAT from DbHETFlt3l-/- mice. The 
PE concentration response curve
-9 -8 -7 -6 -5
0.0
0.5
1.0
time control
DbHET MAT incubation
db/db MAT incubation
**
*
*
^
^# #
C
n=6
R
el
at
iv
e 
re
sp
on
se
 %
of
 8
0m
M
 K
C
l
PE concentration response curve
tim
e c
on
tro
l
Db
HE
T M
AT
 in
cu
ba
tio
n
db
/db
 M
AT
 in
cu
ba
tio
n
-8
-6
-4
-2
0
* *
D
n=6
lo
g 
EC
50
Figure. 3-18. Effect of MAT co-incubation on PE and ACh concentration-responses 
in DbHET and db/db mice (at 18-22 weeks). (A) ACh induced vasorelaxation was 
increased in MA with MAT incubation from DbHET mice, but this effect was abolished in 
MA with MAT incubation from db/db mice. (B and D) Significant logEC50 differences of 
ACh (B) and PE (D) concentration response were found between time control and 
DbHET MAT incubation, as well as between DbHET MAT and db/db MAT incubation. 
(C) PE induced vasoconstriction was decreased in MA with MAT incubation from DbHET 
mice. This effect was still preserved yet impaired in db/db MAT incubation. All data 
presented as mean± SEM. In panel (A and C), Two-way ANOVA was used. *: P < 0.05. 
time control v.s. DbHET MA+ MAT from DbHET mice. ^: P < 0.05. time control v.s. 
DbHET MA+ MAT from db/db mice.  #: P < 0.05. DbHET MA+ MAT from DbHET mice 
v.s. DbHET MA+ MAT from db/db mice. In panel (B and D), One-way ANOVA was used.  
*: P < 0.05.  
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logEC50 values further confirmed the comparable relaxation and constriction response curves 
between MAT incubation from DbHETFlt3l-/- and dbFlt3l-/dbFlt3l- mice. Combined with the data shown 
in Fig.3-18, it is suggested that MAT from db/db mice markedly impairs the augmentation of 
relaxation and anti-contractile responses in normal MA (i.e. when exposed to normal adipose 
tissue). However, genetic depletion of dendritic cells in MAT of diabetic mice significantly 
prevents these effects.  
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Figure. 3-19. Effect of MAT co-incubation on PE and ACh concentration-responses 
in DbHET Flt3l-/- and dbFlt3l-/ dbFlt3l-mice (at 18-22 weeks). (A and C) ACh induced 
vasorelaxation was increased (A) and PE induced vasoconstriction was reduced (C) in MA 
with MAT incubation from both DbHETFlt3l-/- and dbFlt3l-/dbFlt3l- mice. Two-way ANOVA was 
used. In (A) *: time control v.s. DbHETFlt3l-/- mice. ^: time control v.s. dbFlt3l-/dbFlt3l- mice. In 
(C) *: time control v.s. DbHETFlt3l-/- or dbFlt3l-/dbFlt3l- mice. (B and D) Significant logEC50 
differences of ACh (B) and PE (D) concentration response were found between time 
control and DbHETFlt3l-/- or dbFlt3l-/dbFlt3l- mice’s MAT incubation. One-way ANOVA was 
used.  *: time control v.s. DbHETFlt3l-/- or dbFlt3l-/dbFlt3l- mice. All data presented as mean± 
SEM.*, ^: P < 0.05.   
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3.5. Discussion 
       The goal of the present study was to determine the contribution of dendritic cells to the 
development of chronic inflammation and vascular dysfunction associated with T2DM. To 
address this hypothesis, a novel murine model of T2DM combined with genetic deletion of 
dendritic cells, dbFlt3l-/ dbFlt3l- mouse, was first created and then used in our subsequent studies. 
Our key findings can be summarized as follows: (1) Dendritic cell depletion reduced the 
production of pro-inflammatory factors in PVAT from db/db mice. (2) Augmentation of 
vasorelaxation and anti-contractile responses exerted by MAT were lost at both early (6-10 weeks) 
and later (18-22 weeks) stages of T2DM. (3) Dendritic cell depletion restored these 
characteristics of adipose tissue despite maintenance of obesity at the early stage of T2DM. 
However, at the later stage of T2DM, dendritic cell depletion restored the ability of adipose tissue 
to augment vasorelaxation while its anti-contractile activity was lost. 
Murine model of T2DM depleted of dendritic cells  
         Dendritic cells have been studied for over four decades; however, no cell surface protein 
marker until now has been discovered to be uniquely expressed in those immune cells. This 
situation explains the lack of specificity in dendritic cell identification in different murine models. 
The most commonly used model is the CD11c-DTR (diphtheria toxin receptor) transgenic mouse, 
which can be transiently and efficiently depleted of CD11c+ cell populations throughout the body 
(Hochweller, Striegler et al. 2008, Patsouris, Li et al. 2008). The identity of CD11c+ cells is altered 
within different locations (Mortensen 2012). In peripheral tissues, such as adipose tissue, it has 
been questioned as to whether CD11c+ cells specifically represent dendritic cells. This cell 
population likely includes dendritic cells, macrophages and some types of monocytes. Our flow 
cytometry data shown in Fig 3-4 supported the notion that CD11c+ cells in adipose tissue are 
composed of dendritic cells and macrophages. Another important limitation of the CD11c-DTR 
murine model is that administration of a single dose of DT  can maintain CD11c+ cell depletion in 
peripheral tissues for a short period of time (approximately 2 days), after which, CD11c+ cell 
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populations begin to recover (Bar-On and Jung 2010). In order to maintain the low expression of 
CD11c+ cells in peripheral tissues and at the same time mimic the chronic progression of T2DM, 
repeated administration of DT would have to be applied to the same mouse for a period of weeks 
to months. Since DT can be fatal in mice, this procedure is likely to exhibit a variable phenotype 
and high mortality rate in CD11c-DTR mice (Bar-On and Jung 2010). To address these issues, 
we used an alternate murine model with dendritic cell depletion, Flt3l-/- mice (Stefanovic-Racic, 
Yang et al. 2012). Flt3l (ligand for FMS-like tyrosine kinase 3) is a growth factor for hematopoietic 
progenitor cells in mice (McKenna, Stocking et al. 2000). Lack of Flt3l has been reported to 
reduce dendritic cell number in murine lymphoid organs (McKenna, Stocking et al. 2000). 
Compared to CD11c-DTR mice, Flt3l-/- mice are genetically depleted of dendritic cells without the 
need for any chemical administration, making them potentially more suitable for studying the 
chronic progression of T2DM. Our flow cytometry data in Fig. 3-4 demonstrated that this ablation 
can reduce dendritic cell population in VAT without any apparent influence on the M1 
macrophage population. Therefore, we created a T2DM murine model without dendritic cells, 
dbFlt3l-/ dbFlt3l- mice, by cross-breeding Flt3l-/- and DbHET mice. The flow cytometry data in Fig. 3-4 
and Fig. 3-5 showed that CD11c+F4/80- and CD83+CD86+ dendritic cell populations were 
increased in VAT from db/db mice in comparison with DbHET mice. However, after Flt3l depletion, 
dendritic cells were dramatically decreased in VAT from dbFlt3l-/ dbFlt3l- mice in comparison with 
db/db mice. In contrast, CD11c+F4/80+ M1 macrophages were increased in VAT from db/db mice 
compared to DbHET mice, whereas Flt3l depletion did not alter macrophage population in dbFlt3l-/ 
dbFlt3l- mice. As predicted, dendritic cell and macrophage populations were comparable between 
DbHET and DbHETFlt3l-/- mice. On the basis of these observations, we concluded that DbHETFlt3l-/- 
and dbFlt3l-/ dbFlt3l- mice are suitable murine models to study the effect of dendritic cells on 
vascular dysfunction caused by T2DM.      
Metabolic effects of dendritic cell depletion  
       Our data in Fig. 3-1 and Fig. 3-2 showed that T2DM mice exhibit increased total body 
weights as well as larger adipose tissue depots (intestinal mesentery, VAT, MAT, AH and ATA). 
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Further, db/db mice showed markedly higher non-fasting glucose levels compared to healthy 
mice at both early and late stages of T2DM. The depletion of dendritic cells decreased intestinal 
mesentery and VAT weights, as well as non-fasting glucose levels in diabetic mice only at the late 
stage of T2DM, whereas at the early stage of T2DM, dendritic cell depletion did not affect 
phenotypic parameters in diabetic mice. Flt3l-/- mice have been reported  to be characterized by a 
higher metabolic rate compared to wild type mice (Stefanovic-Racic, Yang et al. 2012). Therefore, 
it is possible that dbFtl3l-/ dbFtl3l- mice would still maintain this higher metabolic rate and as a 
consequence, exhibit reduced adipose tissue weight. Previous reports have shown that ablation 
of CD11c+ cells can normalize glucose homeostasis and insulin reactivity by reduction of the 
inflammatory environment in insulin-resistant mice (Patsouris, Li et al. 2008). Our qPCR data in 
Fig. 3-6 and Fig. 3-7 revealed that dendritic cell depletion significantly reduced pro-inflammatory 
factors TNF-α and IL-6 production in diabetic adipose tissue. Glucose and insulin tolerance tests 
(Fig.3-3) show that, in our studies, dendritic cell depletion markedly reduces glucose levels in 
db/db mice, which remained yet significantly higher than healthy controls. These results thus 
suggest that dendritic cells partially contribute to the high glucose levels and insulin resistance 
seen in db/db mice. As our strategy was aimed at depleting only dendritic cells, other immune 
cells may contribute to the development of insulin resistance and glucose elevation in diabetic 
mice – a particular candidate being macrophages, which were not altered by the Flt3-/- ablation. 
Of further importance in interpreting the current studies, pro-inflammatory M1 macrophages still 
accumulated in adipose tissue of the dbFtl3l-/ dbFtl3l- mice (Fig. 3-4). Evidence has indicated that 
M1 macrophages disrupt insulin-stimulated glucose transport and further differentiation of 
adipocytes which results in hypertrophy of adipose tissue (Xie, Ortega et al. 2010). This may 
explain the observation of a partial change of phenotype in the current studies where intestinal 
mesentery and VAT weights were heavier in dbFtl3l-/ dbFtl3l- mice than healthy controls, despite 
lighter than those of db/db mice.  
Changes in inflammatory mediators following dendritic cell depletion 
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       Fig. 3-6 supports the argument that chronic inflammation in adipose tissue is initiated at an 
early stage of T2DM (6-10 weeks of age). In regard to specific mediators, mRNA levels for the 
pro-inflammatory factors, TNF-α and IL-6, were increased in VAT and MAT while mRNA levels for 
the anti-inflammatory mediator, adiponectin, was decreased in VAT from diabetic mice. However, 
mRNA levels of adiponectin in MAT along with the anti-inflammatory mediator IL-10 in VAT and 
MAT were not changed in diabetic mice. Depletion of dendritic cells significantly decreased TNF-
α mRNA levels in VAT and MAT, as well as IL-6 mRNA level in MAT from diabetic mice, without 
any influence on adiponectin and IL-10 mRNA levels. As shown in Fig. 3-7, chronic inflammation 
in adipose tissue appeared to worsen at the later stage of T2DM (18-22 weeks). TNF-α and IL-6 
mRNA levels were increased while adiponectin mRNA levels were decreased in VAT and MAT 
from diabetic mice. Fig. 3-8 provided a piece of evidence on increased levels of  TNF-α protein 
expression in diabetic VAT, compared to healthy controls, whereas the depletion of dendritic cells 
significantly decreased TNF-α protein expression in db/db mice. Interestingly, IL-10 mRNA levels 
were increased in VAT and MAT from diabetic mice. Depletion of dendritic cells significantly 
decreased mRNA levels for TNF-α and IL-6 in VAT and MAT, as well as for IL-10 in MAT from 
diabetic mice, without any influence of other tested factors. Available evidence has demonstrated 
that IL-10 is a compensatory cytokine which suppresses the production of pro-inflammatory 
factors, including TNF-α and IL-6 (Doughty, Carcillo et al. 1998, Sinuani, Beberashvili et al. 2013). 
This might explain the increase of IL-10 production (as an attempt to inhibit production of 
inflammatory cytokines) in adipose tissue from diabetic mice compared to healthy controls. In the 
case of dendritic cell depletion, the decrease in production of TNF-α and IL-6 in diabetic adipose 
tissue reduced the drive for IL-10 production. Collectively, the results of the current studies 
revealed that depletion of dendritic cells significantly decreased the production of pro-
inflammatory factors, TNF-α and IL-6, in diabetic PVAT, resulting in attenuation of chronic 
inflammation caused by T2DM.  
 
Vascular function in T2DM 
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       It is well accepted that PVAT plays an important role in vascular homeostasis through 
paracrine and/or endocrine routes (Szasz, Bomfim et al. 2013, Ozen, Daci et al. 2015). The exact 
mechanism of this effect has been the subject of considerable recent research. Under 
physiological conditions, large quantities of metabolically vasoactive molecules, such as 
adiponectin, H2S and NO are generated from PVAT. These factors  have been shown to be 
responsible for the promotion of vasorelaxation and reduction of vasoconstriction, the latter often 
described as an “anti-contractile” function of adipose tissue (Brown, Zhou et al. 2014, Ozen, Daci 
et al. 2015). Accumulating evidence has revealed that this anti-contractile function from adipose 
tissue is lost in obese mice (Even, Dulak-Lis et al. 2014, Lastra and Manrique 2015). 
Enhancement of vasoconstriction, as opposed to vasorelaxation, in the presence of adipose 
tissue  has also been found in murine high fat diet-induced obese models (Ma, Ma et al. 2010). 
One of the underlying mechanisms to explain the above phenomena is related to the 
overproduction of pro-inflammatory factors and decreased generation of anti-inflammatory 
mediators in obese perivascular adipose tissue (Greenstein, Khavandi et al. 2009, Vachharajani 
and Granger 2009). Application of cytokines TNF-α or IL-6, or an antagonist of adiponectin, to 
PVAT around healthy vasculature significantly reduces dilator activity (Greenstein, Khavandi et al. 
2009). Since our qPCR data in Fig.3-6 and Fig.3-7 have shown that higher mRNA levels of TNF-
α and IL-6 and lower mRNA level of adiponectin are generated in VAT and MAT from db/db mice 
compared to DbHET controls, it is possible that db/db mice would have impaired vascular 
function compared to that of the DbHET mice. Consistent with our hypothesis, the vascular 
function data revealed that incubation with MAT from DbHET mice enhanced vasorelaxation and 
anti-contractile effects on MA (Fig.3-10 and Fig.3-11), whereas MAT from db/db mice lost such 
reactivity. As this occurred at both 6-10 and 18-22 weeks, it is believed to be an early event in the 
development of diabetes-induced vascular dysfunction (Fig.3-12 and Fig.3-13). Therefore, it is 
believed that the impairment of vasorelaxation augmentation and anti-contractile reactivity in 
db/db mice might be attributable to either MAT dysfunction or vascular damage. In order to test 
this hypothesis, MAT transfer experiments were conducted by incubation of DbHET mice’s MAs 
with either MAT from DbHET mice or MAT from db/db mice. Our data showed (Fig.3-18) that 1 
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hour incubation of MAT from db/db mice with healthy MA reduced the anti-contractile property 
and abolished the enhancement of vasorelaxation when compared to MAT incubation with control 
mice. These data suggested that MAT dysfunction contributed to the impairment of 
vasorelaxation augmentation and anti-contractile reactivity in db/db mice, which was consistent 
with other studies (Wang, Luo et al. 2012, Meijer, Bakker et al. 2013).  
Accumulated evidence has shown that incubating coronary arteries with TNF-α for 1 hour 
(Park, Yang et al. 2011) or intraperitoneal injection of IFN-γ for 5 days (Zhang, Potter et al. 2011) 
leads to the impairment of endothelial dependent vasodilation and cause vascular dysfunction. 
Thus, it was considered possible that in the long-term presence of inflamed MAT, the adjacent 
vasculature in vivo would be eventually damaged by inflammatory cytokines secreted from MAT. 
That would partially explain the finding that db/db mice had impaired endothelial dependent 
vasorelaxation of isolated MA than DbHET mice at 18-22 weeks (Fig.3-9). Moreover, we divided 
db/db mice into 6-10 and 18-22 weeks groups. From Fig.3-9, Fig.3-12 and Fig.3-13, we have 
found out that the impairment of vasorelaxation augmentation and anti-contractile reactivity was 
observed in db/db mice at both age groups, whereas MA from db/db mice caused endothelial 
dysfunction only at 18-22 weeks. The precedence of MAT inflammation over vascular dysfunction 
in db/db mice provided another causal linkage between MAT inflammation and vascular 
dysfunction in T2DM. Taken together, db/db mice had impaired augmentation of vasorelaxation 
and anti-contractile reactivity from inflamed MAT at both early and late stage of T2DM, but 
endothelial - dependent vasorelaxation was blunted only at late stage of T2DM.   
Vascular function influenced by dendritic cell depletion 
       Our qPCR data (Fig.3-6 and Fig.3-7) have shown that dendritic cell depletion significantly 
reduced TNF-α and IL-6 production in VAT and MAT from db/db mice. Consistent with these data, 
dendritic cell depletion preserved the augmentation of vasorelaxation and anti-contractile function 
in db/db mice at 6-10 weeks, but only preserved the augmentation of vasorelaxation in db/db 
mice at 18-22 weeks (Fig.3-16 and Fig.3-17). In the MAT transferring experiments shown in Fig. 
3-19, MAT incubation from dbFtl3l-/ dbFtl3l- mice at 18-22 weeks maintained both the augmentation 
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of vasorelaxation and reduction of vasoconstriction on healthy MA, to the similar extent with MAT 
incubation from DbHETFlt3l-/- mice. However, this finding was different from previous result that 
MAT incubation from dbFtl3l-/ dbFtl3l- mice at 18-22 weeks only preserved the augmentation of 
vasorelaxation rather than the anti-contractile function on MA from dbFtl3l-/ dbFtl3l- mice. This 
difference was because the tested MA was from different mice. The MAT transfer experiment 
used MA from DbHETFlt3l-/- mice while the other one was from dbFtl3l-/ dbFtl3l- mice. As shown in 
Fig.3-9, vascular contractility response was significantly lower in dbFtl3l-/ dbFtl3l- mice, compared to 
DbHETFlt3l-/- mice. This reduction of MA contractility could cover the anti-contractile function from 
MAT incubation. It has been reported that adiponectin is essential for the maintenance of 
vascular smooth muscle cell contractility (Ding, Carrão et al. 2012). The low level of adiponectin 
can decrease the production of contractile proteins in smooth muscle cells and alter their 
contractile phenotype. Our qPCR data has shown that adiponectin levels in diabetic adipose 
tissue were not rescued after dendritic cell depletion. Therefore, it is possible that the contractile 
response of MA from dbFtl3l-/ dbFtl3l- mice was lower than MA from DbHETFlt3l-/- mice. However, in 
Fig.3-9, the contractility of MA from dbFtl3l-/ dbFtl3l- mice was still lower than MA from db/db mice. 
The exact mechanism was still unknown. Collectively, dendritic cell depletion preserved the 
augmentation of vasorelaxation and anti-contractile function from MAT at the early stage of T2DM, 
while at the late stage of T2DM, only the augmentation of vasorelaxation from MAT was 
maintained. These vascular effects after dendritic cell depletion effectively contributed to the 
restoration of endothelial dependent vasorelaxation in T2DM mice.    
        In conclusion, our study has shown that (Fig.3-20) db/db mice had higher blood glucose 
levels and increased PVAT weights with dendritic cell accumulation, compared to healthy mice. 
Moreover, elevated production of pro-inflammatory cytokines and reduced production of anti-
inflammatory factors were found in VAT and MAT from db/db mice compared to healthy controls. 
This imbalanced production has led to the impairment of vasorelaxation augmentation and anti-
contractile reactivity derived from db/db mice’s inflamed MAT, which further attenuated 
endothelial dependent vasorelaxation of MA. After dendritic cells were depleted, both PVAT 
weights and blood glucose levels were decreased in dbFtl3l-/ dbFtl3l- mice. Moreover, pro-
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inflammatory cytokines production was significantly reduced in MAT from dbFtl3l-/ dbFtl3l- mice, 
which facilitated the restoration of vasorelaxation augmentation and anti-contractile reactivity from 
MAT. This effect successfully restored endothelial dependent vasorelaxation of MA in dbFtl3l-/ 
dbFtl3l- mice. These findings suggest that dendritic cells are the upstream sources of pro-
inflammatory factors generation. Our study is the first to unveil the role of dendritic cells on the 
regulation of vascular function in T2DM mice, which indicates a novel mechanism of 
cardiovascular disorders associated with T2DM and provides a potential therapeutic target for this 
vascular damage in the development of T2DM.  
  
 
 
 
 
 
 
 
Figure. 3-20. Schematic diagram outlining the role of dendritic cells in 
vascular dysfunction associated with T2DM. In T2DM, more dendritic cells were 
recruited into perivascular adipose tissue and promoted the overproduction of pro-
inflammatory cytokines TNF-α and IL-6 in obese adipose tissue. Under the 
influence of inflamed perivascular adipose tissue, adjacent vessels displayed 
impaired vasorelaxation response and endothelial dysfunction.   
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       In this study, we have shown that during the progression of T2DM, dendritic cells are 
recruited into PVAT as opposed to within the vascular wall; per se. Dendritic cells were also 
shown to contribute to the generation of a pro-inflammatory environment in PVAT and impair 
vasoreactivity of small MA. To further implicate a role for dendritic cells, we used a genetic model 
(Flt3-/-) in which dendritic cell was reduced. Depletion of dendritic cells in db/db mice markedly 
decreased pro-inflammatory cytokine production (despite persistence of marked obesity) and 
further restored vasorelaxation. The data, however, raise additional questions and suggest a 
number of future directions. For example, it remains unclear whether pro-inflammatory cytokines 
are directly secreted by dendritic cells or are secreted by other cell types as a consequence of 
dendritic cell infiltration. In addition, the attenuation of insulin resistance by dendritic cell depletion 
outlined in chapter III remains to be fully investigated. From a mechanistic point of view, it is 
unclear exactly how vascular function was improved by dendritic cell depletion in our model of 
T2DM (for example is there an impact on particular K+ channels which have been implicated in 
the actions of ‘ADRF’)(Zavaritskaya, Zhuravleva et al. 2013, Noblet, Owen et al. 2015)). Finally, it 
would be of value to ascertain whether dendritic cell depletion protects T2DM mice from other 
complications such as cardiac dysfunction or ischemia reperfusion injury. In order to answer 
some of these questions/future directions, the following experiments are suggested. 
 
4.1. Are dendritic cells the main source for pro-inflammatory cytokine 
secretion in adipose tissue of T2DM mice? 
       Under physiological conditions, dendritic cells in the immune system function as 
professional antigen-presenting cells. In this role, these cells usually first recognize and process 
foreign antigens in peripheral tissues. Subsequently they migrate to lymphoid organs and present 
these antigens to effector cells, such as T and B lymphocytes, which then clear the foreign 
antigens in an effort to maintain immune homeostasis (Banchereau and Steinman 1998). Recent 
studies have shown that T lymphocytes infiltrate into obese adipose tissue, secrete multiple 
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cytokine species, and cause adipose tissue inflammation (Nishimura, Manabe et al. 2009). It is, 
therefore, possible that during the progression of T2DM, dendritic cells accumulate in adipose 
tissue and activate T lymphocytes to secrete inflammatory cytokines locally. Interestingly, another 
investigation in diabetic mice reported that adipose tissue-associated dendritic cells lost their 
antigen-presenting function and switched to a secretory phenotype (Macia, Delacre et al. 2006). 
These findings suggest that dendritic cells, themselves, can generate and secrete different 
inflammatory cytokines into adipose tissue. In order to address this controversy and to specifically 
determine, in a model of T2DM, whether dendritic cells directly or indirectly contribute to the 
secretion of inflammatory cytokines is proposed in the following experiments.  
                Since adipose tissue inflammation was shown to be more severe in db/db mice at 18-
22 weeks compared to that at 6-10 weeks (see Fig.2-6 and 2-7), DbHET and db/db mice at 18-22 
weeks will be used to determine the source of inflammatory cytokine production. Initially, CD11c+ 
F4/80- and CD83+CD86+ dendritic cell populations in VAT from both DbHET and db/db mice will 
be detected using flow cytometry (Macia, Delacre et al. 2006). Subsequently, intracellular 
cytokine detection of TNF-α, IL-6 and IFN-γ in flow cytometry will be applied to the isolated 
dendritic cell populations. If the dendritic cells resident in T2DM adipose tissue secrete various 
inflammatory cytokines as we predict, increased protein levels of TNF-α, IL-6 and IFN-γ will be 
observed in db/db compared to DbHET mice. If dendritic cells are not the source of inflammatory 
cytokines, there will be similar expression of TNF-α, IL-6 and IFN-γ protein between DbHET and 
db/db mice. Our previous data (in chapter II) also have shown that M1 macrophages were 
accumulated in VAT from db/db compared to DbHET mice. It is possible that M1 macrophages 
would be responsible for the inflammatory cytokine production. In order to demonstrate this 
hypothesis, the same protocols as above will be employed in CD11c+ F4/80+ M1 macrophage 
population in VAT from db/db and DbHET mice. If the hypothesis were confirmed to be correct, it 
is expected that VAT from db/db mice would have higher TNF-α, IL-6 and IFN-γ levels than 
DbHET mice.  
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4.2. Does genetic depletion of dendritic cells alter insulin sensitivity in 
peripheral tissues of T2DM mice? 
      Consistent with the literature, our data show (see Fig.3-3.) that db/db mice exhibit markedly 
higher blood glucose levels, compared to DbHET mice, during glucose tolerance tests. 
Furthermore, insulin resistance tests showed an impaired glucose lowering effect of insulin in 
db/db mice compared to DbHET controls. Interestingly, our studies also showed that genetic 
depletion of dendritic cells in db/db mice significantly decreases blood glucose levels during 
glucose tolerance tests and improves the glucose lowering effect of insulin. Consistent with this, 
studies in which CD11c+ cells were ablated in high fat fed obese mice demonstrated 
normalization of muscle, liver, and adipose tissue insulin sensitivity during euglycemic clamp 
experiments (Patsouris, Li et al. 2008). Thus, it appears that dendritic cell depletion would also 
improve insulin resistance in the peripheral tissue from db/db mice, which would further extend 
the observation of dendritic cell role in the amelioration of insulin resistance. In order to test this 
hypothesis the following experiments are proposed.    
       Firstly, euglycemic clamp studies will be conducted in DbHET, DbHETFlt3l-/-, db/db and dbFlt3l-/ 
dbFlt3l- mice at 18-22 weeks (Hevener, Olefsky et al. 2007). In these studies, the insulin sensitivity 
of skeletal muscle will be measured by insulin-stimulated glucose disposal rate. The insulin 
sensitivity of liver will be measured by insulin-mediated suppression of hepatic glucose output 
and the insulin sensitivity of adipose tissue will be measured by insulin-induced suppression of 
plasma free fatty acid. Two catheters will be implanted in both jugular veins in the above mice, 
after which they will be fasted for 5 hours. After fasting, equilibration solution containing tracer (5 
μCi/h of [3-3H]D-glucose) will be applied into one catheter until a constant plasma tracer 
concentration is achieved. After equilibration, blood will be collected via a tail nick to obtain basal 
sampling. Subsequently infusion of insulin (6.0 mU/kg/min, 0.12 ml/hr) plus tracer (5 μCi/hr) and 
glucose (50% dextrose) will be initiated until a steady-state blood glucose concentration is 
achieved. At steady state, additional blood samples will be taken to measure post-clamp plasma 
free fatty acid levels. It is predicted that insulin-stimulated glucose disposal rate, insulin-mediated 
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suppression of hepatic glucose output and insulin-induced suppression of plasma free fatty acids 
levels will be significantly decreased in db/db mice, compared to DbHET mice. These results 
would indicate the presence of insulin resistance in skeletal muscle, liver and adipose tissue of 
db/db mice. It is expected that above parameters will be comparable between DbHET and 
DbHETFlt3l-/- mice suggesting that normal insulin reactivity is maintained in DbHET mice despite 
dendritic cell depletion. Given our preliminary glucose and insulin tolerance tests we predict that 
dbFlt3l-/ dbFlt3l- mice will exhibit significant restoration of skeletal muscle, liver, and adipose tissue 
insulin reactivity when compared to db/db counterparts, indicating that dendritic cell depletion 
would protect from T2DM-induced insulin resistance.  
      Secondly, molecular studies will be performed examining insulin sensitivity of the above four 
groups of mice. Since it is well known that skeletal muscle and hepatic insulin resistance in T2DM 
mice are accompanied by increased triglyceride content, it is important to measure enzymes 
involved in triglyceride metabolism to provide another piece of evidence to support our hypothesis 
(Liang, Osborne et al. 2004, Anstee and Goldin 2006). To accomplish this, peroxisome 
proliferator-activated receptor (PPAR) α, acetyl-CoA carboxylase 1 (ACC1), stearoyl CoA 
desaturase-1 (SCD1) and liver X receptor α (LXR α), which participate in lipogenesis and lipid 
oxidation processes, will be examined. mRNA and protein expression for these enzymes will be 
measured in skeletal muscle and liver from DbHET, DbHETFlt3l-/-, db/db and dbFlt3l-/ dbFlt3l- mice at 
18-22 weeks. It is expected that mRNA and protein expressions of PPAR-α, ACC1, SCD1 and 
LXR-α will be increased in db/db mice compared to DbHET mice. However, it is anticipated that 
those levels will be decreased in dbFlt3l-/ dbFlt3l- mice after dendritic cell depletion, whereas those 
enzyme levels will be comparable between DbHET and DbHETFlt3l-/- mice.  
        In summary, this quantification of insulin sensitivity of skeletal muscle, liver and adipose 
tissue, along with alterations of molecular enzymes will present another perspective to unveil the 
effect of dendritic cell depletion on the amelioration of insulin resistance in T2DM mice. Combined 
with glucose and insulin tolerance tests in chapter III, these studies will increase knowledge as to 
the role of dendritic cells in the insulin resistance in T2DM. 
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4.3 Does expression of Kv channels change in T2DM when vascular 
function is restored by dendritic cell depletion?  
      Previous studies have shown that the anti-contractile activity provided by perivascular 
adipose tissue involves the activation of vascular smooth muscle potassium ion channels. In 
particular, Kv (voltage-dependent potassium) channels have been suggested to play a major role 
(Gollasch 2012). Specifically, it has been proposed that release of ADRF (adipocyte-derived 
relaxing factors) from perivascular adipose tissue stimulates the opening of Kv channel and 
decreases calcium influx into vascular smooth muscle cells, leading to vasorelaxation or the ‘anti-
contractile’ effect (Gao, Lu et al. 2007, Gollasch 2012). In pathological conditions, such as 
hypertension, both the expression of Kv channels is decreased and the anti-contractile action of 
perivascular adipose tissue is impaired (Oriowo 2014). However, little research has focused on 
Kv channel expression in mesenteric arteries of T2DM mice. In addition, little is known about 
whether the expression of Kv channel is associated with blunted anti-contractile function induced 
by obese perivascular adipose tissue. Previous investigations  have demonstrated that ARDF 
release is impaired in obese perivascular adipose tissue (Estacio, Jeffers et al. 2000). Combined 
with the findings in chapter III that the anti-contractile function derived from diabetic mesenteric 
adipose tissue was impaired, it is possible that the expression of Kv channels is decreased in the 
vasculature of T2DM mice. Thus, the low level of Kv channels in the diabetic vasculature would 
lead to the loss of anti-contractile function of perivascular adipose tissues. Since our previous 
data in Chapter III has indicated that genetic depletion of dendritic cells restores anti-contractile 
and vasorelaxation augmentation effects of diabetic perivascular adipose tissue, it is possible that 
genetic depletion of dendritic cells would also restore Kv channel expression on vasculature, 
resulting in restoration of vascular function. 
      In order to test above hypothesis, the following experiments are proposed. First order 
mesenteric arteries from DbHET, DbHETFlt3l-/-, db/db and dbFlt3l-/ dbFlt3l- mice at 18-22 weeks will 
be harvested. Western blotting will be conducted on the above vessels to detect the protein levels 
of Kv channels. To assess function, the Kv channel blocker 4-aminopyridine (4-AP) will be added 
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to MAT/mesenteric artery co-incubations in dbFlt3l-/ dbFlt3l- mice, whereas Kv channel agonist 
retigabine will be applied to MAT incubation with mesenteric arteries in db/db mice (Lee, Yang et 
al. 2015). It is anticipated that Kv channel protein levels in mesenteric arteries will be decreased 
in db/db mice compared to DbHET controls. Depletion of dendritic cells has been shown to 
largely reduce pro-inflammatory cytokines production in chapter III. Therefore, depletion of 
dendritic cells would significantly restore Kv channel expression on mesenteric arteries in dbFlt3l-/ 
dbFlt3l- mice. It is also possible that administration of 4-AP will impair the anti-contractile and 
vasorelaxation augmentation effects from MAT in dbFlt3l-/ dbFlt3l- mice. Activation of Kv channels by 
retigabine will partially restore the anti-contractile and vasorelaxation augmentation responses on 
mesenteric arteries from db/db mice. However, it has been reported that the increasing protein 
expression of Kv channels on arteries is not always associated with the increment of Kv channel 
activity, due to the increasing expression of an inhibitory subunit in Kv channel (Lee, Yang et al. 
2015). In that case, the restored expression of Kv channels in dbFlt3l-/ dbFlt3l- mice probably would 
not improve the vascular dysfunction caused by T2DM.  If so, other mechanisms would be 
indicated, such as the restoration of calcium-dependent potassium channel on diabetic 
mesenteric arteries(Weston, Egner et al. 2013). Similar protocols will be adopted as above. 
4.4. Does depletion of dendritic cells protect diabetic mice from ischemia 
/reperfusion injury?  
      It is well known  that T2DM is a metabolic disease accompanied with an increase incidence 
of cardiovascular disorders, including myocardial infarction and congestive heart failure (Greer, 
Ware et al. 2006). These cardiovascular outcomes have been shown to be related to vascular 
dysfunction of small resistance arteries in diabetic mice, such as coronary arteries (Guo, Su et al. 
2005, Moien-Afshari, Ghosh et al. 2008). Our previous data (see Fig.3-7) have shown that when 
dendritic cells were genetically depleted, endothelial-dependent vasorelaxation responses were 
restored in db/db mice. It is, therefore, hypothesized that dendritic cell depletion may also 
decrease ischemia/ reperfusion injury in db/db mice, resulting in a decrease in cardiovascular 
events caused by T2DM. In support of this, one of the molecular mechanisms implicated in  
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ischemia/ reperfusion injury is the increased production of the pro-inflammatory cytokine TNF-α 
(Zhang, Park et al. 2009). Of relevance, our qPCR data (see Fig. 3-5 and Fig.3-6) have shown 
that dendritic cell depletion decreased the production of TNF-α in adipose tissue from db/db mice. 
Collectively, these data provides another piece of evidence to support the hypothesis that 
dendritic cell depletion would protect db/db mice from ischemia/ reperfusion injury.  
       In order to test the above hypothesis, DbHET, DbHETFlt3l-/-, db/db and dbFlt3l-/ dbFlt3l- mice at 
18-22 weeks will be used in the following experiments. Mice will be subjected to escalating 
durations of left coronary artery ischemia surgery (30, 45 and 60 minutes) as described in 
previous studies (Greer, Ware et al. 2006). Mice will be allowed to undergo reperfusion for 28 
days and waif for the development of heart failure. After reperfusion, we will assess the survival 
rate of the mice and left ventricular contractile function using high frequency echocardiography. 
Left ventricle tissue from above mice will be harvested for measurement of TNF-α protein 
expression. It is expected that all the mice will have decreased survival rate in parallel with the 
increasing duration of ischemia (from 30 to 60 minutes). Amongst the experimental groups, db/db 
mice will likely exhibit significantly lower survival rates at each time of ischemia compared to 
DbHET controls. Conversely, dbFlt3l-/ dbFlt3l- mice will exhibit prolonged survival rates in 
comparison with db/db mice. Further it is anticipated that there will be no significant difference in 
survival rates between DbHET and DbHETFlt3l-/- mice. Left ventricular end-diastolic dimension, left 
ventricular end-systolic dimensions and left ventricular fractional shortening parameters are 
predicted to be similar in DbHET and DbHETFlt3l-/- mice following ischemia/ reperfusion injury. In 
contrast, increased left ventricular end-diastolic and end-systolic dimensions along with 
decreased left ventricular fractional shortening parameters are expected to be observed in db/db 
mice compared to DbHET mice and again parallel the duration of ischemia. These results would 
be consistent with an increased propensity for deterioration of left ventricular function and 
development of heart failure in db/db mice. However, dbFlt3l-/ dbFlt3l- mice would exhibit partially 
decreased left ventricular end-diastolic and end-systolic dimensions, along with partially 
increased left ventricular fractional shortening parameters, compared to db/db mice. These 
results would suggest that dendritic cell depletion restores left ventricular function and protects 
160 
 
db/db mice from further heart failure development. Western blotting studies are predicted to show 
increased TNF-α protein levels in the left ventricles of db/db mice compared to DbHET controls, 
whereas TNF-α levels will be decreased in dbFlt3l-/ dbFlt3l- mice compared to db/db mice. 
Immunofluorescence staining of TNF-α levels in left ventricles from above mice not only would 
further support western blotting findings, but also could reveal the location of TNF-α protein 
distribution in the left ventricles. These results would provide molecular basis for cardiac function 
changes in above mice.  
      To sum up, in the future experiments, we will further explore more activities of dendritic cells 
in the development of T2DM. Firstly, we will determine whether dendritic cells have secretory 
function and directly release pro-inflammatory cytokines into diabetic adipose tissue. Secondly, 
we will study whether this pro-inflammatory secretion profile of dendritic cells would be 
responsible for the reduction of peripheral insulin sensitivity in diabetic mice. Thirdly, we will 
confirm whether the depletion of dendritic cells, reduction of inflammatory state and improvement 
of insulin sensitivity in perivascular adipose tissue, would restore Kv channel expression on 
mesenteric arteries. Last, we will test whether depletion of dendritic cells, reduction of 
inflammatory state along with improvement of insulin sensitivity and Kv channel expression, 
would reduce the damage of ischemia/reperfusion injury in diabetic mice.  Through those four 
hypotheses, the role of dendritic cells in vascular dysfunction and insulin resistance caused by 
T2DM would be further revealed. The result would provide a novel therapeutic target for the 
treatment of T2DM.   
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